### **HEALTH ANNUAL STATEMENT**

FOR THE YEAR ENDED DECEMBER 31, 2021 OF THE CONDITION AND AFFAIRS OF THE

### UnitedHealthcare of New England, Inc.

NAIC Grou	(Current) (Prior)		e 95149 Employer's ID	
rganized under the Laws of			State of Domicile or Port of En	nuy
ountry of Domicile		United States	of America	
censed as business type:		Health Maintenand	ce Organization	
HMO Federally Qualified? Yes [	] No[ X]			
corporated/Organized	11/14/1984		Commenced Business	12/27/1984
tatutory Home Office	475 Kilvert Street, Suite 31	0		Warwick, RI, US 02886-1392
	(Street and Number)		(City or	Town, State, Country and Zip Code)
ain Administrative Office			ne, MN006-W500	
Minn	etonka, MN, US 55343	(Street and		952-979-6169
(City or Town	n, State, Country and Zip Code)		(A	rea Code) (Telephone Number)
ail Address 98	800 Health Care Lane, MN006-W50		(City or	Minnetonka, MN, US 55343 Town, State, Country and Zip Code)
	(Street and Number or P.O. Box)			Town, State, Country and Elp Code)
rimary Location of Books and Red	cords	9800 Health Care L (Street and		
	netonka, MN, US 55343			952-979-6169 Area Code) (Telephone Number)
(City or Town	n, State, Country and Zip Code)			rea code) (Telephone Humber)
ternet Website Address		www.unitedhe	althcare.com	
atutory Statement Contact	Will A Gran (Name)	nrud		952-979-6169 (Area Code) (Telephone Number)
w	ill_granrud@uhc.com			952-931-4651
	(E-mail Address)			(FAX Number)
		OFFIC	ERS Treasurer	Peter Marshall Gill
Chief Executive Officer President	Mary Rachel Snyder Elizabeth Corkum Winso	or#	Chief Financial Officer	
		ОТН	IED	
Patrice Evelyn Cooper, Vice		DIRECTORS O		Nyle Brent Cottington, Vice President
Patrice Evelyn	Cooper		hel Snyder	Elizabeth Corkum Winsor #
M:	de	0	_ 1	
State of 111105	State of County		C TO	State of County of
county of Morney	Count	101 7101-4	VVE.	
above, all of the herein described his statement, together with relate of the condition and affairs of the completed in accordance with the that state rules or regulations required.	assets were the absolute properly ed exhibits, schedules and explana said reporting entity as of the repor NAIC Annual Statement Instruction uire differences in reporting not rela cope of this attestation by the desci- differences due to electronic filin	or the said reporting tions therein contain riting period stated a ns and Accounting Protection of the tited to accounting pro-	ed, annexed or referred to, is above, and of its income and ractices and Procedures mani- ractices and procedures, acco-	aid reporting entity, and that on the reporting period stated y liens or claims thereon, except as herein stated, and that a full and true statement of all the assets and liabilities and deductions therefrom for the period ended, and have been ual except to the extent that: (1) state law may differ; or, (2) dring to the best of their information, knowledge and belief, ing electronic filing with the NAIC, when required, that is an ig may be requested by various regulators in lieu of or in
Heather Anastasia L Assistant Secreta			rkum Winsor ident	Peter Alexander Semmer Chief Financial Officer
Subscribed and sworn day of	to before me this		sworn to before me this x of January	Subscribed and sworn to before me this day of
My Col	DA LOUISE RYAN otary Public Minnesota mmission Expires an 31, 2026	CO A EX.	MISSION 1. State to	ginal filing?

# **ASSETS**

			Current Year		Prior Year
		1 Assets	2 Nonadmitted Assets	3 Net Admitted Assets (Cols. 1 - 2)	4 Net Admitted Assets
1.	Bonds (Schedule D)	252,228,035	0		264,362,292
2.	Stocks (Schedule D):				
	2.1 Preferred stocks	0	0	0	0
	2.2 Common stocks	0	0	0	0
3.	Mortgage loans on real estate (Schedule B):				
	3.1 First liens	0	0	0	0
	3.2 Other than first liens	0	0	0	0
4.	Real estate (Schedule A):				
	4.1 Properties occupied by the company (less \$				
	encumbrances)	0	0	0	0
	4.2 Properties held for the production of income (less				
	\$0 encumbrances)	0	0	0	0
	4.3 Properties held for sale (less \$0				
	encumbrances)	0	0	0	0
5.	Cash (\$(439,465), Schedule E - Part 1), cash equivalents				
	(\$111,407,214 , Schedule E - Part 2) and short-term				
	investments (\$0 , Schedule DA)	110,967,749	0	110,967,749	88,551,939
6.	Contract loans, (including \$0 premium notes)	0	0	0	0
7.	Derivatives (Schedule DB)	0	0	0	0
	Other invested assets (Schedule BA)				
	Receivables for securities			0	
	Securities lending reinvested collateral assets (Schedule DL)			0	0
	Aggregate write-ins for invested assets				
12.	Subtotals, cash and invested assets (Lines 1 to 11)	363, 195, 784	0	363, 195, 784	352,914,231
13.	Title plants less \$0 charged off (for Title insurers				
	only)	0		0	
14.	Investment income due and accrued	1,456,210	0	1,456,210	1,596,674
15.	Premiums and considerations:				
	15.1 Uncollected premiums and agents' balances in the course of collection	23,974,985	283,618	23,691,367	27,086,436
	15.2 Deferred premiums and agents' balances and installments booked but				
	deferred and not yet due (including \$0				
	earned but unbilled premiums)	0	0	0	0
	15.3 Accrued retrospective premiums (\$1,314,405 ) and				
	contracts subject to redetermination (\$45,732,263 )	47,046,668	0	47,046,668	47,795,043
16.	Reinsurance:				
	16.1 Amounts recoverable from reinsurers	170,577			
	16.2 Funds held by or deposited with reinsured companies	0	0	0	
	16.3 Other amounts receivable under reinsurance contracts	56,592	0	56,592	
17.	Amounts receivable relating to uninsured plans	18,418,106	28,891	18,389,215	12,913,219
18.1	Current federal and foreign income tax recoverable and interest thereon	912,028	0	912,028	2,614,091
18.2	Net deferred tax asset	3,085,068	0	3,085,068	2,805,020
	Guaranty funds receivable or on deposit			0	0
20.	Electronic data processing equipment and software	0	0	0	0
21.	Furniture and equipment, including health care delivery assets				
	(\$				
	Net adjustment in assets and liabilities due to foreign exchange rates				
	Receivables from parent, subsidiaries and affiliates			3,605,369	
	Health care (\$30,424,243 ) and other amounts receivable			30,424,243	
25.	Aggregate write-ins for other than invested assets	125	125	0	0
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)	403 EEE 000	1 500 770	402 022 101	472 EOC 044
27	Protected Cell Accounts (Lines 12 to 25)	<del>4</del> 90,000,900	1,522,779	492,033,121	410,000,044
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts	0	0	0	0
28.	Total (Lines 26 and 27)	493,555,900	1,522,779		
	DETAILS OF WRITE-INS				
1101.					
1102.					
1103.					
	Summary of remaining write-ins for Line 11 from overflow page		0	0	0
	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0	0		0
	Prepaid Expenses	-	_	-	
2502.	Troparu Exponsos				
2502. 2503.					
	Summary of remaining write-ins for Line 25 from overflow page				
			125		
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	125	125	0	1 0

# **LIABILITIES, CAPITAL AND SURPLUS**

	LIABILITIES, CAP		Current Year		Prior Year
		1	2	3	4
		Covered	Uncovered	Total	Total
1. (	Claims unpaid (less \$810,690 reinsurance ceded)				158,366,925
	Accrued medical incentive pool and bonus amounts				
	Jnpaid claims adjustment expenses		0		
	Aggregate health policy reserves, including the liability of	1,000,000			
7. /	\$25,373,835 for medical loss ratio rebate per the Public				
	Health Service Act	72 931 476	0	72 931 476	29 454 271
	Aggregate life policy reserves			0	
	Property/casualty unearned premium reserves.				0
	Aggregate health claim reserves				
	Premiums received in advance				
	General expenses due or accrued.		0		
	Current federal and foreign income tax payable and interest thereon	, 1.00,01			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
	(including \$0 on realized capital gains (losses))	0	0	0	0
	Net deferred tax liability				0
	Ceded reinsurance premiums payable				
	Amounts withheld or retained for the account of others				
	Remittances and items not allocated.				
	Borrowed money (including \$	20,001		20,001	
	interest thereon \$0 (including				
	\$	0	0	0	0
	Amounts due to parent, subsidiaries and affiliates.				1,570,638
	Derivatives.				0
	Payable for securities				710,000
	Payable for securities lending				0
				0	
	funds held under reinsurance treaties (with \$0				
	authorized reinsurers, \$0 unauthorized				0
	reinsurers and \$0 certified reinsurers)	0	0	0	0
	Reinsurance in unauthorized and certified (\$				
	companies				
	Net adjustments in assets and liabilities due to foreign exchange rates	0	0		0
	iability for amounts held under uninsured plans	7,302,672	0	7,302,672	4,890,749
	ggregate write-ins for other liabilities (including \$9,792				
	current)				
	otal liabilities (Lines 1 to 23)		0		269 , 174 , 406
	Aggregate write-ins for special surplus funds				
	Common capital stock				
	Preferred capital stock				
28.	Gross paid in and contributed surplus.	XXX	XXX	12,000,000	12,000,000
29. 5	Surplus notes	XXX	XXX	0	0
30. A	Aggregate write-ins for other than special surplus funds	xxx	XXX	0	0
31. L	Jnassigned funds (surplus)	xxx	XXX	188,321,609	186,548,803
32. L	.ess treasury stock, at cost:				
3	2.10 shares common (value included in Line 26				
	\$0 )	xxx	xxx	0	0
3	2.20 shares preferred (value included in Line 27				
	\$	xxx	XXX	0	0
33. T	otal capital and surplus (Lines 25 to 31 minus Line 32)				204,411,638
	otal liabilities, capital and surplus (Lines 24 and 33)	XXX	XXX	492,033,121	473,586,044
	DETAILS OF WRITE-INS			,,	-,,,-
	Inclaimed Property	9 792	0	9 792	12 442
2302	Totalina Troporty				
2303					
	Summary of remaining write-ins for Line 23 from overflow page				0
	otals (Lines 2301 thru 2303 plus 2398)(Line 23 above)	9,792	0	9,792	12,442
	otals (Lines 2501 tillu 2505 pius 2550)(Line 25 above)	,		,	· · · · · · · · · · · · · · · · · · ·
	Summary of remaining write-ins for Line 25 from overflow page				0
	otals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	XXX	XXX	0	0
3002					
3003		xxx			
3098.	Summary of remaining write-ins for Line 30 from overflow page	xxx	xxx	0	0
3099. T	otals (Lines 3001 thru 3003 plus 3098)(Line 30 above)	XXX	XXX	0	0

# **STATEMENT OF REVENUE AND EXPENSES**

	STATEMENT OF REVENUE AN			D: V
		Current \	rear 2	Prior Year 3
		Uncovered	Total	Total
1.	Member Months.	XXX	2,141,709	1,984,860
2.	Net premium income ( including \$	XXX	1,634,306,387	1,460,338,132
	Change in unearned premium reserves and reserve for rate credits			
	Fee-for-service (net of \$			
	Risk revenue			
6.	Aggregate write-ins for other health care related revenues			0
7.	Aggregate write-ins for other non-health revenues	XXX	0	0
8.	Total revenues (Lines 2 to 7)	XXX	1,584,388,273	1,433,651,095
	Hospital and Medical:			
9.	Hospital/medical benefits	0	1 , 163 , 786 , 347	1,005,269,685
10.	Other professional services	0	11,853,665	8,513,840
11.	Outside referrals	0	0	0
	Emergency room and out-of-area			0
	Prescription drugs			
	Aggregate write-ins for other hospital and medical.			
	Incentive pool, withhold adjustments and bonus amounts			
16.	Subtotal (Lines 9 to 15)	0	1,353,231,573	1, 191, 136, 381
	Less:			
17.	Net reinsurance recoveries	0	2,956,757	3,607,218
18.	Total hospital and medical (Lines 16 minus 17)	0	1,350,274,816	1, 187, 529, 163
19.	Non-health claims (net)	0	0	0
	Claims adjustment expenses, including \$42,012,771 cost containment expenses			
	General administrative expenses			
	_		100, 167, 979	130,670,033
22.	Increase in reserves for life and accident and health contracts (including \$0			
	increase in reserves for life only)			
23.	Total underwriting deductions (Lines 18 through 22)	0	1,505,707,215	1,369,510,705
24.	Net underwriting gain or (loss) (Lines 8 minus 23)	XXX	78,681,058	64,140,390
25.	Net investment income earned (Exhibit of Net Investment Income, Line 17)	0	5,337,101	5,573,125
	Net realized capital gains (losses) less capital gains tax of \$			
	Net investment gains (losses) (Lines 25 plus 26)		6,596,627	
	Net gain or (loss) from agents' or premium balances charged off [(amount recovered		0,000,021	
28.			(0.00.00.1)	(2.2 2.2)
	\$		(312,281)	(347,345)
29.	Aggregate write-ins for other income or expenses	0	0	(31)
30.	Net income or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus	2007	04 005 404	00 000 507
	27 plus 28 plus 29)		, , ,	69,366,597
31.	Federal and foreign income taxes incurred	XXX	17,793,162	19,876,787
32.	Net income (loss) (Lines 30 minus 31)	XXX	67,172,242	49,489,810
	DETAILS OF WRITE-INS			
0601.		XXX		
0602.		xxx		
0603		xxx		
	Summary of remaining write-ins for Line 6 from overflow page		0	0
0699.	Totals (Lines 0601 thru 0603 plus 0698)(Line 6 above)	XXX	0	0
0701.	Totale (Elitor oco ) and ocoo place ocoo (Elitor o above)			
0702.				
	Summary of remaining write ine for Line 7 from everflow page		0	^
	Summary of remaining write-ins for Line 7 from overflow page		0	0
0799.	Totals (Lines 0701 thru 0703 plus 0798)(Line 7 above)	XXX	0	0
1401.				
1403.				
1498.	Summary of remaining write-ins for Line 14 from overflow page	0	0	0
1499.	Totals (Lines 1401 thru 1403 plus 1498)(Line 14 above)	0	0	0
2901.	Fines and Penalties	0	0	(31
2902.				
2903				
2998.	Summary of remaining write-ins for Line 29 from overflow page	0	0	0
2999.	Totals (Lines 2901 thru 2903 plus 2998)(Line 29 above)	0	0	(31)

**STATEMENT OF REVENUE AND EXPENSES (Continued)** 

	STATEMENT OF REVENUE AND EXPENSES	Oontinaca	
		1 Current Year	2 Prior Year
	CAPITAL AND SURPLUS ACCOUNT		
	0/4 11/12 / 41D 00/14 200 / 4000011		
33.	Capital and surplus prior reporting year	204 411 638	163 161 782
34.	Net income or (loss) from Line 32		
35.	Change in valuation basis of aggregate policy and claim reserves		0
36.	Change in net unrealized capital gains (losses) less capital gains tax of \$	28,083	52,840
37.	Change in net unrealized foreign exchange capital gain or (loss)	0	0
38.	Change in net deferred income tax	280,048	(1,639,940)
39.	Change in nonadmitted assets	493, 166	9,347,146
40	Change in unauthorized and certified reinsurance	0	0
41.	Change in treasury stock	0	0
42.	Change in surplus notes	0	0
43.	Cumulative effect of changes in accounting principles.	0	0
44.	Capital Changes:		
	44.1 Paid in	0	0
	44.2 Transferred from surplus (Stock Dividend)	0	0
	44.3 Transferred to surplus	0	0
45.	Surplus adjustments:		
	45.1 Paid in	0	0
	45.2 Transferred to capital (Stock Dividend)		
	45.3 Transferred from capital		0
46.	Dividends to stockholders		(16,000,000
	Aggregate write-ins for gains or (losses) in surplus		
47.			41,249,856
48.	Net change in capital and surplus (Lines 34 to 47)		
49.	Capital and surplus end of reporting period (Line 33 plus 48)	206, 184, 444	204,411,638
	DETAILS OF WRITE-INS		
4701.			
4702.		-	
4703.		-	
4798.	Summary of remaining write-ins for Line 47 from overflow page	0	0
4799.	Totals (Lines 4701 thru 4703 plus 4798)(Line 47 above)	0	0

### **CASH FLOW**

	OASIII 2011		
		1	2
		Current Year	Prior Year
	Cash from Operations		
1.	Premiums collected net of reinsurance	1,642,845,612	1,464,662,897
2.	Net investment income	7,539,001	6,902,136
3.	Miscellaneous income	0	0
4.	Total (Lines 1 through 3)	1,650,384,613	1,471,565,033
5.	Benefit and loss related payments	1,388,838,485	1,150,211,072
6.	Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts	0	0
7.	Commissions, expenses paid and aggregate write-ins for deductions	162,339,034	184,946,607
8.	Dividends paid to policyholders	0	0
9.	Federal and foreign income taxes paid (recovered) net of \$	16,425,909	24,336,983
10.	Total (Lines 5 through 9)	1,567,603,428	1,359,494,662
11.	Net cash from operations (Line 4 minus Line 10)	82,781,185	112,070,371
	Cash from Investments		
12.	Proceeds from investments sold, matured or repaid:		
	12.1 Bonds	64,862,194	37,432,543
	12.2 Stocks		
	12.3 Mortgage loans		
	12.4 Real estate		0
	12.5 Other invested assets		
	12.6 Net gains or (losses) on cash, cash equivalents and short-term investments		
	12.7 Miscellaneous proceeds		710,000
	12.8 Total investment proceeds (Lines 12.1 to 12.7)		
13.		04,002,134	705,007,505
13.	Cost of investments acquired (long-term only):  13.1 Bonds	52 112 122	97 006 704
	13.2 Stocks		713,678,491
	13.3 Mortgage loans		0
	13.4 Real estate		0
	13.5 Other invested assets		
	13.6 Miscellaneous applications		0
	13.7 Total investments acquired (Lines 13.1 to 13.6)		800,685,285
14.	Net increase (decrease) in contract loans and premium notes		0
15.	Net cash from investments (Line 12.8 minus Line 13.7 minus Line 14)	11,039,061	(15,077,700)
	Cash from Financing and Miscellaneous Sources		
16.	Cash provided (applied):		
	16.1 Surplus notes, capital notes	0	0
	16.2 Capital and paid in surplus, less treasury stock	0	0
	16.3 Borrowed funds		
	16.4 Net deposits on deposit-type contracts and other insurance liabilities	0	0
	16.5 Dividends to stockholders	66,200,733	16,000,000
	16.6 Other cash provided (applied)	(5,203,703)	261,535
17.	Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6)	(71,404,436)	(15,738,465)
	RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS		
18.	Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17)	22,415,810	81,254,206
19.	Cash, cash equivalents and short-term investments:		
	19.1 Beginning of year	88,551,939	7,297,733
	19.2 End of year (Line 18 plus Line 19.1)	110,967,749	88,551,939
		, ,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,

Note: Supplemental disclosures of cash flow information for non-cash transactions:		

# **ANALYSIS OF OPERATIONS BY LINES OF BUSINESS**

					TIONO D		1 -				
		1	2	3	4	5	6 Federal Employees	7 Title	8 Title	9	10
			Comprehensive	Medicare	Dental	Vision	Health	XVIII	XIX		Other
	Not a serious in serious	Total 1,634,306,387	(Hospital & Medical)	Supplement	Only	Only	Benefits Plan	Medicare	Medicaid	Other Health	Non-Health
	Net premium income	1,634,306,387	2,074,638	U		μυ	J	946,956,819	685,274,930		J
	rate credit	(49,918,114)	(38)	0	0	0	0	2,262,633	(52, 180, 709)	0	0
3.	Fee-for-service (net of \$0										
	medical expenses)	0	0	0	0	0	0	0	0	0	XXX
	Risk revenue	0	0	0	0	0	0	0	0	0	XXX
5.	Aggregate write-ins for other health care related revenues	0	0	0	0	0	ο	o	0	0	xxx
6.	Aggregate write-ins for other non-health care related revenues	0	xxx	xxx	XXX	xxx	xxx	xxx	xxx	XXX	0
7.	Total revenues (Lines 1 to 6)	1,584,388,273	2,074,600	0	0	0	0	949,219,452	633,094,221	0	0
	Hospital/medical benefits	1, 163, 786, 347	3,408,464	0	0	0	0	729,594,243	430,783,640	0	XXX
	Other professional services	11,853,665	6,722	0	0	0	0	11,846,943	0	0	XXX
	Outside referrals	0	0	0	0	0	0	0	0	0	XXX
11.	Emergency room and out-of-area	0	0	0	0	0	0	0	0	0	XXX
	Prescription drugs	162.516.582	519.191	0	0	0	0	46.779.438	115,217,953	0	XXX
	Aggregate write-ins for other hospital and medical	0	0	0	0	0	0	0	0	0	XXX
	Incentive pool, withhold adjustments and bonus amounts	15,074,979	(30,674)	0	0	0	0	8,333,892	6,771,761	0	XXX
	Subtotal (Lines 8 to 14)	1,353,231,573	3,903,703	0	0	0	0	796,554,516	552,773,354	0	XXX
	Net reinsurance recoveries	2,956,757	2,342,222	0	0	0	0	0	614,535	0	XXX
	Total medical and hospital (Lines 15 minus 16)	1,350,274,816	1,561,481	0	0	0	0	796.554.516	552.158.819	0	XXX
	Non-health claims (net)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
	Claims adjustment expenses including										
	\$42,012,771 cost containment expenses	55,244,420	417, 172	0	0	0	0	34.828.409	19.998.839	0	0
20.	General administrative expenses	100, 187, 979	50,304	0	0	0	0	70,848,309	29,289,366	0	0
	Increase in reserves for accident and health contracts	0	0	0	0	0	0	0	0	0	XXX
	Increase in reserves for life contracts	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
	Total underwriting deductions (Lines 17 to 22)	1,505,707,215	2,028,957	0	0	0	0	902,231,234	601,447,024	0	0
	Total underwriting gain or (loss) (Line 7 minus Line 23)	78.681.058	45.643	0	0	0	0	46.988.218	31.647.197	0	0
	DETAILS OF WRITE-INS	70,001,000	10,010	-	-	,		10,000,210	01,011,101	<u> </u>	2004
000											XXX
0502.											XXX
0503. 0598.	Summary of remaining write-ins for Line 5 from overflow										XXX
0500	page	9	<u> </u>		0	0	ļ0		0	0	XXX
	Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	0	0	0	0		0	<u> </u>	0	0	XXX
0601.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0602.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0603.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0698.	Summary of remaining write-ins for Line 6 from overflow		VVV	VVV	VVV	VVV	VVV	VVV	VVV	VVV	_
0699.	page	0	XXX XXX	XXX XXX	XXX XXX	XXX	XXX XXX	XXX XXX	XXX XXX	XXX XXX	0
	Totals (Liftes 000 Ftfffu 0003 plus 0098) (Lifte 6 above)	0	^^X	<b>^^</b>	٨٨٨	^**	***	<b>^^^</b>	^^^	<b>^^</b>	V00/
1301.						<del> </del>					XXX
1302.						<del> </del>					XXX
1303.											XXX
	Summary of remaining write-ins for Line 13 from overflow page	0	0	0	0	0	0	0	0	0	xxx
1399.	Totals (Lines 1301 thru 1303 plus 1398) (Line 13 above)	0	0	0	0	0	0	0	0	0	XXX

## **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 1 - PREMIUMS

	1	2	3	4
Line of Business	Direct Business	Reinsurance Assumed	Reinsurance Ceded	Net Premium Income (Cols. 1 + 2 - 3)
Comprehensive (hospital and medical)	5,225,015	0	3, 150, 377	2,074,638
2. Medicare Supplement	0	0	0	0
3. Dental only	0	0	0	0
4. Vision only	0	0	0	0
5. Federal Employees Health Benefits Plan	0	0	0	0
6. Title XVIII - Medicare	947,904,609	0	947,790	946,956,819
7. Title XIX - Medicaid	687,088,473	0	1,813,544	685,274,929
8. Other health	0	0	0	0
9. Health subtotal (Lines 1 through 8)	1,640,218,097	0	5,911,711	1,634,306,386
10. Life	0	0	0	0
11. Property/casualty	0	0	0	0
12. Totals (Lines 9 to 11)	1,640,218,097	0	5,911,711	1,634,306,386

# **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2 - CLAIMS INCURRED DURING THE YEAR

				PART 2 - CLA	MS INCURRED DU	RING THE TEAR					
		1	2	3	4	5	6 Federal	7	8	9	10
		Total	Comprehensive (Hospital & Medical)	Medicare Supplement	Dental Only	Vision Only	Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Other Health	Other Non-Health
1	Payments during the year:		, ,	''	,					-	
	1.1 Direct	1,370,049,154	3,724,483	0	0	0	0	790,642,482	575,682,189	0	0
	1.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
	1.3 Reinsurance ceded	2.399.640	2,350,889	0	0	0	0	(120)	48,871	0	0
	1.4 Net	1,367,649,514	1,373,594	0	0	0	0	790,642,602	575,633,318	0	0
2.		21, 188, 971	51	0	0	0	0	15,954,165	5,234,755	0	 O
3.	· · · · · · · · · · · · · · · · · · ·	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		-					, , , , , , , ,		
٠.	3.1 Direct	131,218,432	495,558	0	0	0	0	100,161,976	30,560,898	0	0
	3.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	 O
	3.3 Reinsurance ceded		244,957	0	0	0	0	70	565,663	0	0
	3.4 Net	130.407.742	250,601	0	0	0	0	100,161,906	29,995,235	0	0
4	Claim reserve December 31, current year from Part 2D:							,,			
	4.1 Direct	732,870	11,462	0	0	0	0	206.684	514,724	0	0
	4.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
	4.3 Reinsurance ceded	6,877	6.877	0	0	0	0	0	0	0	
	4.4 Net	725.993	4.585	0	0	0	0	206.684	514.724	0	0
5.			, 000								
0.	year	11,079,616	44,525	0	0	0	0	5,788,319	5,246,772	0	0
6.	•	4,479,344	(90,513)	0	0	0	0	4,153,645	416,212	0	0
7.	` '	, ,,,	, , , , , ,					,,	,		
	current year	170,577	170,647	0	0	0	0	(70)	0	0	0
8.	Claim liability December 31, prior year from Part 2A:										
	8.1 Direct	158,487,321	378,553	0	0	0	0	98,500,163	59,608,605	0	0
	8.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
	8.3 Reinsurance ceded	120,396	120,446	0	0	0	0	(50)	0	0	0
	8.4 Net	158,366,925	258,107	0	0	0	0	98,500,213	59,608,605	0	0
9.	Claim reserve December 31, prior year from Part 2D:										
	9.1 Direct	877, 197	9,086	0	0	0	0	136,710	731,401	0	0
	9.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
	9.3 Reinsurance ceded	5,451	5,451	0	0	0	0	0	0	0	0
	9.4 Net	871,746	3,635	0	0	0	0	136,710	731,401	0	0
10.	Accrued medical incentive pools and bonuses, prior year	17, 175, 207	56,848	0	0	0	0	13,408,593	3,709,766	0	0
11.	Amounts recoverable from reinsurers December 31,	, ,	,					, ,	, ,		
	prior year	286,779	286,849	0	0	0	0	(70)	0	0	0
12.	Incurred Benefits:										
	12.1 Direct	1,338,156,594	3,934,377	0	0	0	0	788,220,624	546,001,593	0	0
	12.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
	12.3 Reinsurance ceded	2,975,158	2,360,624	0	0	0	0	0	614,534	0	0
	12.4 Net	1,335,181,436	1,573,753	0	0	0	0	788,220,624	545,387,059	0	0
13.	Incurred medical incentive pools and bonuses	15,093,380	(12,272)	0	0	0	0	8,333,891	6.771.761	0	0

<sup>(</sup>a) Excludes \$ ......0 loans or advances to providers not yet expensed.

### **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2A - CLAIMS LIABILITY END OF CURRENT YEAR

			PART ZA - CLAIN	NO LIADILITY END	JE CURKENI TEAR	N				
	1	2 Comprehensive	3 Medicare	4	5	6 Federal Employees Health	7 Title XVIII	8 Title XIX	9	10 Other
	Total	(Hospital & Medical)	Supplement	Dental Only	Vision Only	Benefits Plan	Medicare	Medicaid	Other Health	Non-Health
Reported in Process of Adjustment:										
1.1 Direct	60,624,212	95,858	0	0	0	0	45,486,087	15,042,267	0	0
1.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
1.3 Reinsurance ceded	5, 163	5,093	0	0	0	0	70	0	0	0
1.4 Net	60,619,049	90,765	0	0	0	0	45,486,017	15,042,267	0	0
Incurred but Unreported:										
2.1 Direct	68,609,530	399,700	0	0	0	0	52,691,199	15,518,631	0	0
2.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
2.3 Reinsurance ceded	805,527	239,864	0	0	0	0	0	565,663	0	0
2.4 Net	67,804,003	159,836	0	0	0	0	52,691,199	14,952,968	0	0
Amounts Withheld from Paid Claims and Capitations:										
3.1 Direct	1,984,690	0	0	0	0	0	1,984,690	0	0	0
3.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
3.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
3.4 Net	1,984,690	0	0	0	0	0	1,984,690	0	0	0
4. TOTALS:										
4. 101ALS.	131,218,432	495,558	0	0	0	0	100,161,976	30,560,898	0	0
4.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
4.3 Reinsurance ceded	810,690	244,957	0	0	0	0	70	565,663	0	0
4.4 Net	130,407,742	250,601	0	0	0	0	100,161,906	29,995,235	0	0

### **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2B - ANALYSIS OF CLAIMS UNPAID - PRIOR YEAR - NET OF REINSURANCE

PART 2B - ARAL 1313 OF CLAIMS O	Claims Paid During the Year			nd Claim Liability of Current Year	5	6
	1	2	3	4		Estimated Claim Reserve and Claim
	On Claims Incurred Prior to January 1	On Claims Incurred	On Claims Unpaid December 31 of	On Claims Incurred	Claims Incurred In Prior Years	Liability December 31 of
Line of Business	of Current Year	During the Year	Prior Year	During the Year	(Columns 1 + 3)	Prior Year
Comprehensive (hospital and medical)	96,449	1,393,344	0	255 , 187	96,449	261,742
Medicare Supplement	0	0	0	0	0	0
3. Dental Only	0	0	0	0	0	0
4. Vision Only	0	0	0	0	0	0
Federal Employees Health Benefits Plan	0	0	0	0	0	0
6. Title XVIII - Medicare	64,910,911	725,731,691	248,841	100, 119, 750	65, 159, 752	98,636,924
7 Title XIX - Medicaid	54,204,667	521,428,651	1,269,043	29,240,914	55,473,710	60,340,006
8. Other health	0	0	0	0	0	0
9. Health subtotal (Lines 1 to 8)	119,212,027	1,248,553,686	1,517,884	129,615,851	120,729,911	159,238,672
10. Healthcare receivables (a)		28,317,369	0	2,565,018	752,002	27, 155,046
11. Other non-health	0	0	0	0	0	0
12. Medical incentive pools and bonus amounts	18,677,617	2,511,356	1,996,160	9,083,458	20,673,777	17, 175, 208
13. Totals (Lines 9 - 10 + 11 + 12)	137,137,642	1,222,747,673	3,514,044	136, 134, 291	140,651,686	149,258,834

### **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Comprehensive (Hospital & Medical)

	,	Cumulative Net Amounts Paid							
	1	2	3	4	5				
Year in Which Losses Were Incurred	2017	2018	2019	2020	2021				
1. Prior	(263)	(260)	(259)	(248)	(247)				
2. 2017	3,529	3,184	3, 184	3,184	3, 187				
3. 2018	XXX	3,311	3,200	3,200	3, 189				
4. 2019	XXX	XXX	1,934	1,821	1,820				
5. 2020	XXX	XXX	XXX	1,817	1,637				
6. 2021	XXX	XXX	XXX	XXX	1,564				

Section B - Incurred Health Claims - Comprehensive (Hospital & Medical)

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bo Outstanding at End of Year						
Year in Which Losses Were Incurred	1 2017	2 2018	3 2019	4 2020	5 2021		
1. Prior	(226)	(260)	(259)	(248)	(247)		
2. 2017	4,017	3,207	3,184	3,184	3, 187		
3. 2018	xxx	4,033	3,212	3,200	3, 189		
4. 2019	xxx	XXX	2,319	1,842	1,820		
5. 2020	XXX	XXX	XXX	2,114	1,660		
6. 2021	XXX	XXX	XXX	XXX	1,840		

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Comprehensive (Hospital & Medical)

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2017	4,390	3, 187	1,080	33.9	4,267	97.2	0	0	4,267	97.2
2	2018	3,997	3, 189	329	10.3	3,518	88.0	0	0	3,518	88.0
3.	2019	2,545	1,820	317	17.4	2,137	84.0	0	0	2,137	84.0
4.	2020	2,515	1,637	298	18.2	1,935	76.9	24	0	1,959	77.9
5.	2021	2,075	1,564	375	24.0	1,939	93.4	276	(2)	2,213	106.7

### **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Title XVIII

		Cumulative Net Amounts Paid						
		1	2	3	4	5		
	Year in Which Losses Were Incurred	2017	2018	2019	2020	2021		
1.	Prior	32,655	32,784	32,825	32,630	32,569		
2.	2017	328,111	374,232	374,495	373,775	373,709		
3.	2018	XXX	464,092	518,853	519,062	518,948		
4.	2019	XXX	XXX	579,095	643,632	643,636		
5.	2020	XXX	XXX	XXX	605,101	683,687		
6.	2021	XXX	XXX	XXX	XXX	728,243		

#### Section B - Incurred Health Claims - Title XVIII

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool ar Outstanding at End of Year						
	1 2 3						
Year in Which Losses Were Incurred	2017	2018	2019	2020	2021		
1. Prior	34 , 180	32,784	32,825	32,629	32,569		
2. 2017	390,524	376 , 174	374,495	373,775	373,709		
3. 2018	XXX	540,720	520,896	519,061	518,948		
4. 2019	XXX	XXX	669,533	643,852	643,636		
5. 2020	XXX	XXX	XXX	716,927	683,693		
6. 2021	XXX	XXX	XXX	XXX	834,393		

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Title XVIII

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2017	454 , 190	373,709	17,061	4.6	390,770	86.0	0	0	390,770	86.0
2.	2018	631,597	518,948	27,742	5.3	546,690	86.6	0	0	546,690	86.6
3.	2019	788,396	643,636	33,440	5.2	677,076	85.9	0	0	677,076	85.9
4.	2020	877,530	683,687	32,387	4.7	716,074	81.6	365	3	716,442	81.6
5.	2021	949,219	728,243	29,966	4.1	758,209	79.9	105,792	788	864,789	91.1

### **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Title XIX

	Cumulative Net Amounts Paid						
	1	2	3	4	5		
Year in Which Losses Were Incurred	2017	2018	2019	2020	2021		
1. Prior	28,121	28,391	28,101	28,088	28,084		
2. 2017	445,746	481,745	481,802	481,422	481,414		
3. 2018	XXX	417,471	442,639	443,156	443, 106		
4. 2019	XXX	XXX	428 , 148	470,465	477,378		
5. 2020	xxx	XXX	XXX	437 , 128	489,716		
6. 2021	XXX	XXX	XXX	XXX	521,429		

#### Section B - Incurred Health Claims - Title XIX

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bon Outstanding at End of Year						
	1 2 3 4						
Year in Which Losses Were Incurred	2017	2018	2019	2020	2021		
1. Prior	28,774	28,391	28,101	28,088	28,084		
2. 2017	483,072	482,360	481,802	481,422	481,414		
3. 2018	XXX	456,209	449,238	443,156	443, 106		
4. 2019	XXX	XXX	480,043	478,877	477,378		
5. 2020	XXX	XXX	XXX	492,766	492,841		
6. 2021	XXX	XXX	XXX	XXX	554,060		

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Title XIX

Years in which Premiums were Earned and Claims were Incurred	1 Premiums Earned	2 Claims Pavment	3 Claim Adjustment Expense Payments	4 (Col. 3/2) Percent	5 Claim and Claim Adjustment Expense Payments (Col. 2 + 3)	6 (Col. 5/1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	10 (Col. 9/1) Percent
1. 2017	515,876	481,414	18,194	3.8	499,608	96.8	0	0	499,608	96.8
2. 2018	525,249	443, 106	22,613	5.1	465,719	88.7	0	0	465,719	88.7
3. 2019	514,288	477,378	22,921	4.8	500,299	97.3	0	0	500,299	97.3
4. 2020	553,607	489,716	19,202	3.9	508,918	91.9	3, 125	15	512,058	92.5
5. 2021	633,094	521,429	17,331	3.3	538,760	85.1	32,632	204	571,596	90.3

### **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted) Section A - Paid Health Claims - Grand Total

		Cumulative Net Amounts Paid						
		1	2	3	4	5		
	Year in Which Losses Were Incurred	2017	2018	2019	2020	2021		
1.	Prior	60,513	60,915	60,667	60,470	60,406		
2.	2017	777,386	859,161	859,481	858,381	858,310		
3.	2018	XXX	884,874	964,692	965,418	965,243		
4.	2019	XXX	XXX	1,009,177	1, 115, 918	1, 122, 834		
5.	2020	XXX	XXX	XXX	1,044,046	1, 175, 040		
6.	2021	XXX	XXX	XXX	XXX	1,251,236		

#### Section B - Incurred Health Claims - Grand Total

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonus Outstanding at End of Year						
Year in Which Losses Were Incurred	1 2017	2 2018	3 2019	4 2020	5 2021		
1. Prior	62,728	60,915	60,667	60,469	60,406		
2. 2017	877,613	861,741	859,481	858,381	858,310		
3. 2018	XXX	1,000,962	973,346	965,417	965,243		
4. 2019	XXX	XXX	1, 151,895	1, 124,571	1, 122, 834		
5. 2020	XXX	XXX	XXX	1,211,807	1, 178, 194		
6. 2021	XXX	XXX	XXX	XXX	1,390,293		

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Grand Total

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2017	974,456	858,310		4.2	894,645	91.8	0	0	894,645	91.8
2.	2018	1,160,843	965,243	50,684	5.3	1,015,927	87.5	0	0	1,015,927	87.5
3.	2019	1,305,229	1, 122, 834	56,678	5.0	1,179,512	90.4	0	0	1,179,512	90.4
4.	2020	1,433,652	1,175,040	51,887	4.4	1,226,927	85.6	3,514	18	1,230,459	85.8
5.	2021	1,584,388	1,251,236	47,672	3.8	1,298,908	82.0	138,700	990	1,438,598	90.8

### $\frac{1}{3}$

# **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY

PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY												
	1 Total	2 Comprehensive (Hospital & Medical)	3 Medicare Supplement	4 Dental Only	5 Vision Only	6 Federal Employees Health Benefits Plan	7 Title XVIII Medicare	8 Title XIX Medicaid	9 Other			
Unearned premium reserves				•	Vision Only	Deficitis Fiam	Medicare	Medicald	Other			
1	286	286	0	0	0	0	0	0	0			
Additional policy reserves (a)	0	0	0	0	0	0	0	0	0			
Reserve for future contingent benefits	0	0	0	0	0	0	0	0	0			
Reserve for rate credits or experience rating refunds (including												
\$0 ) for investment income	72,815,130	0	0	0	0	0	25,373,835	47,441,295	0			
Aggregate write-ins for other policy reserves	116,060	20,280	0	0	0	0	95,780	0	0			
6. Totals (gross)	72,931,476	20,566	0	0	0	0	25,469,615	47,441,295	0			
7. Reinsurance ceded	0	0	0	0	0	0	0	0	0			
8. Totals (Net)(Page 3, Line 4)	72,931,476	20,566	0	0	0	0	25,469,615	47,441,295	0			
Present value of amounts not yet due on claims	0	0	0	0	0	0	0	0	0			
Reserve for future contingent benefits	732.870	11,462	0	0	0	0	206.684	514.724	0			
11. Aggregate write-ins for other claim reserves	0	0	0	0	0	0	0	0	0			
12. Totals (gross)	732,870	11,462	0	0	0	0	206,684	514 , 724	0			
13. Reinsurance ceded		6.877	0	0	0	0	0	0	0			
14. Totals (Net)(Page 3, Line 7)	725,993	4,585	0	0	0	0	206,684	514,724	0			
DETAILS OF WRITE-INS												
0501. Medicare Risk Adjustment Payable	95,780	0	0	0	0	0	95,780	0	0			
0502. High-Cost Risk Pool Payable	20,280	20,280	0	0	0	0	0	0	0			
0503.												
0598. Summary of remaining write-ins for Line 5 from overflow page	0	0	0	0	0	0	0	0	0			
0599. Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	116,060	20,280	0	0	0	0	95,780	0	0			
1101.							,					
1102.												
1103.												
1198. Summary of remaining write-ins for Line 11 from overflow page	0	0	0	0	0	0	0	0	0			
1199. Totals (Lines 1101 thru 1103 plus 1198) (Line 11 above)	0	0	0	0	0	0	0	0	n			

(a) Includes \$ \_\_\_\_\_\_0 premium deficiency reserve.

### **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 3 - ANALYSIS OF EXPENSES

		Claim Adjustme	nt Expenses	3	4	5
		1 Cost Containment Expenses	2 Other Claim Adjustment Expenses	General Administrative Expenses	Investment Expenses	Total
1.	Rent (\$0 for occupancy of		·	·	•	
	own building)	1,240,299	365,850	2,009,262	0	3,615,41
2.	Salary, wages and other benefits	21,622,669	6,378,022	35,028,337	0	63,029,02
3.	Commissions (less \$0					
	ceded plus \$0 assumed)	0	0	14,709,921	0	14,709,92
4.	Legal fees and expenses	191,539	56,498	310,290	0	558,32
5.	Certifications and accreditation fees		0		0	
6.	Auditing, actuarial and other consulting services			3,772,167		6.767.79
7.	Traveling expenses		64,246		0	634,8
8.	Marketing and advertising		375,584		0	,
9.	Postage, express and telephone		268,119		0	
10.	Printing and office supplies		466,048		0	
11.	Occupancy, depreciation and amortization		, i		0	
12.	Equipment		52.925		0	
13.	Cost or depreciation of EDP equipment and		52,020	200,000		
10.	software	2,345,869	691,959	3,800,266	0	6,838,0
14.	Outsourced services including EDP, claims, and other services	2 260 001	1 625 222	2 655 227	0	7 551 5
15	Boards, bureaus and association fees			47,106		
15.				684,738		
16.	Insurance, except on real estate					
17.	Collection and bank service charges		40,943	•	0	
18.	Group service and administration fees		•	1,357,807		
19.	Reimbursements by uninsured plans				0	
20.	Reimbursements from fiscal intermediaries			0		
21.	Real estate expenses			0		
22.	Real estate taxes	37,794	15,805	112,528	0	166 , 1
23.	Taxes, licenses and fees:					
	23.1 State and local insurance taxes			, ,	0	
	23.2 State premium taxes		0		0	
	23.3 Regulatory authority licenses and fees					
	23.4 Payroll taxes	711,924	296,992	2,094,284	0	3,103,2
	23.5 Other (excluding federal income and real estate taxes)	0	0	0	0	
24.					204,947	204,9
25.	Aggregate write-ins for expenses	5.500.352	1,401,557	7,505,533	0	14,407,4
26.	Total expenses incurred (Lines 1 to 25)	-,,	13,231,649		204,947	, ,
27.	Less expenses unpaid December 31, current year				113,061	(a)6,412,9
28.	Add expenses unpaid December 31, prior year		271,040		0	9,948,9
29.	Amounts receivable relating to uninsured plans, prior year		,	, ,	0	
30.	Amounts receivable relating to uninsured plans, current year	0	0	18,389,215	0	18,389,2
31.	Total expenses paid (Lines 26 minus 27 plus 28 minus 29 plus 30)	42, 125, 125	13,269,156	109, 163, 128	91,886	164,649,2
	DETAILS OF WRITE-INS					
2501.	Sundry General Expenses	4,667,524	1,157,752	6,665,636	0	12,490,9
2502.	Professional Fees/Consulting	611,923	180,498	991,304	0	1,783,7
2503.	Information Technology	177,446	52,341	287,459	0	517,2
2598.			10,966	(438,866)	0	(384,4
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25					

### **EXHIBIT OF NET INVESTMENT INCOME**

		1	2
		Collected During Year	_
1.	U.S. government bonds		
1.1	Bonds exempt from U.S. tax		
1.2	Other bonds (unaffiliated)	` '	
1.3	Bonds of affiliates	* *	, ,
2.1	Preferred stocks (unaffiliated)	· /	
2.11	Preferred stocks of affiliates		0
2.2	Common stocks (unaffiliated)		0
2.21	Common stocks of affiliates	0	0
3.	Mortgage loans		
4.	Real estate		
5	Contract Loans		
6	Cash, cash equivalents and short-term investments		
7	Derivative instruments	(f)0	0
8.	Other invested assets		0
9.	Aggregate write-ins for investment income		0
10.	Total gross investment income	5,682,307	5,542,048
11.	Investment expenses		(g)204,947
12.	Investment taxes, licenses and fees, excluding federal income taxes		(g)0
13.	Interest expense		(h)0
14.	Depreciation on real estate and other invested assets		(i)0
15.	Aggregate write-ins for deductions from investment income		
16.	Total deductions (Lines 11 through 15)		
17.	Net investment income (Line 10 minus Line 16)		5,337,101
	DETAILS OF WRITE-INS		
0901.			
0902.			
0903.			
0998.	, ,	0	
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9, above)	0	0
1501.			
1502.			
1503.			
1598.	Summary of remaining write-ins for Line 15 from overflow page		
1599.	Totals (Lines 1501 thru 1503 plus 1598) (Line 15, above)		0
(a) Inclu	des\$	55 paid for accrued int	erest on purchases.
(b) Inclu	des \$0 accrual of discount less \$0 amortization of premium and less \$	0 paid for accrued div	vidends on purchases.
(c) Inclu	des \$0 accrual of discount less \$0 amortization of premium and less \$	0 paid for accrued int	erest on purchases.
(d) Inclu	des \$	ncumbrances.	
(e) Inclu	des \$	37 paid for accrued int	erest on purchases.
(f) Inclu	des \$0 accrual of discount less \$0 amortization of premium.		
	des \$0 investment expenses and \$0 investment taxes, licenses and fees, excluding fregated and Separate Accounts.	ederal income taxes, att	ributable to

**EXHIBIT OF CAPITAL GAINS (LOSSES)** 

(i) Includes \$ \_\_\_\_\_0 depreciation on real estate and \$ \_\_\_\_\_0 depreciation on other invested assets.

		1	2	3	4	5
				T		
		D " 10 ' " )	0" " '	Total Realized Capital	Change in	Change in Unrealized
		Realized Gain (Loss)	Other Realized	Gain (Loss)	Unrealized Capital	Foreign Exchange
-		On Sales or Maturity	Adjustments	(Columns 1 + 2)	Gain (Loss)	Capital Gain (Loss)
1.	U.S. Government bonds		0	1,594,172	28,083	0
1.1	Bonds exempt from U.S. tax	0	0	0	0	0
1.2	Other bonds (unaffiliated)	165	0	165	0	0
1.3	Bonds of affiliates	0	0	0	0	0
2.1	Preferred stocks (unaffiliated)	0	0	0	0	0
2.11	Preferred stocks of affiliates	0	0	0	0	0
2.2	Common stocks (unaffiliated)	0	0	0	0	0
2.21	Common stocks of affiliates	0	0	0	0	0
3.	Mortgage loans	0	0	0	0	0
4.	Real estate	0	0	0	0	0
5.	Contract loans	0	0	0	0	0
6.	Cash, cash equivalents and short-term investments	0	0	0	0	0
7.	Derivative instruments	0	0	0	0	0
8.	Other invested assets	0	0	0	0	0
9.	Aggregate write-ins for capital gains (losses)	0	0	0	0	0
10.	Total capital gains (losses)	1,594,337	0	1,594,337	28,083	0
	DETAILS OF WRITE-INS					
0901.						
0902.						
0903.						
0998.	Summary of remaining write-ins for Line 9 from					
0030.	overflow page	0	0	0	0	0
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9, above)	0	0	0	n	0
	above)	U	U	U	U	U

# **EXHIBIT OF NON-ADMITTED ASSETS**

	EXHIBIT OF NON-ADMITTE	DASSETS		2
		1 Current Year Total Nonadmitted Assets	2 Prior Year Total Nonadmitted Assets	3 Change in Total Nonadmitted Assets (Col. 2 - Col. 1)
1.	Bonds (Schedule D)	_	0	0
	Stocks (Schedule D):			
	2.1 Preferred stocks	0	0	0
	2.2 Common stocks	_	0	
3.	Mortgage loans on real estate (Schedule B):			
J.	3.1 First liens	0	0	0
	3.2 Other than first liens.		0	
	Real estate (Schedule A):	0		0
4.	4.1 Properties occupied by the company	0	0	0
	4.1 Properties occupied by the company			
			0	
_	4.3 Properties held for sale	0	0	
5.	Cash (Schedule E - Part 1), cash equivalents (Schedule E - Part 2) and short-term investments (Schedule DA)			
6.	Contract loans			
7.	Derivatives (Schedule DB)			0
8.	Other invested assets (Schedule BA)			0
9.	Receivables for securities			
10.	Securities lending reinvested collateral assets (Schedule DL)			0
11.	Aggregate write-ins for invested assets			
12.	Subtotals, cash and invested assets (Lines 1 to 11)			
13.	Title plants (for Title insurers only)			
14.	Investment income due and accrued	0	0	0
15.	Premiums and considerations:			
	15.1 Uncollected premiums and agents' balances in the course of collection	283,618	346,676	63,058
	15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due	0	0	0
	15.3 Accrued retrospective premiums and contracts subject to redetermination	0	0	0
16.	Reinsurance:			
	16.1 Amounts recoverable from reinsurers			0
	16.2 Funds held by or deposited with reinsured companies	0	0	0
	16.3 Other amounts receivable under reinsurance contracts	0	0	0
17.	Amounts receivable relating to uninsured plans	28,891	5,827	(23,064)
18.1	Current federal and foreign income tax recoverable and interest thereon	0	0	0
18.2	Net deferred tax asset	0	0	0
19.	Guaranty funds receivable or on deposit	0	0	0
20.	Electronic data processing equipment and software	0	0	0
21.	Furniture and equipment, including health care delivery assets	0	0	0
22.	Net adjustment in assets and liabilities due to foreign exchange rates		0	0
23.	Receivable from parent, subsidiaries and affiliates			0
24.	Health care and other amounts receivable			452,903
25.	Aggregate write-ins for other than invested assets		394	269
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)		2,015,945	493, 166
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts		0	0
28.	Total (Lines 26 and 27)	1,522,779	2,015,945	493, 166
	DETAILS OF WRITE-INS			
1101.				
1102.				
1103.				
1198.	Summary of remaining write-ins for Line 11 from overflow page	0	0	0
1199.	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0	0	0
2501.	Prepaid Expenses		394	269
2501.	ттерати схреноез	123		209
2502.				
2503. 2598.	Summary of remaining write-ins for Line 25 from overflow page		Λ	0
			JO.4	
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	125	394	269

### **EXHIBIT 1 - ENROLLMENT BY PRODUCT TYPE FOR HEALTH BUSINESS ONLY**

			Total Members at End of			6	
Source of Enrollment	1 Prior Year	2 First Quarter	3 Second Quarter	4 Third Quarter	5 Current Year	Current Year Member Months	
Health Maintenance Organizations	1,031	176,799	178,379	179,989	180,005	2, 141,709	
Provider Service Organizations	0	0	0	0	0	0	
Preferred Provider Organizations	0	0	0	0	0	0	
4. Point of Service	0	0	0	0	0	0	
5. Indemnity Only	0	0	0	0	0	0	
Aggregate write-ins for other lines of business.	171,639	0	0	0	0	0	
7. Total	172,670	176,799	178,379	179,989	180,005	2,141,709	
DETAILS OF WRITE-INS							
O601. Medicare		0	0	0	0	0	
0602. Medicaid	92,736	0	0	0	0	0	
0603.							
0698. Summary of remaining write-ins for Line 6 from overflow page	0	0	0	0	0	0	
0699. Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	171,639	0	0	0	0	0	

#### UNITEDHEALTHCARE OF NEW ENGLAND, INC.

# NOTES TO STATUTORY BASIS FINANCIAL STATEMENTS AS OF AND FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020

#### 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND GOING CONCERN

#### **Organization and Operation**

UnitedHealthcare of New England, Inc (the "Company"), licensed as a health maintenance organization ("HMO"), offers its enrollees a variety of managed care programs and products through contractual arrangements with health care providers. The Company is a wholly owned subsidiary of United HealthCare Services, Inc. ("UHS"), a management corporation that provides services to the Company under the terms of a management agreement (the "Agreement"). UHS is a wholly owned subsidiary of UnitedHealth Group Incorporated ("UnitedHealth Group"). UnitedHealth Group is a publicly held company trading on the New York Stock Exchange.

The Company was incorporated on November 14, 1984, as an HMO and operations commenced in December 27, 1984. The Company is certified as an HMO by the Rhode Island Department of Business Regulation (the "Department"), Massachusetts Division of Insurance, New Hampshire Insurance Department, Vermont Department of Financial Protection – Insurance Division, and Pennsylvania Insurance Department. The Company has entered into contracts with physicians, hospitals, and other health care provider organizations to deliver health care services for all enrollees.

The Company offers comprehensive commercial products to individual and employer groups. Each contract outlines the coverage provided and renewal provisions.

The Company serves as a plan sponsor offering Medicare Parts A and B, along with Medicare Part D prescription drug insurance coverage, (collectively "Medicare Plans") under contracts with the Centers for Medicare and Medicaid Services ("CMS").

The Company has a contract with the State of Rhode Island and Providence Plantations, Department of Human Services, to provide health care services to Medicaid eligible beneficiaries in Rhode Island. The current contract is effective through June 30, 2022, and is subject to annual renewal provisions thereafter.

#### A. Accounting Practices

The statutory basis financial statements (herein referred to as "financial statements") are presented on the basis of accounting practices prescribed or permitted by the Department.

The Department recognizes only statutory accounting practices, prescribed or permitted by the State of Rhode Island (the "State"), for determining and reporting the financial condition and results of operations of an HMO, for determining its solvency under Rhode Island Insurance Law. The State prescribes the use of the National Association of Insurance Commissioners' ("NAIC") Accounting Practices and Procedures manual ("NAIC SAP") in effect for the accounting periods covered in the financial statements.

No significant differences exist between the practices prescribed or permitted by the State and the NAIC SAP which materially affect the statutory basis net income and capital and surplus, as illustrated in the table below:

Nat	to come	SSAP#	F/S Page #	F/S Line #	December 31, 2021	December 31, 2020
Net	Income					
(1)	Company state basis (Page 4, Line 32, Columns 2 & 3)	XXX	XXX	XXX	\$ 67,172,242	\$ 49,489,810
(2)	State prescribed practices that are an increase/(decrease) from NAIC SAP:					
(3)	Not Applicable State permitted practices that are an increase/(decrease) from NAIC SAP: Not Applicable				- -	- -
(4)	NAIC SAP (1 - 2 - 3 = 4)	XXX	XXX	XXX	\$ 67,172,242	\$ 49,489,810
Cap	oital and Surplus					
(5)	Company state basis (Page 3, Line 33, Columns 3 & 4)	XXX	XXX	XXX	\$ 206,184,444	\$ 204,411,638
(6)	State prescribed practices that are an increase/(decrease) from NAIC SAP:					
	Not Applicable				-	-
(7)	State permitted practices that are an increase/(decrease) from NAIC SAP: Not Applicable				_	_
(8)	NAIC SAP (5 - 6 - 7 = 8)	XXX	XXX	XXX	\$ 206,184,444	\$ 204,411,638

#### B. Use of Estimates in the Preparation of the Financial Statements

The preparation of these financial statements in conformity with the NAIC Annual Statement Instructions and the NAIC SAP include certain amounts that are based on the Company's estimates and judgments. These estimates require the Company to apply complex assumptions and judgments, often because the Company must make estimates about the effects of matters that are inherently uncertain and will change in subsequent periods. The most significant estimates relate to hospital and medical benefits, claims unpaid, aggregate health policy reserves (including medical loss ratio ("MLR") rebates), aggregate health claim reserves, risk corridor, and risk adjustment estimates. The Company adjusts these estimates each period as more current information becomes available. The impact of any changes in estimates is included in the determination of net income in the period in which the estimate is adjusted.

#### C. Accounting Policy

**Basis of Presentation** — The Company prepares its financial statements on the basis of accounting practices prescribed or permitted by the Department. These statutory practices differ from accounting principles generally accepted in the United States of America ("GAAP").

Accounting policy disclosures that are required by the NAIC Annual Statement instructions are as follows:

- (1–2) Bonds are stated at book/adjusted carrying value if they meet NAIC designation of one or two and stated at the lower of book/adjusted carrying value or fair value if they meet an NAIC designation of three or higher The Company does not have any mandatory convertible securities or Investment Analysis Office of the NAIC ("IAO") identified funds (i.e.: exchange traded funds or bond mutual funds) in its bond portfolio. Amortization of bond premium or accretion of discount is calculated using the constant-yield interest method. Bonds and short-term investments are valued and reported using market prices published by the IAO in accordance with the NAIC Valuation of Securities manual prepared by the IAO or an external pricing service;
- (3-4) The Company holds no common or preferred stock;
- (5) The Company holds no mortgage loans on real estate;

- (6) U.S. government and agency securities and corporate debt securities include loan-backed securities (mortgage-backed securities and asset-backed securities), which are valued using the retrospective adjustment methodology. Prepayment assumptions for the determination of the book/adjusted carrying value, commonly referred to as amortized cost, of loan-backed securities are based on a three-month constant prepayment rate history obtained from external data source vendors. The Company's investment policy limits investments in nonagency residential mortgage-backed securities, including home equity and sub-prime mortgages, to 10% of total cash and invested assets. Total combined investments in mortgage-backed securities and asset-backed securities cannot exceed more than 30% of total cash and invested assets;
- (7) The Company holds no investments in subsidiaries, controlled, or affiliated entities;
- (8) The Company has no investment interests with respect to joint ventures, partnerships, or limited liability companies;
- (9) The Company holds no derivatives;
- (10) Premium Deficiency Reserves ("PDR") (inclusive of conversion reserves) and the related expenses are recognized when it is probable that expected future health care expenses, claims adjustment expenses ("CAE") direct administration costs, and an allocation of indirect administration costs under a group of existing contracts will exceed anticipated future premiums and reinsurance recoveries considered over the remaining lives of the contracts, and are recorded as aggregate health policy reserves in the financial statements. Indirect administration costs arise from activities that are not specifically identifiable to a specific group of existing contracts, and therefore, those costs are fully allocated among the various contract groupings. The allocation of indirect administration costs to each contract grouping is made proportionately to the expected margins remaining in the premiums after future health care expenses, CAE and direct administration costs are considered. The data and assumptions underlying such estimates and the resulting reserves are periodically updated, and any adjustments are reflected as an increase or decrease in reserves for life and accident and health contracts in the financial statements in the period in which the change in estimate is identified. The Company does anticipate investment income as a factor in the PDR calculation (see Note 30);
- (11) CAE are those costs expected to be incurred in connection with the adjustment and recording of accident and health claims. Pursuant to the terms of the Agreement (see Note 10), the Company pays a management fee to its affiliate, UHS, in exchange for administrative and management services. A detailed review of the administrative expenses of the Company and UHS is performed to determine the allocation between CAE and general administrative expenses ("GAE") to be reported in the financial statements. It is the responsibility of UHS to pay CAE in the event the Company ceases operations. The Company has recorded an estimate of unpaid CAE associated with incurred but unpaid claims, which is included in unpaid CAE in the financial statements. Management believes the amount of the liability for unpaid CAE as of December 31, 2021 is adequate to cover the Company's cost for the adjustment and recording of unpaid claims; however, actual expenses may differ from those established estimates. Adjustments to the estimates for unpaid CAE, are reflected in operating results in the period in which the change in estimate is identified:
- (12) The Company does not carry any fixed assets in the financial statements;
- (13) Health care and other amounts receivable consist of pharmacy rebates receivable estimated based on the most currently available data from the Company's claims processing systems and from data provided by the Company's affiliated pharmaceutical benefit manager, OptumRx, Inc. ("OptumRx"). Health care and other amounts receivable also include receivables for amounts due to the Company for provider advances and claim overpayments to providers, hospitals and health care organizations, risk share receivables, and State stop loss receivables. Health care and other amounts receivable are considered nonadmitted assets under the NAIC SAP if they do not meet admissibility requirements. Accordingly, the Company has excluded receivables that do not meet the admissibility criteria from the financial statements (see Note 28).

The Company has also deemed the following to be significant accounting policies:

#### **ASSETS**

### Cash and Invested Assets

• Bonds include securities with a maturity of greater than one year at the time of purchase;

- Cash equivalents include securities that have original maturity dates of three months or less from the date of acquisition. Cash equivalents also consist of the Company's share of a qualified cash pool sponsored and administered by UHS. The investment pool is recorded at cost or book/adjusted carrying value depending on the composition of the underlying securities. Interest income from the pool accrues daily to participating members based upon ownership percentage. Cash equivalents, excluding money-market funds, are reported at cost or book/adjusted carrying value depending on the nature of the underlying security, which approximates fair value. Money-market funds are reported at fair value or net asset value ("NAV") as a practical expedient;
- Realized capital gains and losses on sales of investments are calculated based upon specific identification of the investments sold. These gains and losses are reported as net realized capital gains less capital gains tax in the financial statements;
- The Company continually monitors the difference between amortized cost and estimated fair value of its investments. If any of the Company's investments experience a decline in value that the Company has determined is other-than-temporary, or if the Company has determined it will sell a security that is in an impaired status, the Company will record a realized loss in net realized capital gains less taxes, in the financial statements. The new cost basis is not changed for subsequent recoveries in fair value. The prospective adjustment method is utilized for loan-backed securities for periods subsequent to the loss recognition (see Note 5).

#### Other Assets

• Premiums and Considerations — The Company reports uncollected premium balances from its insured members, groups, CMS, and state Medicaid agency as premiums and considerations in the financial statements. Uncollected premium balances that are over 90 days past due, with the exception of amounts due from government insured plans, are considered nonadmitted assets. In addition to those balances, current balances are also considered nonadmitted if the corresponding balance greater than 90 days past due is deemed more than inconsequential. Premiums and considerations also include amounts for commercial risk adjustment receivables as defined in Section 1343 of the Affordable Care Act ("ACA"), CMS risk corridor receivables, CMS risk adjustment receivables for the Medicare Plans, Medicaid performance guarantee receivables, and the Rhode Island risk share program's estimated accrued retrospective premiums. The Company has a risk share arrangement with the Rhode Island Executive Office of Health and Human Services ("EOHHS");

Premium adjustments for the CMS risk corridor and the Rhode Island risk share programs are accounted for as premium adjustments subject to retrospectively rated features (see Note 24). Premium adjustments for the commercial ACA Section 1343 risk adjustment, CMS risk adjustment, and Medicaid pay for performance programs are accounted for as premium adjustments subject to redetermination (see Note 24).

### **LIABILITIES**

Claims Unpaid and Aggregate Health Claim Reserves — Claims unpaid and aggregate
health claim reserves include claims processed but not yet paid, estimates for claims
received but not yet processed, estimates for the costs of health care services enrollees
have received but for which claims have not yet been submitted, and payments and
liabilities for physician, hospital, and other medical costs disputes.

The estimates for incurred but not yet reported claims are developed using an actuarial process that is consistently applied, centrally controlled, and automated. The actuarial models consider factors such as historical submission and payment data, cost trends, customer and product mix, seasonality, utilization of health care services, contracted service rates, and other relevant factors. The Company estimates such liabilities for physician, hospital, and other medical cost disputes based upon an analysis of potential outcomes, assuming a combination of litigation and settlement strategies. These estimates may change as actuarial methods change or as underlying facts upon which estimates are based change. The Company did not change actuarial methods during 2021 and 2020. Management believes the amount of claims unpaid and aggregate health claim reserves is a best estimate of the Company's liability for unpaid claims and aggregate health claim reserves as of December 31, 2021; however, actual payments may differ from those established estimates.

The Company contracts with hospitals, physicians, and other providers of health care under capitated or discounted fee for service arrangements, including a hospital per diem to provide medical care services to enrollees. Some of these contracts are with related parties (see Note 10). Capitated providers are at risk for the cost of medical care services provided to the Company's enrollees; however, the Company is ultimately responsible for the provision of services to its enrollees should the capitated provider be unable to provide the contracted services.

• Aggregate Health Policy Reserves —The Company establishes a liability, net of ceded reinsurance, for estimated accrued retrospective and redetermination premiums due from the Company based on the actuarial method and assumptions for each respective contract. Aggregate health policy reserves includes commercial risk adjustment payables as defined in Section 1343 of the ACA, CMS risk adjustment payables for the Medicare Plans, estimated MLR rebates payable on the comprehensive commercial and Medicare Plans, and the Rhode Island risk share program's with EOHHS.

Premium adjustments for the estimated MLR rebates are accounted for as premium adjustments subject to retrospectively rated features (see Note 24). Premium adjustments for the commercial ACA Section 1343 risk adjustment, CMS risk adjustment, and EOHHS risk adjustment are accounted for as premium adjustments subject to redetermination (see Note 24). PDR is specifically outlined in Note 30.

 Premiums Received in Advance — Premiums received in full for the policies processed during the current period, but prior to the commencement of the service period, are recorded as premiums received in advance in the financial statements

#### CAPITAL AND SURPLUS AND MINIMUM STATUTORY REQUIREMENTS

• Restricted Cash Reserves —

The Company is in compliance with various states regulatory deposit requirements as of December 31, 2021 and 2020, respectively, for qualification purposes as a domestic and foreign insurer. These restricted cash reserves are stated at book/adjusted carrying value, which approximates fair value. These restricted deposits are included in bonds in the financial statements. Interest earned on these deposits accrues to the Company (see Note 5).

• Minimum Capital and Surplus —

Under the laws of the State of Rhode Island, the Company's domiciliary state, the Department requires the Company to maintain a minimum capital and surplus equal to \$2,500,000.

Risk-based capital ("RBC") is a regulatory tool for measuring the minimum amount of capital appropriate for a managed care organization to support its overall business operations in consideration of its size and risk profile. The Company has an arrangement with the State to maintain above 275% of the RBC Authorized Control Level. Under the laws of the State of Massachusetts, the Division of Insurance requires the company to maintain a minimum capital and surplus equal to \$1,000,000 or 2% of the first \$150,000,000 annual premium revenue and 1% of annual premium revenue in excess of \$150,000,000 or an amount equal to the sum of 3 months uncovered health care expenditures as reported on the most recent financial statement filed with the commissioner or an amount equal to the sum of 8 percent of annual health care expenditures except those paid on a capitated basis or managed hospital payment basis as reported on the most recent financial statement filed with the commissioner; and 4 percent of annual hospital expenditures paid on a managed hospital payment basis as reported on the most recent financial statement filed with the commissioner.

The Company is also subject to minimum capital and surplus requirements in other states where it is licensed to do business.

The Company is in compliance with the minimum required capital and surplus amounts where it is licensed to do business, as of December 31, 2021 and 2020.

#### **STATEMENTS OF OPERATIONS**

 Net Premium Income and Change in Unearned Premium Reserves and Reserve for Rate Credits — Revenues consist of net premium income that is recognized in the period in which enrollees are entitled to receive health care services. Net premium income is shown net of reinsurance premiums paid and reinsurance premiums incurred but not paid in the financial statements. The corresponding change in unearned premium from year to year is reflected as a change in unearned premium reserves and reserve for rate credits in the financial statements. Comprehensive commercial health plans with MLRs on fully insured products, as calculated under the definitions in the ACA and implementing regulations, that fall below certain targets are required to rebate ratable portions of premiums annually. The Company classifies changes to the estimated rebates and retrospective premium adjustments as change in unearned premium reserves and reserve for rate credits in the financial statements (see Note 24). In addition, pursuant to Section 1343 of the ACA, the Company records premium adjustments for changes to the commercial risk corridor and commercial risk adjustment balances which are reflected in change in unearned premium reserves and reserve for rate credits and net premium income, respectively, in the financial statements (see Note 24).

Medicare Plans with MLRs on fully insured products, as calculated under the definitions in the ACA and implementing regulations, that fall below certain targets are required to rebate ratable portions of premiums annually. In addition, the Company records premium adjustments for changes to the CMS Medicare Plans risk corridor program. Changes to these estimates are reflected in change in unearned premium reserves and reserve for rate credits in the financial statements (see Note 24). Net premium income also includes premium under the Medicare Plans which includes CMS premiums, including amounts pursuant to the CMS risk adjustment program (see Note 24), and member premiums.

The Medicaid plan is subject to experience rated rebates, including MLRs and risk corridor programs, risk adjustment program, and performance guarantees based on various utilization measures. The Company records premium adjustments for the changes to the estimates for experience rated rebates and risk corridor programs which are reflected in change in unearned premium reserves and reserve for rate credits and for the risk adjustment program and performance guarantees which are reflected in net premium income in the financial statements (see Note 24). Net premium income also includes amounts paid by state and federal governments on a per member basis in exchange for the provision and administration of medical benefits under the Medicaid, home nursing risk-sharing payments, high-dollar risk pool payments, and maternity payments. Premiums are contractual and are recognized in the coverage period in which members are entitled to receive services, except in the case of maternity payments. Maternity income is billed on contractual rates and recognized as income as each birth case is identified by the Company.

 Total Hospital and Medical Expenses — Total hospital and medical expenses include claims paid, claims processed but not yet paid, estimates for claims received but not yet processed, estimates for the costs of health care services enrollees have received but for which claims have not yet been submitted, and payments and liabilities for physician, hospital, and other medical costs disputes.

Total hospital and medical expenses also include amounts incurred for incentive pool, withhold adjustments, and bonus amounts that are based on the underlying contractual provisions with the respective providers. In addition, adjustments to claims unpaid estimates and aggregate health claim reserves are reflected in the period once the change in estimate is identified and included in total hospital and medical expenses in the financial statements

• General Administrative Expenses — General expenses that have been paid as of the reporting date in addition to general expenses that have been incurred but are not due until a subsequent period are reported as general administrative expenses. Pursuant to the terms of the Agreement (see Note 10), the Company pays a management fee to UHS in exchange for administrative and management services. Costs for items not included within the scope of the Agreement are directly expensed as incurred. State income taxes are also a component of GAE. A detailed review of the administrative expenses of the Company and UHS is performed to determine the allocation between CAE and GAE to be reported in the financial statements.

#### **REINSURANCE**

 Reinsurance Ceded — The Company has an insolvency-only reinsurance agreement with UnitedHealthcare Insurance Company ("UHIC"), an affiliate whereby 60% of net premium income is ceded to UHIC (see Note 23).

In the normal course of business, the Company seeks to limit its exposure to loss on any single insured and to recover a portion of benefits paid by ceding premium to other insurance enterprises or reinsurers under excess coverage contracts or specific transfer of risk agreements. The Company remains primarily liable as the direct insurer on the risks reinsured (see Note 23).

The Company has a reinsurance agreement through which 60% of comprehensive commercial earned member premiums, hospital and medical benefits, and operating expenses are ceded to the reinsurer. The Company also has a Medicaid stop loss reinsurance agreement with UHIC (see Note 23).

- Amounts Recoverable from Reinsurers The Company records amounts recoverable from reinsurers which represents amounts contractually due to the Company as net reinsurance recoveries in the financial statements.
- Ceded Reinsurance Premiums Payable The ceded reinsurance premiums payable
  balance represents amounts due to the reinsurers for specified coverage which will be paid
  based on the contract terms.

#### **OTHER**

• Vulnerability Due to Certain Concentrations — The Company is subject to substantial federal and state government regulation, including licensing and other requirements relating to the offering of the Company's existing products in new markets and offerings of new products, both of which may restrict the Company's ability to expand its business.

The Company has no commercial customers that individually exceed 10% of total direct premiums written and uncollected premiums, including receivables for contracts subject to redetermination, for the years ended December 31, 2021 and 2020.

Direct premiums written and uncollected premiums, including receivables for contracts subject to redetermination, from members and CMS related to the Medicare Plans as a percentage of total direct premiums written and total uncollected premiums, including receivables for contracts subject to redetermination, are 58% and 65% as of December 31, 2021 and 62% and 53% as of December 31, 2020, respectively.

Direct premiums written and uncollected premiums, including receivables for contracts subject to redetermination, from the State of Rhode Island, Department of Human Services as a percentage of total direct premiums written and total uncollected premiums, including receivables for contracts subject to redetermination, are 42% and 34% as of December 31, 2021 and 38% and 45% as of December 31, 2020, respectively.

**Recently Issued Accounting Standards** — In July 2020, the NAIC revised Statement of Statutory Accounting Principles ("SSAP") No. 106, *Affordable Care Act Section 9010 Assessment* for the repeal of the Affordable Care Act Section 9010 Assessment, effective January 1, 2021. The Company adopted the revision on the effective date.

The Company reviewed all other recently issued guidance in 2021 and 2020 that has been adopted for 2021 or subsequent years' implementation and has determined that none of the items would have a significant impact to the financial statements.

#### D. Going Concern

The Company has the ability and will continue to operate for a period of time sufficient to carry out its commitments, obligations and business objectives.

#### 2. ACCOUNTING CHANGES AND CORRECTIONS OF ERRORS

No changes in accounting principles or corrections of errors have been recorded during the years ended December 31, 2021 and 2020.

#### 3. BUSINESS COMBINATIONS AND GOODWILL

**A–E.** The Company was not party to a business combination during the years ended December 31, 2021 and 2020, and does not carry goodwill in its financial statements.

#### 4. DISCONTINUED OPERATIONS

### A. Discontinued Operation Disposed of or Classified as Held for Sale

- (1–4) The Company did not have any discontinued operations disposed of or classified as held for sale during 2021 and 2020.
- B. Change in Plan of Sale of Discontinued Operation Not applicable.
- C. Nature of any Significant Continuing Involvement with Discontinued Operations after Disposal Not applicable.
- D. Equity Interest Retained in the Discontinued Operation after Disposal Not applicable.

#### 5. INVESTMENTS

For purposes of calculating gross realized gains and losses on sales of investments, the amortized cost of each investment sold is used. The gross realized gains and losses on sales of long-term investments were \$1,463,092 and \$0, respectively, for 2021 and \$791 and \$64, respectively, for 2020. There were no realized gains and losses on sales of short-term investments for 2021 or 2020. The net realized gain is included in net realized capital gains less capital gains tax in the financial statements. Total proceeds on the sale of long-term investments were \$24,358,287 and \$0 and for short-term investments were \$0 and \$747,465,042 in 2021 and 2020, respectively.

As of December 31, 2021 and 2020, the book/adjusted carrying value, fair value, and gross unrecognized unrealized gains and losses of the Company's investments, excluding cash and cash equivalents of \$110,967,749 and \$88,551,939 respectively, are disclosed in the table below:

U.S. government and agency securities State and agency municipal securities City and county municipal securities Corporate debt securities Total bonds

				2	021			
			Gross		Gross		Gross	
	Book/Adjusted		Inrecognized	ι	Inrecognized	Ur	recognized	
			/Adjusted Unrealized			Unre	alized Losses	Fair
	Carrying Value		Gains		< 1 Year		> 1 Year	Value
\$	54,623,522	\$	1,103,737	\$	303,860	\$	14,370	\$ 55,409,029
	27,345,799		1,481,513		13,728		-	28,813,584
	20,886,475		1,097,572		75,387		-	21,908,660
	149,372,239		2,045,603		1,690,124		771,799	 148,955,919
\$	252,228,035	\$	5,728,425	\$	2,083,099	\$	786,169	\$ 255,087,192

Less than one year One to five years Five to ten years Over ten years Total bonds

			2	2021		
Book/Adjusted	ι	Gross Jnrecognized Unrealized		Gross  Jnrecognized  realized Losses	Gross nrecognized palized Losses	Fair
Carrying Value		Gains		< 1 Year	> 1 Year	Value
\$ 14,941,041	\$	129,279	\$	-	\$ -	\$ 15,070,320
56,170,103		1,152,012		308,518	-	57,013,597
109,190,281		3,407,048		1,072,460	641,419	110,883,450
71,926,610		1,040,086		702,121	144,750	72,119,825
\$ 252,228,035	\$	5,728,425	\$	2,083,099	\$ 786,169	\$ 255,087,192

U.S. government and agency securities State and agency municipal securities City and county municipal securities Corporate debt securities Total bonds

	U	Gross Inrecognized	Gross ecognized	Gross recognized		
Book/Adjusted Carrying Value		Unrealized Gains	 lized Losses < 1 Year	 alized Losses > 1 Year	Fair Value	
\$ 79,845,943	\$	4,809,898	\$ 14,206	\$ -	\$	84,641,635
27,898,482		2,061,088	-	-		29,959,570
20,277,713		1,498,731	-	-		21,776,444
136,340,154		4,727,935	 73,652	 24,036		140,970,401
\$ 264,362,292	\$	13,097,652	\$ 87,858	\$ 24,036	\$	277,348,050

Included in U.S. government and agency securities and corporate debt securities in the tables above are mortgage-related loan-backed securities, which do not have a single maturity date. For the years to maturity table above, these securities have been presented in the maturity group based on the securities' final maturity date and at a book/adjusted carrying value of \$64,262,601 and fair value of \$64,654,142.

The following table illustrates the fair value and gross unrecognized unrealized losses, aggregated by investment category and length of time that the individual securities have been in a continuous unrecognized unrealized loss position as of December 31, 2021 and 2020:

U.S. government and agency securities State and agency municipal securities City and county municipal securities Corporate debt securities Total bonds

				2	021									
<1`	Year			> 1 Year				Total						
Fair Value				Unrecognized Unrealized		Fair Value				Gross Unrecognized Unrealized Losses		Fair Value		Gross nrecognized Unrealized Losses
\$ 20,429,708 386,272 3,084,684	\$	303,860 13,728 75,387	\$	943,494 - -	\$	14,370 - -	\$	21,373,202 386,272 3.084,684	\$	318,230 13,728 75,387				
\$ 65,492,938 89,393,602	\$	1,690,124 2,083,099	_	14,179,476 15,122,970	\$	771,799 786,169	\$	79,672,414 104,516,572	\$	2,461,923 2,869,268				

U.S. government and agency securities Corporate debt securities Total bonds

					_	020						
_		<1`	Year		> 1	Year			Total			
_	Fair Value		Gross Unrecognized Unrealized Losses		Fair Value	Gross Unrecognized Unrealized Losses		Fair Value		Gross Unrecogniz Unrealized Losses		
	\$	4,384,877 17,678,097	\$	14,206 73,652	\$ - 3,741,447	\$	- 24,036	\$	4,384,877 21,419,544	\$	14,206 97,688	
	\$	22,062,974	\$	87,858	\$ 3,741,447	\$	24,036	\$	25,804,421	\$	111,894	

The unrecognized unrealized losses on investments in U.S. government and agency securities, state and agency municipal securities, city and county municipal securities, and corporate debt securities at December 31, 2021 and 2020, were mainly caused by interest rate fluctuations and not by unfavorable changes in the credit ratings associated with these securities. The Company evaluates impairment at each reporting period for each of the securities whereby the fair value of the investment is less than its book/adjusted carrying value. The contractual cash flows of the U.S. government and agency securities are guaranteed either by the U.S. government or an agency of the U.S. government. It is expected that the securities would not be settled at a price less than the cost of the investment, and the Company does not intend to sell the investment until the unrealized loss is fully recovered. The Company assessed the credit quality of the state and agency municipal securities, city and county municipal securities and corporate debt securities, noting whether a significant deterioration since purchase or other factors that may indicate an other-than-temporary impairment ("UHCIC"), such as the length of time and extent to which fair value has been less than cost, the financial condition, and near-term prospects of the issuer as well as specific events or circumstances that may influence the operations of the issuer and the Company's intent to sell the investment. Additionally, the Company evaluated its intent and ability to retain loan-backed securities for a period of time sufficient to recover the amortized cost. As a result of these reviews, the Company recorded an OTTI of \$0 and \$147 as of December 31, 2021 and 2020, respectively, which are included in net realized capital gains less taxes in the financial statements.

**A–C.** The Company has no mortgage loans, real estate loans, restructured debt, or reverse mortgages. The Company also has no real estate property occupied by the Company, real estate property held for the production of income, or real estate property held for sale.

#### D. Loan-Backed Securities

- (1) U.S. government and agency securities and corporate debt securities include loan-backed securities (mortgage-backed securities and asset-backed securities), which are valued using the retrospective adjustment methodology. Prepayment assumptions for the determination of the book/adjusted carrying value, commonly referred to as amortized cost, of loan-backed securities are based on a three-month constant prepayment rate history obtained from external data source vendors.
- (2) The Company did not recognize any OTTIs on loan-backed securities as of December 31, 2021 and 2020.
- (3) The Company did not have any loan-backed securities with OTTIs to report by CUSIP as of December 31, 2021 or 2020.
- (4) The following table illustrates the fair value, gross unrecognized unrealized losses, and length of time that the loan-backed securities have been in a continuous unrecognized unrealized loss position as of December 31, 2021 and 2020:

	2021
The aggregate amount of unrealized losses:	
1. Less than 12 months	\$ 553,357
2. 12 months or longer	128,042
The aggregate related fair value of securities with unrealized losses:	
1. Less than 12 months	30,333,577
2. 12 months or longer	4,351,894
	2020
The aggregate amount of unrealized losses:	2020
The aggregate amount of unrealized losses:  1. Less than 12 months	\$ <b>2020</b> 20,824
	\$
1. Less than 12 months	\$ 20,824
Less than 12 months     2. 12 months or longer	\$ 20,824

- (5) The Company believes that it will continue to collect timely the principal and interest due on its loan-backed securities that have an amortized cost in excess of fair value. The unrealized losses were primarily caused by interest rate changes and not by unfavorable changes in the credit quality associated with these securities that impacted the assessment on collectability of principal and interest. At each reporting period, the Company evaluates available-for-sale debt securities for any credit-related impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the expected cash flows, and the underlying credit quality and credit ratings of the issuers, noting no significant credit deterioration since purchase. As of December 31, 2021, the unrealized loss on any security that the Company classified as intent to sell was not material to the Company's investment portfolio. Any other securities in an unrealized loss position as of December 31, 2021, the Company considers to be temporary.
- E. Dollar Repurchase Agreements and/or Securities Lending Transactions Not applicable.
- F. Repurchase Agreements Transactions Accounted for as Secured Borrowing Not applicable.
- G. Reverse Repurchase Agreements Transactions Accounted for as Secured Borrowing Not applicable.
- H. Repurchase Agreements Transactions Accounted for as a Sale Not applicable.
- I. Reverse Repurchase Agreements Transactions Accounted for as a Sale Not applicable.
- J. Real Estate Not applicable.
- K. Low-Income Housing Tax Credits Not applicable.

#### L. Restricted Assets

(1) Restricted assets, including pledged securities as of December 31, 2021 and 2020, are presented below:

			1		2		3		4		5	6 Gross	7
	Restricted Asset Category	(A No Res	otal Gross dmitted & nadmitted) tricted From irrent Year	( N Re	Fotal Gross Admitted & onadmitted) stricted From Prior Year		Increase/ (Decrease) (1 Minus 2)		Total Current Year Nonadmitted Restricted	Ye	otal Current ear Admitted Restricted 1 minus 4)	(Admitted & Nonadmitted) Restricted to Total Assets (a)	Admitted Restricted to Total Admitted Assets (b)
a.	Subject to contractual obligation for which liability is not shown	\$		¢		\$		ę		¢			
b.	Collateral held under security lending	Φ	-	Φ	-	φ	-	Ą	-	Φ	-	-	-
c	agreements Subject to repurchase		-		-		-		-		-	-	-
	agreements		-		-		-		-		-	-	-
d.	Subject to reverse repurchase agreements		-		-		-		_		-	-	-
e.	Subject to dollar repurchase agreements												
f.	Subject to dollar reverse		-		-		-		-		-	_	-
q.	repurchase agreements Placed under option		-		-		-		-		-	-	-
h	contracts Letter stock or securities		-		-		-		-		-	-	-
	restricted as to sale— excluding FHLB capital												
i.	stock FHLB capital stock		-		-		-		-		-	-	-
j.	On deposit with states		3,436,068		2,771,097		664,971		-		3,436,068	<1 %	<1 %
k.	On deposit with other												
I.	regulatory bodies Pledged as collateral to FHLB (including assets backing funding		-		-		-		-		-	-	-
m.	agreements) Pledged as collateral not captured in other		-		-		-		-		-	-	-
	categories		-		-		-		-		-	-	-
n.	Other restricted assets			-		_	<u> </u>	-	<u> </u>	-	<u> </u>	=	Ξ
ο.	Total restricted assets	\$	3,436,068	\$	2,771,097	\$	664,971	\$	<u> </u>	\$	3,436,068	<u>&lt;1 %</u>	<u>&lt;1 %</u>

- (a) Column 1 divided by Asset Page, Column 1, Line 28 (b) Column 5 divided by Asset Page, Column 3, Line 28
  - (2–4) The Company has no assets pledged as collateral not captured in other categories and no other restricted assets as of December 31, 2021 or 2020.
- M. Working Capital Finance Investments Not applicable.
- N. Offsetting and Netting of Assets and Liabilities

The Company does not have any offsetting or netting of assets and liabilities as it relates to derivatives, repurchase and reverse repurchase agreements, and securities borrowing and securities lending activities.

#### O. 5GI Securities

The Company does not have any investments with an NAIC designation of 5GI as of December 31, 2021 and 2020.

P. Short Sales — Not applicable.

#### Q. Prepayment Penalty and Acceleration Fees

The following table illustrates prepayment penalty and acceleration fees as of of December 31, 2021:

	Ge	neral Account
1. Number of CUSIPs		4
2. Aggregate Amount of Investment Income	\$	41,193

#### R. Reporting Entity's Share of Cash Pool by Asset Type

The Company's investment in the qualified cash pool is reported in cash equivalents. The Company's investment in the qualified cash pool is \$97,016,876 and \$72,069,395 as of December 31, 2021 and December 31, 2020, respectively. The following table presents the percent share distribution by underlying asset type of the total qualified cash pool balance as of December 31, 2021:

Asset Type	Percent Share
(1) Cash	-
(2) Cash Equivalents	52%
(3) Short-Term Investments	48%
(4) Total	100%

#### 6. JOINT VENTURES, PARTNERSHIPS, AND LIMITED LIABILITY COMPANIES

**A–B**. The Company has no investments in joint ventures, partnerships, or limited liability companies that exceed 10% of admitted assets and did not recognize any impairment write-down for its investments in joint ventures, partnerships, and limited liability companies during the statement periods.

#### 7. INVESTMENT INCOME

- **A.** The Company excludes all investment income due and accrued amounts that are over 90 days past due from the financial statements.
- **B.** There were no investment income amounts excluded from the financial statements.

### 8. DERIVATIVE INSTRUMENTS

**A–B.** The Company has no derivative instruments.

#### 9. INCOME TAXES

### A. Deferred Tax Asset/Liability

(1) The components of the net deferred tax asset at December 31, 2021 and 2020 are as follows:

		2021			2020			Change	
	1	2	3 (Col 1+2)	4	5	6 (Col 4+5)	7 (Col 1 - 4)	8 (Col 2 - 5)	9 (Col 7+8)
	Ordinary	Capital	Total	Ordinary	Capital	Total	Ordinary	Capital	Total
(a) Gross deferred tax assets (b) Statutory valuation allowance adjustments	\$ 3,163,356	\$ - 	\$ 3,163,356	\$ 2,902,880	\$ - 	\$ 2,902,880	\$ 260,476	\$ - 	\$ 260,476
(c) Adjusted gross deferred tax assets (1a - 1b)	3,163,356	-	3,163,356	2,902,880	-	2,902,880	260,476	-	260,476
(d) Deferred tax assets nonadmitted									
(e) Subtotal net admitted deferred tax asset (1c - 1d)	3,163,356	-	3,163,356	2,902,880		2,902,880	260,476		260,476
(f) Deferred tax liabilities	78,288		78,288	97,860		97,860	(19,572)		(19,572)
(g) Net admitted deferred tax asset/(net deferred tax liability) (1e - 1f)	\$ 3,085,068	<u>\$</u>	\$ 3,085,068	\$ 2,805,020	<u>\$ -</u> _	\$ 2,805,020	\$ 280,048	<u>\$ -</u>	\$ 280,048

(2) The components of the adjusted gross deferred tax assets admissibility calculation under SSAP No. 101, *Income Taxes*, are as follows:

		2021			2020			Change	
	1	2	3	4	5	6	7	8	9
Admission Calculation			(Col 1 + 2)			(Col 4 + 5)	(Col 1 - 4)	(Col 2 - 5)	(Col 7 + 8)
Components SSAP No. 101	Ordinary	Capital	Total	Ordinary	Capital	Total	Ordinary	Capital	Total
(a) Federal income taxes paid in prior years recoverable through loss carrybacks	\$ 3,163,356	\$ -	\$ 3,163,356	\$ 2,902,880	\$ -	\$ 2,902,880	\$ 260,476	\$ -	\$ 260,476
(b) Adjusted gross deferred tax assets expected to be realized (excluding the amount of deferred tax assets from 2(a) above) after application of the threshold limitation. (The lesser of 2(b)1 and 2(b)2 below) 1. Adjusted gross deferred	-			-	-	-	-	-	-
tax assets expected to be realized following the balance sheet date 2. Adjusted gross deferred tax assets allowed per limitation threshold	- XXX	- XXX	30,464,906	- XXX	- XXX	30,240,993	- XXX	- XXX	- 223,913
(c) Adjusted gross deferred tax assets (excluding the amount of deferred tax assets from 2(a) and 2(b) above) offset by gross deferred tax liabilities						<u>.</u>	<u> </u>		<u>.                                    </u>
(d) Deferred tax assets admitted as the result of application of SSAP No. 101 Total (2(a) + 2(b) + 2(c))	\$ 3,163,356	<u>\$ -</u>	<u>\$ 3,163,356</u>	\$ 2,902,880	<u>\$ -</u>	\$ 2,902,880	\$ 260,476	<u>\$ -</u>	\$ 260,476

(3) The ratio percentage and adjusted capital and surplus used to determine the recovery period and threshold limitations for the admissibility calculation are presented below:

	2021	2020
(a) Ratio percentage used to determine recovery period and threshold limitation amount	>300 %	>300 %
(b) Amount of adjusted capital and surplus used to determine recovery period and threshold limitation		
in 2(b)(2) above	\$ 203,099,376	\$ 201,606,618

(4) The impact to the gross deferred tax assets balances as a result of tax-planning strategies as of December 31, 2021 and 2020 is presented below:

	2021		202	0	Change			
	1	2	3	4	5	6		
Impact of Tax-Planning Strategies	Ordinary	Capital	Ordinary	Capital	(Col 1 - 3) Ordinary	(Col 2 - 4) Capital		
(a) Determination of adjusted gross deferred tax assets and net admitted deferred tax assets by tax character as a percentage.     1. Adjusted gross DTAs amount from								
Note 9A1(c)  2. Percentage of adjusted gross DTAs by tax character attributable to the impact	\$ 3,163,356	\$ -	\$ 2,902,880	\$ -	\$ 260,476	\$ -		
of tax-planning strategies 3. Net admitted adjusted gross DTAs	- %	- %	- %	- %	- %	- %		
amount from Note 9A1(e) 4. Percentage of net admitted adjusted gross DTAs by tax character admitted	\$ 3,163,356	\$ -	\$ 2,902,880	\$ -	\$ 260,476	\$ -		
because of the impact of tax-planning strategies	- %	- %	- %	- %	- %	- %		
(b) Does the Company's tax-planning strategies include the use of reinsurance?			Yes		No	Χ		

### B. Unrecognized Deferred Tax Liabilities

(1–4) There are no unrecognized deferred tax liabilities for the years ended December 31, 2021 and 2020.

### C. Significant Components of Income Taxes

(1) The current federal income taxes incurred for the years ended December 31, 2021 and 2020 are as follows:

	1	2	3
	2021	2020	(Col 1 - 2) Change
Current income tax			
(a) Federal	\$ 17,793,162	\$ 19,876,787	\$ (2,083,625)
(b) Foreign			<u> </u>
(c) Subtotal	17,793,162	19,876,787	(2,083,625)
(d) Federal income tax on net capital gains	334,811	122	334,689
(e) Utilization of capital loss carryforwards	-	-	-
(f) Other			
(q) Total federal income taxes incurred	\$ 18,127,973	\$ 19,876,909	\$ (1,748,936)

(2–4) The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities as of December 31, 2021 and 2020, are as follows:

	1	2	3
	2021	2020	(Col 1 - 2) Change
2 Deferred tax assets:			
(a) Ordinary:			
(1) Discounting of unpaid losses	\$ 453,439	\$ 565,536	\$ (112,097)
(2) Unearned premium reserve	2,365,021	1,913,899	451,122
(3) Policyholder reserves	-	-	-
(4) Investments	-	-	-
(5) Deferred acquisition costs	-	-	-
(6) Policyholder dividends accrual	-	-	-
(7) Fixed assets	-	-	-
(8) Compensation and benefits accrual	-	-	-
(9) Pension accrual	-	-	-
(10) Receivables — nonadmitted	319,758	423,266	(103,508)
(11) Net operating loss carryforward	-	-	-
(12) Tax credit carryforward	-	-	-
(13) Other (including items <5% of total ordinary tax assets)	25,138	179	24,959
(99) Subtotal	3,163,356	2,902,880	260,476
(b) Statutory valuation allowance adjustment	_	_	_
(c) Nonadmitted	_	_	_
( )			
(d) Admitted ordinary deferred tax assets (2a99 - 2b - 2c)	3,163,356	2,902,880	260,476
(e) Capital:			
(1) Investments	-	_	-
(2) Net capital loss carryforward	-	-	-
(3) Real estate	-	-	-
(4) Other (including items <5% of total capital tax assets)			
(99) Subtotal	-	-	-
(f) Statutory valuation allowance adjustment	-	-	-
(g) Nonadmitted			
(h) Admitted capital deferred tax assets (2e99 - 2f - 2g)	<u> </u>		
(i) Admitted deferred tax assets (2d + 2h)	3,163,356	2,902,880	260,476
3 Deferred tax liabilities:			
(a) Ordinary:			
(1) Investments	-	-	=
(2) Fixed assets	-	-	-
(3) Deferred and uncollected premium	-	-	-
<ul><li>(4) Policyholder reserves</li><li>(5) Other (including items &lt;5% of total ordinary tax liabilities)</li></ul>	- 78,288	97,860	- (19,572)
(b) other (mordaling items 10% of total ordinary tax habilities)	70,200	37,000	(13,072)
(99) Subtotal	78,288	97,860	(19,572)
(b) Capital:			
(1) Investments	_	_	_
(2) Real estate	-	-	-
(3) Other (including items <5% of total capital tax liabilities)			
(99) Subtotal			
(c) Deferred tax liabilities (3a99 + 3b99)	78,288	97,860	(19,572)
4 Net deferred tax assets/liabilities (2i - 3c)	\$ 3,085,068	\$ 2,805,020	\$ 280,048

The other ordinary deferred tax liability of \$78,288 and \$97,860 for 2021 and 2020, respectively, consists of loss reserve discounting.

The Company assessed the potential realization of the gross deferred tax asset and as a result no statutory valuation allowance was required and no allowance was established as of December 31, 2021 and 2020.

**D.** The provision for federal income taxes incurred is different from that which would be obtained by applying the statutory federal income tax rate of 21% to net income before federal income taxes incurred, less capital gains tax. A summarization of the significant items causing this difference as of December 31, 2021 and 2020 is as follows:

	2021		2020		
		Effective		Effective	
	Amount	Tax Rate	Amount	Tax Rate	
Tax provision at the federal statutory rate	\$ 17,913,045	21%	\$ 14,567,011	21%	
Tax-exempt interest	(168,685)	<1	(167,425)	<1	
Health insurer fee	-	-	5,188,523	7	
Tax effect of nonadmitted assets	103,565	<1	1,962,901	3	
Change in statutory valuation allowance		<del>-</del>	(34,161)	<1	
Total statutory income taxes	\$ 17,847,925	21%	\$21,516,849	31%	
Federal income taxes incurred	\$ 17,793,162	21%	\$ 19,876,787	29%	
Capital gains tax	334,811	<1	122	<1	
Change in net deferred income tax	(280,048)	<1	1,639,940	2	
Total statutory income taxes	\$ 17,847,925	21%	\$ 21,516,849	31%	

**E.** At December 31, 2021, the Company had no net operating loss carryforwards.

Current federal income taxes recoverable of \$912,028 and \$2,614,091 as of December 31, 2021 and 2020, respectively, are included in the financial statements. Federal income taxes paid, net of refunds were \$16,425,909 and \$24,336,983 in 2021 and 2020, respectively.

Federal income taxes incurred of \$18,127,973 and \$19,876,909 for 2021 and 2020, respectively, are available for recoupment in the event of future net losses.

The Company has not admitted any aggregate amounts of deposits that are included within Section 6603 ("Deposits made to suspend running of interest on potential underpayments, etc.") of the Internal Revenue Service ("IRS") Code.

- F. The Company is included in the consolidated federal income tax return with its ultimate parent, UnitedHealth Group. The entities included within the consolidated return are included in the NAIC Statutory Statement Schedule Y - Information Concerning Activities of Insurer Members Of A Holding Company Group. Federal income taxes are paid to or refunded by UnitedHealth Group pursuant to the terms of a tax-sharing agreement, approved by the Board of Directors, under which taxes approximate the amount that would have been computed on a separate company basis, with the exception of net operating losses and capital losses. For these losses the Company receives a benefit at the federal rate in the current year for current taxable losses incurred in that year to the extent losses can be utilized in the consolidated federal return of UnitedHealth Group. UnitedHealth Group currently files income tax returns in the U.S. federal jurisdiction, various states, and foreign jurisdictions. The U.S. IRS has completed exams on UnitedHealth Group's consolidated income tax returns for fiscal years 2016 and prior. UnitedHealth Group's 2017 through 2020 tax returns are under review by the IRS under its Compliance Assurance Program. With the exception of a few states, UnitedHealth Group is no longer subject to income tax examinations prior to the 2014 tax year. In general, the Company is subject to examination in non-U.S. jurisdictions for years 2015 and forward. The Company does not believe any adjustments that may result from these examinations will be material to the Company.
- G. Tax Contingencies Not applicable.
- H. Repatriation Transition Tax Not applicable.
- I. Alternative Minimum Tax Credit Not applicable.

#### 10. INFORMATION CONCERNING PARENT, SUBSIDIARIES, AND AFFILIATES

**A–B.** In the ordinary course of business, the Company contracts with several affiliates to provide a wide variety of services to the Company's members. These agreements are filed with and approved by the Department according to Management's understanding of the current requirements and standards. Within the confines of the applicable filed and approved agreements (including subsequent amendments thereto), the amount and types of services provided by these affiliated entities can change year over year.

UHS maintains a private short-term investment pool in which affiliated companies may participate (see Note 1). At December 31, 2021 and 2020, the Company's portion was \$97,016,876 and \$72,069,395, respectively and is included in cash equivalents in the financial statements.

The Company has a tax-sharing agreement with UnitedHealth Group (see Note 9).

The Company paid dividends of \$66,200,733 and \$16,000,000 in 2021 and 2020, respectively, to its parent (see Note 13).

The Company holds a \$50,000,000 subordinated revolving credit agreement with UnitedHealth Group at an interest rate of London InterBank Offered Rate plus a margin of 0.50%. This credit agreement is subordinate to the extent it does not conflict with any credit facility held by either party. The agreement was renewed effective October 31, 2012 and shall continue until terminated pursuant to the terms of the credit agreement. No amounts were outstanding under the line of credit as of December 31, 2021 and 2020.

The Company has entered into reinsurance agreements with an affiliated entity (see Note 23).

#### C. Transactions With Related Parties Who Are Not Reported On Schedule Y

The Company has no material related party transactions that meet the disclosure requirements pursuant to SSAP No. 25, *Affiliates and Other Related Parties* ("SSAP No. 25") that are not included in NAIC Statutory Statement Schedule Y—Part 2 Summary Of Insurer's Transactions With Any Affiliates.

At December 31, 2021 and 2020, the Company reported \$3,605,369 and \$0, respectively, as receivables from parent, subsidiaries and affiliates, \$0 and \$1,570,638, respectively, as amounts due to parent, subsidiaries, and affiliates, which are included in the financial statements. These balances are generally settled within 90 days from the incurred date. Any balances due to the Company that are not settled within 90 days are considered nonadmitted assets.

E. The administrative services, access fees, and cost of care services provided by affiliates are calculated using one or more of the following methods: (1) a percentage of premiums; (2) use of assets; (3) direct pass-through of charges; (4) per member per month; (5) per employee per month; (6) per claim; or (7) a combination thereof consistent with the provisions contained in each contract. These amounts are included in GAE, CAE, and hospital and medical expenses in the financial statements. The following table identifies the amounts reported for the administrative services, access fees, and cost of care services provided by related parties for the years ended December 31, 2021 and 2020, which meet the disclosure requirements pursuant to SSAP No. 25, regardless of the effective date of the contract:

	2021	2020
OptumRx	\$ 181,712,253	\$ 165,537,181
United Behavioral Health	126,339,260	108,160,460
UHS	108,377,377	113,306,182
naviHealth, Inc.	14,855,896	-
OptumInsight, Inc.	3,888,143	3,620,649
XLHome, P.C.	2,669,022	-

OptumRx provides services that may include, but are not limited to, administrative services related to pharmacy management and pharmacy claims processing for enrollees, manufacturer rebate administration, pharmacy incentive services, specialty drug pharmacy services, durable medical equipment services including orthotics and prosthetics and personal health products catalogues showing the healthcare products and benefit credits enrollees needed to redeem the respective products.

United Behavioral Health provides services related to mental health and substance abuse treatment.

UHS provides, or arranges for the provision of, management, administrative, and other services deemed necessary or appropriate for UHS to provide management and operational support to the Company. The services can include, but are not limited to, the categories of management and operational services outlined in the Agreement, such as human resources, legal, facilities, general administration, treasury and investment functions, claims adjudication and payment, benefit administration, disease management, health care decision support, medical management, credentialing, preventative health services, utilization management reporting and expenses incurred for new business that will be effective in the subsequent year.

naviHealth, Inc. provides comprehensive post-acute services and care delivery.

OptumInsight, Inc. provides services that may include, but are not limited to, claim analytics and recovery of medical expense overpayments, retroactive fraud, waste and abuse, subrogation and premium audit services. All recoveries are returned to the Company by OptumInsight, Inc. on a monthly basis.

XLHome, P.C. provides housecall services through a pass-through agreement with UHS.

The Company has premium payments that are received and claim payments and direct expenses such as broker commissions, Department exam fees, ACA assessments and premium taxes that are processed and paid by an affiliated UnitedHealth Group entity. Premiums, claims, and direct expenses applicable to the Company are settled at regular intervals throughout the month via the intercompany settlement process and any amounts outstanding are reflected in receivables from parent, subsidiaries, and affiliates and payable amounts due to parent, subsidiaries, and affiliates, in the financial statements.

- **F.** The Company's parent provides a guarantee to the Company to provide the necessary capital contributions so the Company does not fall below the 275% RBC Authorized Control Level as required by the State.
- **G.** The Company is part of an insurance holding company system with UnitedHealth Group as the ultimate parent. Management believes that the Company's transactions with affiliates are fair and reasonable; however, operations of the Company may not be indicative of those that would have occurred if it had operated as an independent company.
- **H.** The Company does not have any amount deducted from the value of an upstream intermediate entity or ultimate parent owned, either directly or indirectly, via a downstream subsidiary, controlled, or affiliated entity.
- I. The Company does not have any investments in a subsidiary, controlled, or affiliated entity that exceeds 10% of admitted assets.
- **J.** The Company does not have any investments in impaired subsidiaries, controlled, or affiliated entities.
- **K.** The Company does not have any investments in foreign insurance subsidiaries.
- L. The Company does not hold any investments in a downstream noninsurance holding company.
- **M.** The Company does not have any investments in noninsurance subsidiaries, controlled, or affiliated entities.
- N. The Company does not have any investments in insurance subsidiaries, controlled, or affiliated entities
- **O.** The Company does not have any investments in subsidiary, controlled, or affiliated entities or joint ventures, partnerships and limited liability companies in which the Company's share of losses exceeds the investment.

#### 11. **DEBT**

**A–B.** The Company had no outstanding debt with third-parties or outstanding Federal Home Loan Bank agreements during 2021 and 2020.

# 12. RETIREMENT PLANS, DEFERRED COMPENSATION, POSTEMPLOYMENT BENEFITS AND COMPENSATED ABSENCES AND OTHER POSTRETIREMENT BENEFIT PLANS

**A–I.** The Company has no defined benefit plans, defined contribution plans, multiemployer plans, consolidated/holding company plans, postemployment benefits, or compensated absences plans and is not impacted by the Medicare Modernization Act on postretirement benefits, since all personnel are employees of UHS, which provides services to the Company under the terms of the Agreement (see Note 10).

# 13. CAPITAL AND SURPLUS, DIVIDEND RESTRICTIONS, AND QUASI-REORGANIZATIONS

- **A–B.** The Company has 100 shares authorized and 10 shares issued and outstanding of no par value common stock. The Company has no preferred stock outstanding. All issued and outstanding shares of common stock are held by the Company's parent, UHS.
- **C.** Dividend payment requirements are outlined in the domiciliary state statutes and may be further restricted by the Department.
- **D.** The Company paid an ordinary cash dividend to UHS of \$20,400,000 on December 30, 2021, which required no approval and was recorded as a reduction to unassigned surplus in the financial statements. The Company paid an extraordinary cash dividend to UHS of \$45,800,733 on December 30, 2021, which was approved by the Department and recorded as a reduction to unassigned surplus in the financial statements.

The Company paid ordinary cash dividends to UHS of \$11,000,000 on December 17, 2020 and \$5,000,000 on June 22, 2020, which was approved by the Department and recorded as a reduction to unassigned surplus in the financial statements.

- **E.** The amount of ordinary dividends that may be paid out during any given period is subject to certain restrictions as specified by state statute.
- **F.** There are no restrictions placed on the Company's unassigned surplus.
- **G.** The Company is not a mutual reciprocal or a similarly organized entity and does not have advances to surplus not repaid.
- **H.** The Company does not hold any stock, including stock of affiliated companies for special purposes, such as conversion of preferred stock, employee stock options, or stock purchase warrants.
- I. The Company does not have any special surplus funds.
- **J.** The portion of unassigned surplus, excluding net income, and dividends, represented (or reduced) by each item below is as follows:

	2021	2020
Unrealized capital gains on investments Net deferred income taxes Nonadmitted assets	\$ 264,162 3,085,068 (1,522,779)	\$ 236,080 2,805,020 (2,015,946)
Total	\$ 1,826,451	\$ 1,025,154

**K-M.** The Company does not have any outstanding surplus notes and has never been a party to a quasi-reorganization.

# 14. LIABILITIES, CONTINGENCIES AND ASSESSMENTS

## A. Contingent Commitments

The Company has no contingent commitments.

### B. Assessments

The Company is not aware of any guaranty fund assessments or premium tax offsets, potential or accrued, that could have a material financial effect on the operations of the entity.

## C. Gain Contingencies

The Company is not aware of any gain contingencies that should be disclosed in the financial statements.

- D. Claims Related Extra Contractual Obligation and Bad Faith Losses Stemming from Lawsuits Not applicable.
- E. Joint and Several Liabilities Not applicable.

#### F. All Other Contingencies

The Company's business is regulated at the federal, state, and local levels. The laws and rules governing the Company's business and interpretations of those laws and rules are subject to frequent change. Broad latitude is given to the agencies administering those regulations. Further, the Company must obtain and maintain regulatory approvals to market and sell many of its products.

The Company has been, or is currently involved, in various governmental investigations, audits and reviews. These include routine, regular and special investigations, audits and reviews by CMS, state insurance and health and welfare departments and other governmental authorities. The Company cannot reasonably estimate the range of loss, if any, that may result from any material government investigations, audits and reviews in which it is currently involved given the inherent difficulty in predicting regulatory action, fines and penalties, if any, and the various remedies and levels of judicial review available to the Company in the event of an adverse finding.

On February 14, 2017, the Department of Justice ("DOJ") announced its decision to pursue certain claims within a lawsuit initially asserted against the Company and filed under seal by a whistleblower in 2011. The whistleblower's complaint, which was unsealed on February 15, 2017, alleges that the Company made improper risk adjustment submissions and violated the False Claims Act. On February 12, 2018, the court granted in part and denied in part the Company's motion to dismiss. In May 2018, the DOJ moved to dismiss the Company's counterclaims, which were filed in March 2018, and moved for partial summary judgment. In March 2019, the court denied the government's motion for partial summary judgment and dismissed the Company's counterclaims without prejudice. The Company cannot reasonably estimate the outcome that may result from this matter given its procedural status.

Because of the nature of its businesses, the Company is frequently made party to a variety of legal actions and regulatory inquiries, including class actions and suits brought by members, care providers, consumer advocacy organizations, customers and regulators, relating to the Company's businesses, including management and administration of health benefit plans and other services.

The Company records liabilities for its estimates of probable costs resulting from these matters where appropriate. Estimates of costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where the matters involve: indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the early stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to estimate the losses or ranges of losses for those matters where there is a reasonable possibility, or it is probable that a loss may be incurred. Although the outcomes of any such legal actions cannot be predicted, in the opinion of management, the resolution of any currently pending or threatened actions will not have a material adverse effect on the financial statements of the Company.

The Company routinely evaluates the collectability of all receivable amounts included in the financial statements. Impairment reserves are established for those amounts where collectability is uncertain. Based on the Company's past experience, exposure related to uncollectible balances and the potential of loss for those balances not currently reserved for is not material to the Company's statutory basis financial condition.

There are no other assets that the Company considers to be impaired at December 31, 2021 and 2020, except as disclosed in Note 5.

### 15. LEASES

**A–B.** According to the Agreement between the Company and UHS (see Note 10), operating leases for the rental of office facilities and equipment are the responsibility of UHS. Fees associated with the lease agreements are included as a component of the Company's management fee.

# 16. INFORMATION ABOUT FINANCIAL INSTRUMENTS WITH OFF-BALANCE-SHEET RISK AND FINANCIAL INSTRUMENTS WITH CONCENTRATIONS OF CREDIT RISK

(1–4) The Company does not hold any financial instruments with off-balance-sheet risk or have any concentrations of credit risk.

# 17. SALE, TRANSFER, AND SERVICING OF FINANCIAL ASSETS AND EXTINGUISHMENTS OF LIABILITIES

**A–C.** The Company did not participate in any transfer of receivables, financial assets or wash sales.

# 18. GAIN OR LOSS TO THE REPORTING ENTITY FROM UNINSURED PLANS AND THE UNINSURED PORTION OF PARTIALLY INSURED PLANS

**A–B.** The Company has no operations from Administrative Services Only Contracts or Administrative Services Contracts in 2021 and 2020.

#### C. Medicare or Other Similarly Structured Cost Based Reimbursement Contract

The Medicare Part D program is a partially insured plan. The Company recorded a receivable of \$10,203,708 and \$7,316,254 at December 31, 2021 and 2020, respectively, for cost reimbursement under the Medicare Part D program for the catastrophic reinsurance and low-income member cost-sharing subsidies. The Company also recorded a receivable of \$7,550,587 and \$5,596,965 and also a payable of \$6,042,526 and \$2,377,532 at December 31, 2021 and 2020, respectively, for the Medicare Part D coverage gap discount program. The receivables and payables are recorded in amounts receivable relating to uninsured plans and liability for amounts held under uninsured plans, respectively, in the financial statements.

The Company's Medicaid contract with the State includes provisions for various types of enhanced payments to participating providers. Funds are received from the State and the Company subsequently disburses these funds to providers as directed by the State. There is no risk to the Company as a result of these pass-through payments. The Company recorded a receivable of \$634,920 and \$0 as of December 31, 2021 and December 31, 2020, respectively and also a payable of \$1,260,146 and \$2,513,217 as of December 31, 2021 and 2020, respectively. The receivables and payables are recorded in amounts receivable relating to uninsured plans and liability for amounts held under uninsured plans, respectively, in the financial statements for the additional pass-through payments to providers.

# 19. DIRECT PREMIUM WRITTEN/PRODUCED BY MANAGING GENERAL AGENTS/THIRD-PARTY ADMINISTRATORS

The Company did not have any direct premiums written or produced by managing general agents or third-party administrators in 2021 and 2020.

#### 20. FAIR VALUE MEASUREMENTS

The NAIC SAP defines fair value, establishes a framework for measuring fair value, and outlines the disclosure requirements related to fair value measurements. The fair value hierarchy is as follows:

Level 1 — Quoted (unadjusted) prices for identical assets in active markets.

Level 2 — Other observable inputs, either directly or indirectly, including:

- Quoted prices for similar assets in active markets;
- Quoted prices for identical or similar assets in nonactive markets (few transactions, limited information, noncurrent prices, high variability over time, etc.);
- Inputs other than quoted prices that are observable for the asset (interest rates, yield curves, volatilities, default rates, etc.);
- Inputs that are derived principally from or corroborated by other observable market data.

Level 3 — Unobservable inputs that cannot be corroborated by observable market data.

The estimated fair values of bonds and cash equivalents are based on quoted market prices, where available. The Company obtains one price for each security primarily from a third-party pricing service ("pricing service"), which generally uses quoted prices or other observable inputs for the determination of fair value. The pricing service normally derives the security prices through recently reported trades for identical or similar securities, making adjustments through the reporting date based upon available observable market information. For securities not actively traded, the pricing service may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. Inputs that are often used in the valuation methodologies include, but are not limited to, non-binding broker quotes, benchmark yields, credit spreads, default rates, and prepayment speeds. As the Company is responsible for the determination of fair value, it performs quarterly analyses on the prices received from the pricing service to determine whether the prices are reasonable estimates of fair value. Specifically, the Company compares the prices received from the pricing service to a secondary pricing source, prices reported by its custodian, its investment consultant, and third-party investment advisors. Additionally, the Company compares changes in the reported market values and returns to relevant market indices to test the reasonableness of the reported prices. The Company's internal price verification procedures and review of fair value methodology documentation provided by independent pricing services have not historically resulted in an adjustment in the prices obtained from the pricing service.

In instances in which the inputs used to measure fair value fall into different levels of the fair value hierarchy, the fair value measurement has been determined based on the lowest-level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular item to the fair value measurement in its entirety requires judgment, including the consideration of inputs specific to the asset or liability.

#### A. Fair Value

### (1) Fair Value Measurements at Reporting Date

The following tables present information about the Company's financial assets that are measured and reported at fair value at December 31, 2021 and 2020, in the financial statements according to the valuation techniques the Company used to determine their fair values:

	December 31, 2021											
Description for Each Class of Asset or Liability	(L	evel 1)	(Level 2)		Net Asset Value (NAV)		Total					
a. Assets at fair value:												
Perpetual preferred stock:												
Industrial and misc	\$	-	\$ -	\$ -	\$ -	\$	-					
Parent, subsidiaries, and affiliates						_						
Total perpetual preferred stocks		-					-					
Bonds:												
U.S. governments	2	,443,911	-	-	-		2,443,911					
Industrial and misc		-	-	-	-		-					
Hybrid securities		-	-	-	-		-					
Parent, subsidiaries, and affiliates		-				_						
Total bonds	2	,443,911					2,443,911					
Common stock:												
Industrial and misc		-	-	-	-		-					
Parent, subsidiaries, and affiliates							-					
Total common stocks							<u>-</u>					
Derivative assets:												
Interest rate contracts		-	-	-	-		-					
Foreign exchange contracts		-	-	-	-		-					
Credit contracts		-	-	-	-		-					
Commodity futures contracts		-	-	-	-		-					
Commodity forward contracts							-					
Total derivatives		-	-	-	-		-					
Money-market funds	14	,390,338	-	-	-		14,390,338					
Qualified cash pool	97	,016,876					97,016,876					
Total assets at fair value/NAV	\$ 113	,851,125	\$ -	\$ -	\$ -	\$ 1	13,851,125					
b. Liabilities at fair value:												
Derivative liabilities	\$	<u>-</u>	<u>\$ -</u>	\$ -	\$ -	\$						
Total liabilities at fair value	\$	-	\$ -	<u>\$ - </u>	<u>\$ -</u>	\$						

	December 31, 2020											
Description for Each Class of Asset or Liability	(Level 1)		(Level 2)	(Level 3)	Net Asset Value (NAV)	<b>.</b>	Total					
Assets at fair value:     Perpetual preferred stock:     Industrial and misc	\$	-	\$ -	\$ -	\$ -	\$	-					
Parent, subsidiaries, and affiliates	_	<u>-</u>		-			-					
Total perpetual preferred stocks	_	-					<u> </u>					
Bonds: U.S. governments Industrial and misc		4,492,494 -	- -	- -	- -		4,492,494 -					
Hybrid securities Parent, subsidiaries, and affiliates		-		<u>-</u>	<u>-</u>		-					
Total bonds		4,492,494					4,492,494					
Common stock: Industrial and misc Parent, subsidiaries, and affiliates			-	-	-		-					
Total common stocks		<u>-</u>					-					
Derivative assets:												
Interest rate contracts		-	-	-	-		-					
Foreign exchange contracts		-	-	-	-		-					
Credit contracts		-	-	-	-		-					
Commodity futures contracts Commodity forward contracts		<u>-</u>					<u>-</u>					
Total derivatives		-	-	-	-		-					
Money-market funds Qualified cash pool		17,208,562 72,069,395	- -	-	- -		17,208,562 72,069,395					
Total assets at fair value/NAV	\$	93,770,451	\$ -	\$ -	\$ -	\$	93,770,451					
b. Liabilities at fair value:												
Derivative liabilities	\$	-	\$ -	\$ -	\$ -	\$	-					
Total liabilities at fair value	\$	-	\$ -	\$ -	\$ -	\$	-					

- (2) The Company does not have any financial assets with a fair value hierarchy of Level 3 that were measured and reported at fair value.
- (3) Transfers between fair value hierarchy levels, if any, are recorded as of the beginning of the reporting period in which the transfer occurs. There were no transfers between Levels 1, 2 or 3 of any financial assets or liabilities during the years ended December 31, 2021 or 2020.
- (4) The Company has no investments reported with a fair value hierarchy of Level 2 or Level 3 and therefore has no valuation technique to disclose.
- (5) The Company has no derivative assets and liabilities to disclose.
- **B.** Fair Value Combination Not applicable.

#### C. Aggregate Fair Value Hierarchy

The aggregate fair value by hierarchy of all financial instruments as of December 31, 2021 and 2020 is presented in the table below:

	December 31, 2021												
Type of Financial Instrument	Aggregate Fair Value	Admitted Assets	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	Not Practicable (Carrying Value)						
U.S. government and agency securities State and agency municipal securities City and county municipal securities Corporate debt securities Cash equivalents	\$ 55,409,029 28,813,584 21,908,660 148,955,919 111,407,214	\$ 54,623,522 27,345,799 20,886,475 149,372,239 111,407,214	\$ 14,021,401 - - - - 111,407,214	\$ 41,387,628 28,813,584 21,908,660 148,955,919	\$ - - - -	\$ - - - - -	\$ - - - - -						
Total bonds and cash equivalents	\$ 366,494,406	\$ 363,635,249	\$ 125,428,615	\$ 241,065,791	\$ -	\$ -	\$ -						
				December 31, 2020									
Type of Financial Instrument	Aggregate Fair Value	Admitted Assets	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	Not Practicable (Carrying Value)						
U.S. government and agency securities State and agency municipal securities City and county municipal securities Corporate debt securities Cash equivalents	\$ 84,641,635 29,959,570 21,776,444 140,970,401 89,277,957	\$ 79,845,942 27,898,482 20,277,713 136,340,155 89,277,957	\$ 38,274,497 - - - - 89,277,957	\$ 46,367,138 29,959,570 21,776,444 140,970,401	\$ - - - -	\$ - - - - -	\$ - - - - -						
Total bonds and cash equivalents	\$ 366,626,007	\$ 353,640,249	\$ 127,552,454	\$ 239,073,553	\$ -	\$ -	\$ -						

- **D.** Not Practicable to Estimate Fair Value Not applicable.
- E. Investments Measured Using the NAV Practical Expedient Not applicable.

#### 21. OTHER ITEMS

#### **COVID-19 Trends and Uncertainties**

The COVID-19 pandemic continues to evolve and the ultimate overall impact to the Company's financial statements is uncertain and dependent on the future pacing, intensity and duration of the pandemic, the severity of new variants of the COVID-19 virus, the effectiveness and extent of administration of vaccination and treatments and general economic uncertainty.

### A. Unusual or Infrequent Items

The Company did not encounter any unusual or infrequent items for the years ended December 31, 2021 and 2020.

## B. Troubled Debt Restructuring: Debtors

The Company has no troubled debt restructurings as of December 31, 2021 and 2020.

# C. Other Disclosures

The Company does not have any amounts not recorded in the financial statements that represent segregated funds held for others. The Company also does not have any exposures related to forward commitments that are not derivative instruments.

# D. Business Interruption Insurance Recoveries

The Company has not received any business interruption insurance recoveries during 2021 and 2020.

#### E. State Transferable and Non-transferable Tax Credits

The Company has no transferable or non-transferable state tax credits.

#### F. Sub-Prime Mortgage-Related Risk Exposure

- (1) The investment policy for the Company limits investments in loan-backed securities, which includes sub-prime issuers. Further, the policy limits investments in private-issuer mortgage securities to 10% of the portfolio, which also includes sub-prime issuers. The exposure to unrealized losses on sub-prime issuers is due to changes in market prices. There are no realized losses due to not receiving anticipated cash flows. The investments covered have an NAIC designation of 1 or 2.
- (2) The Company has no direct exposure through investments in sub-prime mortgage loans.
- (3) The Company has no direct exposure through other investments.
- (4) The Company has no underwriting exposure to sub-prime mortgage risk through mortgage guaranty or financial guaranty insurance coverage.

#### G. Retained Assets

The Company does not have any retained asset accounts for beneficiaries.

#### H. Insurance-Linked Securities Contracts

As of December 31, 2021, the Company is not aware of any possible proceeds of insurance-linked securities.

I. The Amount That Could Be Realized on Life Insurance Where the Reporting Entity is Owner and Beneficiary or Has Otherwise Obtained Rights to Control the Policy — Not applicable.

#### 22. EVENTS SUBSEQUENT

Subsequent events have been evaluated through February 28, 2022, which is the date these financial statements were available for issuance.

## TYPE I — Recognized Subsequent Events

Any material Type I events subsequent to December 31, 2021, have been recognized in the financial statements and corresponding disclosures.

### TYPE II — Non-Recognized Subsequent Events

There are no material non-recognized Type II events that require disclosure.

#### 23. REINSURANCE

**Reinsurance Agreements** — In the normal course of business, the Company seeks to reduce potential losses that may arise from catastrophic events that cause unfavorable underwriting results by reinsuring certain levels of such risk with affiliated and other nonaffiliated reinsurers. The Company remains primarily liable as the direct insurer on all risks reinsured.

The Company has a reinsurance agreement with UHIC, an affiliate of the Company, through which 60% of earned comprehensive commercial member premiums, hospital and medical expenses, and operating expenses are transfer to UHIC. Reinsurance premiums of \$3,145,247 and \$3,814,544 for the years ended December 31, 2021 and 2020, respectively, were netted against net premium income in the financial statements. Reinsurance recoveries of \$2,342,222 and \$2,321,722 for the years ended December 31, 2021 and 2020, respectively, are included in net reinsurance recoveries in the financial statements. The Company transferred GAE and CAE of \$638,439 and \$1,893,058 in 2021 and 2020, respectively, to UHIC under this agreement. The Company recorded receivables related to changes in reserve estimates that includes changes related to medical loss ratio rebates of \$251,904 and \$125,967 in 2021 and 2020, respectively, which are netted against claims unpaid and aggregate health policy reserves within the financial statements. The Company recorded paid claim receivables related to this agreement, including payments made for the medical loss ratio rebates of \$170,577 and \$286,777 in 2021 and 2020, respectively, which are included in amounts recoverable from reinsurers within the financial statements. The Company recorded ceded reserves for provider incentives of \$66,787 and \$85,272 in 2021 and 2020, respectively, which is included in accrued medical incentive pool and bonus amounts in the financial statements. The agreement also provides insolvency-only protection for its enrollees. Fees related to this agreement, which are calculated based on a percentage of earned premiums, of \$1,598,829 and \$1,467,290 in 2021 and 2020, respectively, are netted against net premium income in the financial statements. This agreement also provides for reserve cap protection. Reinsurance contracts do not relieve the Company from its obligations to policyholders. Failure of reinsurers to honor their obligations could result in losses to the Company.

The Company also has a reinsurance agreement for its Medicaid product with UHIC. Under the provisions of the contract, the reinsurer indemnifies the Company for 80% of all eligible inpatient services in excess of \$300,000 per Medicaid member during each contract year. The Company ceded premiums of \$1,167,635 in 2021 and \$1,048,966 in 2020 to UHIC under this agreement. Reinsurance recoveries of \$614,535 and \$1,285,626 as of December 31, 2021 and 2020, respectively, are included in net reinsurance recoveries in the financial statements.

The effect of both internal and external reinsurance agreements outlined above on net premium income, hospital and medical expenses, GAE and CAE is presented below:

	2021	2020
Premiums:		
Direct	\$ 1,640,218,097	\$ 1,466,668,932
Ceded:		
Affiliate	5,911,710	6,330,800
Net premium income	\$ 1,634,306,387	\$ 1,460,338,132
Hospital and medical expenses:		
Direct	\$ 1,353,231,573	\$ 1,191,136,381
Ceded:		
Affiliate	2,956,757	3,607,218
Net hospital and medical expenses	<u>\$ 1,350,274,816</u>	<u>\$ 1,187,529,163</u>
General administrative expenses and		
claims adjustment expenses:		
Direct	\$ 156,070,837	\$ 183,874,600
Ceded: Affiliate	638,439	1,893,058
Ailliate	000,409	1,090,000
Net general administrative expenses and		
claims adjustment expenses	\$ 155,432,398	<u>\$ 181,981,542</u>

The Company recognized reinsurance recoveries related to internal and external reinsurance agreements of \$2,956,757 and \$3,607,218 in 2021 and 2020, respectively, which are recorded as net reinsurance recoveries in the financial statements. In addition, reinsurance recoverables related to internal reinsurance agreements of \$170,577 and \$286,777 for paid losses are recorded as amounts recoverable from reinsurers and \$810,690 and \$120,396 for unpaid losses are recorded as a reduction to claims unpaid in 2021 and 2020, respectively, in the financial statements.

# A. Ceded Reinsurance Report

## Section 1 — General Interrogatories

(1) Are any of the reinsurers, listed in Schedule S as non-affiliated, owned in excess of 10% or controlled, either directly or indirectly, by the Company or by any representative, officer, trustee, or director of the Company?

(2) Have any policies issued by the Company been reinsured with a company chartered in a country other than the United States (excluding U.S. branches of such companies) that is owned in excess of 10% or controlled directly or indirectly by an insured, a beneficiary, a creditor, or any other person not primarily engaged in the insurance business?

### Section 2 — Ceded Reinsurance Report — Part A

(1) Does the Company have any reinsurance agreements in effect under which the reinsurer may unilaterally cancel any reinsurance for reasons other than for nonpayment of premium or other similar credit?

(2) Does the reporting entity have any reinsurance agreements in effect that the amount of losses paid or accrued through the statement date may result in a payment to the reinsurer of amounts that, in aggregate and allowing for offset of mutual credits from other reinsurance agreements with the same reinsurer, exceed the total direct premium collected under the reinsured policies?

#### Section 3 — Ceded Reinsurance Report — Part B

(1) What is the estimated amount of the aggregate reduction in surplus (for agreements other than those under which the reinsurer may unilaterally cancel for reasons other than for nonpayment of premium or other similar credits that are reflected in Section 2 above) of termination of all reinsurance agreements, by either party, as of the date of this statement? Where necessary, the Company may consider the current or anticipated experience of the business reinsured in making this estimate.

The Company estimates there should be no aggregate reduction in surplus for termination of all reinsurance agreements as of December 31, 2021.

(2) Have any new agreements been executed or existing agreements amended, since January 1 of the year of this statement, to include policies or contracts that were in force or which had existing reserves established by the Company as of the effective date of the agreement?

Yes ( ) No (X)

- **B.** Uncollectible Reinsurance During 2021 and 2020, there were no uncollectible reinsurance recoverables
- C. Commutation of Ceded Reinsurance There was no commutation of reinsurance in 2021 or 2020.
- D. Certified Reinsurer Rating Downgraded or Status Subject to Revocation Not applicable.
- E. Reinsurance Credit.
  - (1) The Company has no ceding reinsurance contracts subject to Appendix A-791 *Life and Health Reinsurance Agreements* ("A-791") that include a provision which limits the reinsurer's assumption of significant risk.
  - (2) The Company has no ceding reinsurance contracts not subject to A-791, for which reinsurance accounting was applied and which include a provision that limits the reinsurer's assumption of risk.
  - (3) The Company's reinsurance contracts do not contain features which result in delays in payment in form or in fact.
  - (4) The Company has not reflected a reinsurance accounting credit for any assumption reinsurance contracts not subject to Appendix A-791 and not yearly renewable term, which meet the risk transfer requirements of SSAP No. 61R, *Life, Deposit-Type, and Accident and Health Reinsurance* ("SSAP No. 61R").
  - (5) The Company did not cede any risk which is not subject to A-791 and not yearly renewable term reinsurance, under any reinsurance contract during the period covered by these financial statements, for which the statutory accounting treatment and GAAP accounting treatment were not the same.
  - (6) The Company's ceded reinsurance contracts which are not subject to A-791 and not yearly renewable term reinsurance, are treated the same for GAAP and statutory accounting principles.

#### 24. RETROSPECTIVELY RATED CONTRACTS AND CONTRACTS SUBJECT TO REDETERMINATION

- **A**. The Company estimates accrued retrospective premium adjustments for its group health insurance business based on mathematical calculations in accordance with contractual terms.
- **B**. Estimated accrued retrospective premiums due to (from) the Company are recorded in premiums and considerations and aggregate health policy reserves in the financial statements and as an adjustment to change in unearned premium reserves and reserve for rate credits in the financial statements.
- C. Pursuant to the ACA, the Company's commercial and Medicare business is subject to retrospectively rated features based on the actual MLR experienced on the commercial and Medicare lines of business and redetermination features for premium adjustments for changes to each member's health scores based on guidelines determined by the ACA. The total amount of direct premiums written for the commercial and Medicare lines of business for which a portion is subject to the retrospectively rated and redetermination features was \$5,225,015 and \$6,336,048, and \$947,904,610 and \$905,136,716, representing <1% and <1%, and 58% and 62% of total direct premiums written as of December 31, 2021 and December 31, 2020, respectively.

The Company has Medicare Part D risk-corridor amounts from CMS which are subject to a retrospectively rated feature. The Company has estimated accrued retrospective premiums related to certain Part D premiums based on guidelines determined by CMS. The formula is tiered and based on the bid MLR. The amount of Medicare Part D direct premiums written subject to the retrospectively rated feature was \$30,658,390 and \$29,625,019, representing 2% and 2% of total direct premiums written as of December 31, 2021 and December 31, 2020, respectively.

CMS has released the final Medicaid Managed Care Rule which is subject to each State's administration elections. This rule is the first major update to the Medicaid Managed Care regulations in more than a decade, which includes a minimum loss ratio requirement. Pursuant to the regulations, premiums associated with the Company's Medicaid line of business is subject to retrospectively rated features based on the actual MLR experienced on this product. The calculation is pursuant to the Medicaid Managed Care guidance. The total amount of direct premiums written for the Medicaid line of business for which a portion is subject to the retrospectively rated and redetermination features was \$687,088,473 and \$555,196,168, representing 42% and 38% of total direct premiums written as of December 31, 2021 and December 31, 2020, respectively.

D. The Company is required to maintain specific minimum loss ratios on the comprehensive commercial and Medicare lines of business. The following table discloses the minimum MLR rebate liability for the Medicare line of business which is included in aggregate health policy reserves in the financial statements for the years ended December 31, 2021 and 2020:

	1	2 Small Group	3 Large Group	4 Other Categories	5
	Individual	Employer	Employer	with Rebates	Total
Prior reporting year					
(1) Medical loss ratio rebates incurred	\$ -	\$ -	\$ -	\$ 27,406,965	\$ 27,406,965
(2) Medical loss ratio rebates paid	-	-	-	-	-
(3) Medical loss rebates unpaid	-	-	-	27,472,424	27,472,424
(4) Plus reinsurance assumed amounts	XXX	XXX	XXX	XXX	-
(5) Less reinsurance ceded amounts	XXX	XXX	XXX	XXX	-
(6) Rebates unpaid net of reinsurance	XXX	XXX	XXX	XXX	27,472,424
Current reporting year-to-date					
(7) Medical loss ratio rebates incurred	-	-	-	(2,098,589)	(2,098,589)
(8) Medical loss ratio rebates paid	-	-	-	-	-
(9) Medical loss rebates unpaid	-	-	-	25,373,835	25,373,835
(10) Plus reinsurance assumed amounts	XXX	XXX	XXX	XXX	-
(11) Less reinsurance ceded amounts	XXX	XXX	XXX	XXX	-
(12) Rebates unpaid net of reinsurance	XXX	XXX	XXX	XXX	25,373,835

# E. Risk-Sharing Provisions of the Affordable Care Act

(1) The Company has accident and health insurance premiums in 2021 and 2020 subject to the risk-sharing provisions of the ACA.

The ACA imposed fees and premium stabilization provisions on health insurance issuers offering comprehensive commercial health insurance. The three premium stabilization programs are commonly referred to as the 3Rs — risk adjustment, reinsurance, and risk corridors.

Risk Adjustment — The risk adjustment program is a permanent program designed to mitigate the potential impact of adverse selection that generally applies to non-grandfathered individual and small group plans inside and outside of exchanges. The program helps to stabilize market premiums by transferring funds from plans with relatively low-risk enrollees to plans with relatively high-risk enrollees. The data used by CMS to determine the risk adjustment transfer amount is subject to audits along with the true-up to the final CMS report, which may result in a material change to arrive at the final risk adjustment amount from the initial risk adjustment estimate recorded. Premium adjustments pursuant to the risk adjustment program are accounted for as premium subject to redetermination and user fees are accounted for as assessments.

**Reinsurance and Risk Corridors**— The transitional reinsurance program and risk corridors program were temporary programs which expired at the end of 2016. The details of the years impacted and the amounts received are included in Note 24E 4 and Note 24E 5 below.

(2) The following table presents the current year impact of risk-sharing provisions of the ACA on assets, liabilities, and operations:

a. Permanent ACA Risk Adjustment Program	December 31, 2021
Assets	
Premium adjustments receivable due to ACA Risk Adjustment (including high-risk pool payments)	\$ 314,714
<u>Liabilities</u>	
2. Risk adjustment user fees payable for ACA Risk Adjustment	1,732
<ol><li>Premium adjustments payable due to ACA Risk Adjustment (including high-risk pool premium)</li></ol>	20,280
Operations (Revenue & Expense)	
Reported as revenue in premium for accident and health contracts (written/collected) due to ACA Risk Adjustment	94,473
<ol><li>Reported in expenses as ACA Risk Adjustment user fees (incurred/paid)</li></ol>	1,772
b. Transitional ACA Reinsurance Program	
<u>Assets</u>	
1. Amounts recoverable for claims paid due to ACA Reinsurance	\$ -
2. Amounts recoverable for claims unpaid due to ACA Reinsurance (Contra Liability)	-
<ol><li>Amounts receivable relating to uninsured plans for contributions for ACA Reinsurance</li></ol>	-
<u>Liabilities</u>	
Liabilities for contributions payable due to ACA Reinsurance	
<ul> <li>not reported as ceded premium</li> <li>Ceded reinsurance premiums payable due to ACA Reinsurance</li> </ul>	-
Ceded reinstrance premiums payable due to ACA Reinstrance     Liabilities for amounts held under uninsured plans contributions	-
for ACA Reinsurance	-
Operations (Revenue & Expense)	
7. Ceded reinsurance premiums due to ACA Reinsurance	-
8. Reinsurance recoveries (income statement) due to ACA	
reinsurance payments or expected payments	-
ACA Reinsurance contributions - not reported as ceded premium	-
c. Temporary ACA Risk Corridors Program	
<u>Assets</u>	
1. Accrued retrospective premium due to ACA Risk Corridors	\$ -
<u>Liabilities</u>	
<ol><li>Reserve for rate credits or policy experience rating refunds due to ACA Risk Corridors</li></ol>	-
Operations (Revenue & Expense)	
<ul><li>3. Effect of ACA Risk Corridors on net premium income (paid/received)</li><li>4. Effect of ACA Risk Corridors on change in reserves for rate credits</li></ul>	- -

(3) The following table is a rollforward of the prior year ACA risk-sharing provisions for asset and liability balances, along with reasons for adjustments to prior year balances:

	the Pr	d During ior Year ess Written ecember 31	the on Bu	Received or Paid as of the Current Year on Business Written before December 31		Prior Year Accrued Less Payments	Adjus To Prior Year	To Prior Year	-		calances as of orting Date  Cumulative  Balance from  Prior Years	
-	of the P	rior Year 2	of th	ne Prior Year 4	(Col 1 - 3)	(Col 2 - 4)	Balances 7	Balances 8	_	(Col 1 - 3 + 7)	(Col 2 - 4 + 8)	
	Receivable	(Payable)	Receiva	-	Receivable	-	Receivable	(Payable)	Ref	Receivable	(Payable)	
a. Permanent ACA Risk Adjustment Program												
Premium adjustment receivable (including high-risk pool payments)	\$ 7,922	\$ -	\$ -	· \$ -	\$ 7,922	\$ -	\$ (7,922)	\$ -	Α	\$ -	\$ -	
<ol><li>Premium adjustment (payable)</li></ol>												
(including high-risk pool premium)		(251,223)		(443,263)		192,040		(192,040)	В			
<ol><li>Subtotal ACA Permanent Risk</li></ol>												
Adjustment Program	7,922	(251,223)		(443,263)	7,922	192,040	(7,922)	(192,040)				
Transitional ACA Reinsurance Program												
Amounts recoverable for claims paid	-	-		· -	-	-	-	-	С	-	-	
Amounts recoverable for claims									_			
unpaid (contra liability)	-	-	-	-	-	-	-	-	D	-	-	
Amounts receivable relating to									_			
uninsured plans 4. Liabilities for contributions payable	-	-	•		-	-	-	-	Ε	-	-	
due to ACA Reinsurance—not												
reported as ceded premium	_	_			_	_	_	_	F	_	_	
Ceded reinsurance premiums payable	-	_			_	_	-	-	G	_	_	
Liability for amounts held under												
uninsured plans	_	_			_	_	_	-	Н	_	-	
7. Subtotal ACA Transitional												
Reinsurance Program	_	_			_	_	_	-		_	-	
. Temporary ACA Risk Corridors Program												
Accrued retrospective premium	-	-			_	-	-	-	- 1	_	-	
Reserve for rate credits or policy												
experience rating refunds	-	-			-	-	-	-	J	-	-	
3. Subtotal ACA Risk					<u> </u>							
Corridors Program	-	-			-	-	-	-		-	-	
. Total for ACA Risk-Sharing Provisions	\$ 7,922	\$ (251,223)	\$ -	\$ (443,263)	\$ 7,922	\$ 192,040	\$ (7,922)	\$ (192,040)		\$ -	\$ -	
Explanation of Adjustments  A. The risk adjustment receivable as of December			e through (					<u></u>	ad to n	rior periode was	adjusted based	
on the CMS' Summary Report on Permanent F Benefit Year Risk Adjustment Data Validation. Benefit Year, and Benefit Year 2019 Risk Adju. Adjustment Transfers published January 20, 2 B. The risk adjustment payable as of December: the CMS' Summary Report on Permanent Risk Year Risk Adjustment Data Validation Adjustm Year, and Benefit Year 2019 Risk Adjustment Transfers published January 20, 2022. C. N/A E. N/A E. N/A B. N/A I. N/A I. N/A J. N/A	Adjustments to ustment Data \ 2022. 31, 2020 utiliz a Adjustment T ents to Risk A	o Risk Adjustme Validation IVA re ed paid claims to Transfers for the djustment Tran	ent Transfer esults, as w through Oct e 2020 Ben sfers publis	s published Januar ell as CMS' Updated ober 31, 2020. As d efit Year. The risk a shed January 15, 20	y 15, 2021, CM d Summary Rep of the Reporting djustment paya 121, CMS' Final	S' Final Rule an ort of 2018 Ben Date, the risk ble was further Rule amending	mending Risk A nefit Year Risk A adjustment pay adjusted based g Risk Adjustme	djustment Data Adjustment Dat able related to d on CMS' Upda nt Data Validat	Valida a Valid prior p ated Si ion be	ation beginning w lation Adjustment periods was adjust ummary Report of ginning with the 2	ith the 2019 ts to Risk sted based on of 2017 Benefit	

(4) The Company does not have any risk corridor receivables or payables to present in the table below:

	Accrued	Accrued During the			December of or the			Differences				Adjustments					Unsettled Balances as of the Reporting Date			
	Prior Year on Business Written Before December 31 of the Prior Year		Busi	Prior Year Accrued Less Payments (Col				Prior Year Accrued Less Payments (Col 2-4)		To Prior Year Balances		Year \		To Prior Year Balances			Cumulative Balance from Prior Years (Col 1–3+7)		Balan Prio	nulative nce from r Years 2–4+8)
	1		2		3		4		5		6		7		8			9		10
Risk Corridors Program Year:	Receivable	(P	ayable)	Rec	eivable	(Pa	yable)	Rec	eivable	(Pa	yable)	Rece	eivable	(Pa	yable)	Ref	Rec	eivable	(Pa	yable)
a. 2014																				
Accrued retrospective premium     Reserve for rate credits or policy     experience rating refunds	\$ -	\$	-	\$	-	\$	-	\$	-	\$	-	\$	-	\$	-	A B	\$	-	\$	-
b. 2015																				
1. Accrued retrospective premium	-		-		-		-		-		-		-		-	С		-		-
Reserve for rate credits or policy experience rating refunds	-		-		-		-		-		-		-		-	D		-		-
c. 2016																				
Accrued retrospective premium     Reserve for rate credits or policy experience rating refunds	-		-		-		-				-		-		-	E F		-		-
d. Total for Risk Corridors	\$ -	\$	-	\$	-	\$	-	\$	-	\$	-	\$	-	\$	-	-	\$	-	\$	-

#### Explanation of Adjustments

- D.

(5) The following table discloses ACA risk corridor receivable balances by risk corridor program year:

	1		2		3	4	5		6
Risk Corridors Program Year:		Final	Non-Accrue Amounts for Impairment Other Reason	or or	ts received om CMS	Asset Balance Gross of Non- admissions) (1-2-3)	 admitted nount	Net Ad	mitted Asset (4-5)
a. 2014	\$	763	\$	-	\$ 763	\$ -	\$ -	\$	-
b. 2015		-		-	-	-	-		-
c. 2016		-		-	-	-	-		-
d. Total (a+b+c)	\$	763	\$	-	\$ 763	\$ =	\$ _	\$	_

### 25. CHANGE IN INCURRED CLAIMS AND CLAIMS ADJUSTMENT EXPENSES

A. Changes in estimates related to the prior year incurred claims are included in total hospital and medical expenses in the current year in the financial statements. The following tables disclose paid claims, incurred claims, and the balance in claims unpaid, accrued medical incentive pool and bonus amounts, aggregate health claim reserves, health care and other amounts receivable and reinsurance recoverables for the years ended December 31, 2021 and 2020:

		2021	
- -	Current Year Incurred Claims	Prior Years Incurred Claims	Total
Beginning of year claim reserve Paid claims—net of health care receivables	\$ -	\$ (176,413,879)	\$ (176,413,879)
and reinsurance recoveries collected End of year claim reserve	1,251,235,342 138,699,310	137,603,143 3,514,043	1,388,838,485 142,213,353
Incurred claims excluding the change in health care receivables and reinsurance recoverables as presented below	1,389,934,652	(35,296,693)	1,354,637,959
Beginning of year health care receivables and reinsurance recoverables End of year health care receivables	-	27,441,823	27,441,823
and reinsurance recoverables	(31,052,689)	(752,277)	(31,804,966)
Total incurred claims	\$ 1,358,881,963	<u>\$ (8,607,147)</u>	\$ 1,350,274,816
		2020	
	Current Year Incurred Claims	Prior Years Incurred Claims	Total
Beginning of year claim reserve Paid claims—net of health care receivables*	\$ -	\$ (151,373,360)	\$ (151,373,360)
and reinsurance recoveries collected End of year claim reserve	1,044,046,238 167,761,422	106,165,372 8,652,457	1,150,211,610 176,413,879
Incurred claims excluding the change in health care receivables and reinsurance recoverables as presented below	1,211,807,660	(36,555,531)	1,175,252,129
Beginning of year health care receivables* and reinsurance recoverables End of year health care receivables*	-	39,718,857	39,718,857
and reinsurance recoverables	(25,952,298)	(1,489,525)	(27,441,823)
Total incurred claims	\$ 1,185,855,362	\$ 1,673,801	\$ 1,187,529,163
*Health care receivebles evaludes provider leans o	and advances not	et averaged of CO and	

<sup>\*</sup>Health care receivables excludes provider loans and advances not yet expensed of \$0 and \$538 for 2020 and 2019, respectively.

The liability for claims unpaid, accrued medical incentive pool and bonus amounts, aggregate health claim reserves, health care and other amounts receivable and reinsurance recoverables as of December 31, 2020 was \$148,972,056. As of December 31, 2021, \$137,603,143 has been paid for incurred claims attributable to insured events of prior years. Reserves remaining for prior years, health care and other amounts receivable and reinsurance recoverables are now \$2,761,766 as a result of re-estimation of unpaid claims. Therefore, there has been \$8,607,147 favorable prior year development since December 31, 2020 to December 31, 2021. The primary drivers consist of favorable development as a result of a change in the provision for adverse deviations in experience of \$7,310,959, favorable development of \$5,662,527 in retroactivity for inpatient, outpatient, physician, and pharmacy claims partially offset by unfavorable change of \$3,460,173 in risk share activity.

At December 31, 2020, the Company recorded \$1,673,801 unfavorable prior year development related to a change of \$4,211,757 in risk share, \$1,517,501 in stop loss, \$1,094,628 in provider settlement; \$956,444 in capitation, \$352,418 in reinsurance, and \$313,668 in retroactivity for inpatient, outpatient and physician; partially offset by favorable development of \$6,716,777 as a result of a favorable change in the provision for adverse deviations in experience. Original estimates are increased or decreased, as additional information becomes known regarding individual claims, which could have an impact to the accruals for medical loss ratio rebates and retrospectively rated contracts. As a result of the prior year effects, on a regular basis, the Company adjusts revenue and the corresponding liability and/or receivable related to retrospectively rated policies and the impact of the change is included as a component of change in unearned premium reserves and reserve for rate credits in the financial statements.

The Company incurred CAE of \$55,244,420 and \$51,311,487 in 2021 and 2020, respectively. These costs are included in the management service fees paid by the Company to UHS as a part of the Agreement (see Note 10). The following table discloses paid CAE, incurred CAE, and the balance in unpaid CAE reserve for 2021 and 2020:

	2021	2020
Total claims adjustment expenses Less: current year unpaid claims adjustment expenses Add: prior year unpaid claims adjustment expenses	\$ 55,244,420 (1,006,386) 1,156,247	\$ 51,311,487 (1,156,247) 1,153,055
Total claims adjustment expenses paid	\$ 55,394,281	\$ 51,308,295

**B.** The Company did not make any significant changes in methodologies and assumptions used in the calculation of the liability for claims unpaid and unpaid CAE in 2021.

# 26. INTERCOMPANY POOLING ARRANGEMENTS

**A–G.** The Company did not have any intercompany pooling arrangements in 2021 or 2020.

# 27. STRUCTURED SETTLEMENTS

A-B. The Company did not have structured settlements in 2021 or 2020.

# 28. HEALTH CARE AND OTHER AMOUNTS RECEIVABLE

A. Pharmacy rebates receivable are recorded when reasonably estimated or billed by the affiliated pharmaceutical benefit manager in accordance with pharmaceutical rebate contract provisions. Information used to support rebates billed to the manufacturer is based on utilization information gathered by the pharmaceutical benefit manager and adjusted for significant changes in pharmaceutical contract provisions.

The Company evaluates admissibility of all pharmacy rebates receivable based on the administration of each underlying pharmaceutical benefit management agreement. The Company has nonadmitted and excluded all pharmacy rebates receivable that do not meet the admissibility criteria of SSAP No. 84, *Health Care and Government Insured Plan Receivables* ("SSAP No. 84") from the financial statements.

For each pharmaceutical management agreement for which a portion of the total pharmacy rebates receivable can be admitted based on the admissibility criteria of SSAP No. 84, the pharmacy rebate transaction history is summarized as follows:

	<b>Estimated</b>		Actual	Actual	Actual
	Pharmacy	Pharmacy	Rebates	Rebates	Rebates
	Rebates as	Rebates as	Received	Received	Received
	Reported on	Billed or	within 90	within 91 to	More than
	Financial	Otherwise	Days of	180 Days of	180 Days
Quarter	Statements	Confirmed	Billing	Billing	after Billing
12/31/2021	\$ 20,706,827	\$ 6,765,545	\$ -	\$ -	\$ -
9/30/2021	20,335,866	20,670,446	12,751,473	-	-
6/30/2021	20,430,061	20,526,483	17,829,519	2,026,728	-
3/31/2021	20,367,318	20,197,223	15,853,091	3,217,838	353,130
12/31/2020	17,188,497	16,630,918	13,469,974	2,890,964	134,521
9/30/2020	16,857,695	16,692,037	13,841,799	2,368,500	301,118
6/30/2020	16,884,654	16,357,959	13,566,548	2,525,664	323,009
3/31/2020	17,052,463	16,508,283	6,371,604	10,225,103	163,243
12/31/2019	15,187,697	15,442,744	11,383,470	2,790,752	975,573
9/30/2019	14,964,097	15,109,846	11,002,671	2,720,992	1,219,144
6/30/2019	15,219,293	15,161,792	10,377,693	4,284,234	383,859
3/31/2019	15,373,602	15,058,555	11,918,966	1,747,268	1,320,266

Of the amount reported as health care and other amounts receivable, \$28,229,001 and \$23,350,606 relates to pharmacy rebates receivable as of December 31, 2021 and 2020, respectively. This increase is primarily due to increased membership.

**B.** The Company has nonadmitted all risk-sharing receivables from the financial statements.

The Company also admitted receivables of \$1,154,534 and \$0 of provider receivables resulting from capitation arrangements and \$1,040,709 and \$2,141,391 for receivables from the State of Rhode Island for the stop loss program as of December 31, 2021 and December 31, 2020, respectively, which are included in health care and other amounts receivable in the financial statements.

#### 29. PARTICIPATING POLICIES

The Company did not have any participating contracts in 2021 or 2020.

# 30. PREMIUM DEFICIENCY RESERVES

The Company has not recorded any PDR as of December 31, 2021 or 2020. The analysis of PDR was completed as of December 31, 2021 and 2020. The Company did consider anticipated investment income when calculating the PDR.

The following table summarizes the Company's PDR as of December 31, 2021 and 2020:

		2021
1. Liability carried for premium deficiency reserves	\$	-
2. Date of the most recent evaluation of this liability	12	/31/2021
3. Was anticipated investment income utilized in this calculation?	Yes 🗀	No
		2020
1. Liability carried for premium deficiency reserves	\$	-
2. Date of the most recent evaluation of this liability	12	/31/2020
3. Was anticipated investment income utilized in this calculation?	Yes 🗀	Π No Γ

### 31. ANTICIPATED SALVAGE AND SUBROGATION

Due to the type of business being written, the Company has no salvage. As of December 31, 2021 and 2020, the Company had no specific accruals established for outstanding subrogation, as it is considered a component of the actuarial calculations used to develop the estimates of claims unpaid and aggregate health claim reserves.

# **GENERAL INTERROGATORIES**

# PART 1 - COMMON INTERROGATORIES GENERAL

1.1	Is the reporting entity a member of an Insurance Holding Company System consisting of two or more affiliated persons, one or more of w is an insurer?		Yes [ X	] No [	]
1.2	If yes, complete Schedule Y, Parts 1, 1A, 2 and 3.  If yes, did the reporting entity register and file with its domiciliary State Insurance Commissioner, Director or Superintendent, or with such regulatory official of the state of domicile of the principal insurer in the Holding Company System, a registration statement providing disclosure substantially similar to the standards adopted by the National Association of Insurance Commissioners (NAIC) in its Model Insurance Holding Company System Regulatory Act and model regulations pertaining thereto, or is the reporting entity subject to standards and disclosure requirements substantially similar to those required by such Act and regulations?	Yes [ X	] No [	] N/A [	1
1.3	State Regulating?		Rhode I	sland	
1.4	Is the reporting entity publicly traded or a member of a publicly traded group?		Yes [ X	] No [	]
1.5	If the response to 1.4 is yes, provide the CIK (Central Index Key) code issued by the SEC for the entity/group.		000073	31766	
2.1	Has any change been made during the year of this statement in the charter, by-laws, articles of incorporation, or deed of settlement of the reporting entity?		Yes [	] No [ X	]
2.2	If yes, date of change:				
3.1	State as of what date the latest financial examination of the reporting entity was made or is being made.		12/31/	2018	
3.2	State the as of date that the latest financial examination report became available from either the state of domicile or the reporting entity. This date should be the date of the examined balance sheet and not the date the report was completed or released.		12/31/	2018	
3.3	State as of what date the latest financial examination report became available to other states or the public from either the state of domicile or the reporting entity. This is the release date or completion date of the examination (balance sheet date).		06/11/	′2020	
3.4	By what department or departments? Rhode Island Department of Business Regulation				
3.5	Have all financial statement adjustments within the latest financial examination report been accounted for in a subsequent financial statement filed with Departments?	Yes [	] No [	] N/A [	Х]
3.6	Have all of the recommendations within the latest financial examination report been complied with?	Yes [	] No [	] N/A [	Х ]
4.1 4.2	During the period covered by this statement, did any agent, broker, sales representative, non-affiliated sales/service organization or any combination thereof under common control (other than salaried employees of the reporting entity), receive credit or commissions for or composition as substantial part (more than 20 percent of any major line of business measured on direct premiums) of:  4.11 sales of new business?  4.12 renewals?  During the period covered by this statement, did any sales/service organization owned in whole or in part by the reporting entity or an affiliated sales/service organization or any combination or any com			] No [ X ] No [ X	
	receive credit or commissions for or control a substantial part (more than 20 percent of any major line of business measured on direct premiums) of:  4.21 sales of new business?		Yes [	] No [ X	1
	4.22 renewals?		_	] No [ X	-
5.1	Has the reporting entity been a party to a merger or consolidation during the period covered by this statement?		Yes [	] No [ X	]
5.2	If yes, provide the name of the entity, NAIC Company Code, and state of domicile (use two letter state abbreviation) for any entity that has ceased to exist as a result of the merger or consolidation.	S			
	1 Name of Entity NAIC Company Code State of Domicile				
6.1	Has the reporting entity had any Certificates of Authority, licenses or registrations (including corporate registration, if applicable) suspenderevoked by any governmental entity during the reporting period?		Yes [	] No [ X	]
6.2	If yes, give full information:	·			
7.1	Does any foreign (non-United States) person or entity directly or indirectly control 10% or more of the reporting entity?		Yes [	] No [ X	]
7.2	If yes,		,	2.0	
	<ul><li>7.21 State the percentage of foreign control;</li></ul>	<u>-</u>	(	0.0	%
	1 2 Nationality Type of Entity				

8.1 8.2	Is the company a subsidiary of a depository institution holding compa If the response to 8.1 is yes, please identify the name of the DIHC.					Yes [	]	No [	Х]	
8.3 8.4	Is the company affiliated with one or more banks, thrifts or securities If response to 8.3 is yes, please provide below the names and location regulatory services agency [i.e. the Federal Reserve Board (FRB), the Insurance Corporation (FDIC) and the Securities Exchange Commission	on (city and state of the main office) of any affiliates rue office of the Comptroller of the Currency (OCC), the	egulated	by a fed	deral	Yes [ )	( ]	No [	]	
	1	2	3	4	5	6	1			
	Affiliate Name  Optum Bank, Inc.	Location (City, State)	FRB NO	OCC	FDIC	SEC	_			
	Optum bank, Inc.			NO	YES					
8.5	Is the reporting entity a depository institution holding company with si Federal Reserve System or a subsidiary of the reporting entity?					Yes [	_	No [	Х]	
8.6	If response to 8.5 is no, is the reporting entity a company or subsidiar Federal Reserve Board's capital rule?				es [	] No [	Χ]	N/A	[ ]	
9.	What is the name and address of the independent certified public according Deloitte & Touche LLP, Minneapolis, MN.									
10.1	Has the insurer been granted any exemptions to the prohibited non-a requirements as allowed in Section 7H of the Annual Financial Reportance or regulation?	rting Model Regulation (Model Audit Rule), or substa	ntially sii	nilar sta	ite	Yes [	]	No [	Х ]	
10.2	If the response to 10.1 is yes, provide information related to this exen	nption: 								
10.3	Has the insurer been granted any exemptions related to the other red	uirements of the Annual Financial Reporting Model	Regulation	on as		V [	,	Ni. T	V 1	
10.4	allowed for in Section 18A of the Model Regulation, or substantially s If the response to 10.3 is yes, provide information related to this exen	nption:				Yes [	J	NO [	λ ]	
10.5 10.6	Has the reporting entity established an Audit Committee in compliance of the response to 10.5 is no or n/a, please explain	ce with the domiciliary state insurance laws?				] No [	]	N/A	[ ]	
11.	What is the name, address and affiliation (officer/employee of the rep firm) of the individual providing the statement of actuarial opinion/cert Gary A. Iannone, Vice President of Actuarial Services of United Healt Inc., 185 Asylum Street, Hartford, CT 06103	oriting entity or actuary/consultant associated with ar tification? thCare Services Inc., an affiliate of UnitedHealthcare	of New	al consu England	Iting I,					
12.1	Does the reporting entity own any securities of a real estate holding of					Yes [	]	No [	Х]	
	12.11 Name of real	estate holding company								
		arcels involved								
40.0		djusted carrying value				\$			0	
12.2	If, yes provide explanation:									
13.	FOR UNITED STATES BRANCHES OF ALIEN REPORTING ENTIT									
13.1	What changes have been made during the year in the United States									
13.2	1 0	entity through its United States Branch on risks when	ever loc	ated?		Yes [	-	No [	]	
13.3	Have there been any changes made to any of the trust indentures du					Yes [	•		]	
13.4	If answer to (13.3) is yes, has the domiciliary or entry state approved Are the senior officers (principal executive officer, principal financial of					] No [	]	N/A	[ ]	
14.1	similar functions) of the reporting entity subject to a code of ethics, what a. Honest and ethical conduct, including the ethical handling of actual	hich includes the following standards?				Yes [ )	( ]	No [	]	
	relationships; b. Full, fair, accurate, timely and understandable disclosure in the per c. Compliance with applicable governmental laws, rules and regulation		ity;							
	d. The prompt internal reporting of violations to an appropriate persor									
14.11	e. Accountability for adherence to the code. If the response to 14.1 is No, please explain:									
14.2	Has the code of ethics for senior managers been amended?					Yes [ )	( ]	No [	]	
14.21	If the response to 14.2 is yes, provide information related to amendm	. ,				-		·	-	
14.3	Non-material updates to the existing code. Amendments include expa a commitment to ethical marketing, defining intellectual property, and Have any provisions of the code of ethics been waived for any of the	articulating our commitments to human rights, inclu	sion and	diversit	y	Yes [	J	No [	X 1	
14.31	If the response to 14.3 is yes, provide the nature of any waiver(s).					-	-	-	-	

2 If the response	st? e to 15.1 is yes, indicate the American Bankers Association etter of Credit and describe the circumstances in which the	on (ABA) Routing Number a	nd the name of the issuing or confirming	Yes [ ]	No [ X
1 American Bankers Association	2		3	4	
(ABA) Routing	g Issuing or Confirming Bank Name	Circumstances Th	nat Can Trigger the Letter of Credit	Amour	nt
	BOAR	D OF DIRECTORS			
Is the purchas	e or sale of all investments of the reporting entity passed	D OF DIRECTORS upon either by the board of	directors or a subordinate committee	Yes [ X ]	No ſ
Does the repo	orting entity keep a complete permanent record of the proc	ceedings of its board of direc	ctors and all subordinate committees	Yes [ X ]	
	ting entity an established procedure for disclosure to its bo its officers, directors, trustees or responsible employees the			Yes [ X ]	No [
		FINANCIAL			
Has this state Accounting Pr	ment been prepared using a basis of accounting other tha inciples)?	an Statutory Accounting Prin	ciples (e.g., Generally Accepted	Yes [ ]	No [ X
Total amount	loaned during the year (inclusive of Separate Accounts, e	exclusive of policy loans):	20.11 To directors or other officers	\$	
			20.12 To stockholders not officers		
		:	20.13 Trustees, supreme or grand (Fraternal Only)	Φ.	
Total amount	of loons outstanding at the and of year (inclusive of Sanar	rata Assaunta, avaluaiva af	(Fraternal Only)	.\$	
policy loans):	of loans outstanding at the end of year (inclusive of Separ	rate Accounts, exclusive of	20.21 To directors or other officers	\$	
pooy			20.22 To stockholders not officers	\$	
		:	20.23 Trustees, supreme or grand (Fraternal Only)		
obligation beir	ets reported in this statement subject to a contractual obling reported in the statement?		party without the liability for such	Yes [ ]	No [ X
If yes, state th	e amount thereof at December 31 of the current year:	:	21.21 Rented from others	\$	
			21.22 Borrowed from others		
			21.23 Leased from others		
Does this state	ement include payments for assessments as described in ciation assessments?	the Annual Statement Instru	21.24 Other uctions other than guaranty fund or		
If answer is ye			21 Amount paid as losses or risk adjustment		
			22 Amount paid as expenses		
			23 Other amounts paid		
Does the repo	orting entity report any amounts due from parent, subsidiar				
If yes, indicate	e any amounts receivable from parent included in the Pago rer utilize third parties to pay agent commissions in which	e 2 amount:the amounts advanced by t	he third parties are not settled in full within	\$	3,065
90 days? If the response	e to 24.1 is yes, identify the third-party that pays the agent	ts and whether they are a re	lated party.	Yes [ ]	No [ X
		Is the			
		Third-Party Agen			
	Name of Third-Party	a Related Party (Yes/No)			
	li i	NVESTMENT			
	stocks, bonds and other securities owned December 31 of session of the reporting entity on said date? (other than s			Yes [ X ]	No [

25.02	If no, give full and complete information relating thereto				
25.03		ogram including value for collateral and amount of loaned securities, and tive is to reference Note 17 where this information is also provided)			
25.04	For the reporting entity's securities lending program, report amo	unt of collateral for conforming programs as outlined in the Risk-Based Capital	\$		0
25.05	For the reporting entity's securities lending program, report amo	unt of collateral for other programs.	\$		0
25.06		ecurities) and 105% (foreign securities) from the counterparty at theYes [	] No [	] N/A	[ X ]
25.07	Does the reporting entity non-admit when the collateral received	from the counterparty falls below 100%? Yes [	] No [	] N/A	[ X ]
25.08	Does the reporting entity or the reporting entity 's securities lend conduct securities lending?	ing agent utilize the Master Securities lending Agreement (MSLA) to Yes [	] No [	] N/A	[ X ]
25.09	For the reporting entity's securities lending program state the ar	nount of the following as of December 31 of the current year:			
	25.092 Total book adjusted/carrying value of re	invested collateral assets reported on Schedule DL, Parts 1 and 2	\$		0
26.1	control of the reporting entity, or has the reporting entity sold or	entity owned at December 31 of the current year not exclusively under the transferred any assets subject to a put option contract that is currently in 03).	Yes [ )	( ] No [	]
26.2	If yes, state the amount thereof at December 31 of the current y	ear: 26.21 Subject to repurchase agreements	\$		0 0
		26.23 Subject to dollar repurchase agreements	\$		0
		26.24 Subject to reverse dollar repurchase agreements  26.26 Placed under option agreements			
		26.26 Letter stock or securities restricted as to sale - excluding FHLB Capital Stock			
		26.27 FHLB Capital Stock	\$		0
		26.28 On deposit with states	\$ \$	3,43	36,068 0
		26 30 Pledged as collateral - excluding collateral pledged in	n		
		an FHLB			
		26.31 Pledged as collateral to FHLB - including assets backing funding agreements	\$ \$		0 0
26.3	For category (26.26) provide the following:				
26.3	For category (26.26) provide the following:  1  Nature of Restriction	2 Description		3 ount	
26.3	1		Am	ount	
26.3	Nature of Restriction  Does the reporting entity have any hedging transactions reporte	d on Schedule DB?	Am Yes [	ount ] No [	_
	Nature of Restriction  Does the reporting entity have any hedging transactions reporte	Description	Am Yes [	ount ] No [	_
27.1 27.2	Nature of Restriction  Does the reporting entity have any hedging transactions reporte  If yes, has a comprehensive description of the hedging program	d on Schedule DB? been made available to the domiciliary state? Yes [	Am Yes [	ount ] No [	_
27.1 27.2	Nature of Restriction  Does the reporting entity have any hedging transactions reporte  If yes, has a comprehensive description of the hedging program  If no, attach a description with this statement.  7.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITION.	d on Schedule DB? been made available to the domiciliary state? Yes [	Yes [	ount ] No [	[ ]
27.1 27.2 INES 2	Nature of Restriction  Nature of Restriction  Does the reporting entity have any hedging transactions reporter of the sed of the hedging program of the hedge variable and the hedge variable and the response to 27.3 is YES, does the reporting entity utilize:	Description  d on Schedule DB?	Yes [ ] No [	No [ ] No [	[ ]
27.1 27.2 LINES 2 27.3	Nature of Restriction  Does the reporting entity have any hedging transactions reporter of the second of the hedging program of the hedgi	Description  d on Schedule DB?	Yes [ Yes [ Yes [ Yes [ Yes [	No [ ] No [ ] No [ ] No [ ] No [	[ ]
27.1 27.2 LINES 2 27.3	Nature of Restriction  Does the reporting entity have any hedging transactions reporter of the second of the hedging program of the hedgi	Description  d on Schedule DB?	Yes [ Yes [ Yes [ Yes [ Yes [	No [ ] No [ ] No [	[ ]
27.1 27.2 LINES 2 27.3	Nature of Restriction  Does the reporting entity have any hedging transactions reporter lifyes, has a comprehensive description of the hedging program If no, attach a description with this statement.  7.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITY Does the reporting entity utilize derivatives to hedge variable and lift the response to 27.3 is YES, does the reporting entity utilize:  27 27 27 27 By responding YES to 27.41 regarding utilizing the special according to the reporting that the special according to	Description  d on Schedule DB?	Yes [	No [ ] No [	
27.1 27.2 INES 2 27.3 27.4	Nature of Restriction  If yes, has a comprehensive description of the hedging program of the notation at the notation with this statement.  7.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITY  Does the reporting entity utilize derivatives to hedge variable and of the response to 27.3 is YES, does the reporting entity utilize:  You will be responding YES to 27.41 regarding utilizing the special accordiolowing:  The reporting entity has obtained explicit approval from the Hedging strategy subject to the special accounting proval reserves and provides the impact of the hedging strate reserves and provides the impact of the hedging strate Financial Officer Certification has been obtained which	Description  d on Schedule DB?	Yes [	No [ ] No [ ] No [ ] No [ ] No [	
27.1 27.2 INES 2 27.3 27.4	Nature of Restriction  If yes, has a comprehensive description of the hedging program of the near	Description  d on Schedule DB?	Yes [	No [ ] No [	
27.1 27.2 INES 2 27.3 27.4	Nature of Restriction  Does the reporting entity have any hedging transactions reporter of the second program of the hedging entity of the hedgin	Description  d on Schedule DB?  been made available to the domiciliary state?	Yes [	No [   No [ ]	[ ]
27.1 27.2 IINES 2 27.3 27.4 27.5	Nature of Restriction  Nature of Restriction  Does the reporting entity have any hedging transactions reported from the program of the hedging program of the nedgeng program of the ne	Description  d on Schedule DB?  been made available to the domiciliary state?	Yes [	No [   No [ ]	[ ] ] X ]0
27.1 27.2 INES 2 27.3 27.4 27.5	Nature of Restriction  Does the reporting entity have any hedging transactions reporter of the second program of the hedging program of the nedgeng program of t	Description  d on Schedule DB?  been made available to the domiciliary state?	Yes [	Ount    No [   N	[ ] ] X ]0
27.1 27.2 INES 2 27.3 27.4 27.5	Nature of Restriction  If yes, has a comprehensive description of the hedging program of no, attach a description with this statement.  Nature of Restriction of the hedging program of no, attach a description with this statement.  Nature of Restriction of the hedging program of the response to 27.5: FOR LIFE/FRATERNAL REPORTING ENTITION  Does the reporting entity utilize derivatives to hedge variable and of the response to 27.3 is YES, does the reporting entity utilize:  27  27  27  By responding YES to 27.41 regarding utilizing the special accordiolowing:  The reporting entity has obtained explicit approval from the Hedging strategy subject to the special accounting provious to the special official within the clearly Derivous transfer of the hedging strate of the hedging	Description  d on Schedule DB?  been made available to the domiciliary state?  Pes [  ES ONLY:  nuity guarantees subject to fluctuations as a result of interest rate sensitivity?  41 Special accounting provision of SSAP No. 108  42 Permitted accounting practice  43 Other accounting guidance  unting provisions of SSAP No. 108, the reporting entity attests to the  the domiciliary state.  visions is consistent with the requirements of VM-21.  Is that the hedging strategy is incorporated within the establishment of VM-21 gy within the Actuarial Guideline Conditional Tail Expectation Amount.  Indicates that the hedging strategy meets the definition of a Clearly Defined fined Hedging Strategy is the hedging strategy being used by the company in  of the current year mandatorily convertible into equity, or, at the option of the ear.  estate, mortgage loans and investments held physically in the reporting entity's and other securities, owned throughout the current year held pursuant to a coordance with Section 1, III - General Examination Considerations, F. eements of the NAIC Financial Condition Examiners Handbook, complete the following:	Yes [	Ount    No [   N	[ ] ] XX]0
27.1 27.2 INES 2 27.3 27.4 27.5	Nature of Restriction  Nature of Restriction  Does the reporting entity have any hedging transactions reported if yes, has a comprehensive description of the hedging program if no, attach a description with this statement.  7.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITION Does the reporting entity utilize derivatives to hedge variable and if the response to 27.3 is YES, does the reporting entity utilize:  27 27 27 27  By responding YES to 27.41 regarding utilizing the special accordiolowing:  • The reporting entity has obtained explicit approval from extracting entity has obtained explicit approval from the Hedging strategy subject to the special accounting proverse and provides the impact of the hedging strate exerves and provides t	Description  d on Schedule DB?  been made available to the domiciliary state?	Yes [	Ount    No [   N	[ ] ] XX]0

# **GENERAL INTERROGATORIES**

9.02	For all agreements that do not comply with the requirements of the INAIC Financial Condition Examiners Handbook, provide the name, location
	and a complete explanation:

1	2	3
Name(s)	Location(s)	Complete Explanation(s)

1	2	3	4
Old Custodian	New Custodian	Date of Change	Reason

29.05 Investment management – Identify all investment advisors, investment managers, broker/dealers, including individuals that have the authority to make investment decisions on behalf of the reporting entity. For assets that are managed internally by employees of the reporting entity, note as such. ["...that have access to the investment accounts"; "...handle securities"]

1	2
Name of Firm or Individual	Affiliation
J.P. Morgan Asset Management	U
DWS Investment Management Americas Inc.	U
BlackRock Financial Management, Inc	U
Internally Managed	1
, , , , , , , , , , , , , , , , , , , ,	

29.06 For those firms or individuals listed in the table for 29.05 with an affiliation code of "A" (affiliated) or "U" (unaffiliated), provide the information for

1	2	3	4	5
				Investment
				Management
Central Registration				Agreement
Depository Number	Name of Firm or Individual	Legal Entity Identifier (LEI)	Registered With	(IMA) Filed
107038	J.P. Morgan Asset Management	549300W78QHV4XMM6K69	SEC	NO
104518	DWS Investment Management Americas Inc.	CZ83K4EEEX8QVCT3B128	SEC	NO
107105	BlackRock Financial Management, Inc	549300LVXY1VJKE13M84	SEC	NO
	• • • • • • • • • • • • • • • • • • • •			

30.2 If yes, complete the following schedule:

the table below.

1	2	3
OLIGIP "		Book/Adjusted
CUSIP#	Name of Mutual Fund	Carrying Value
30.2999 - Total		0

30.3 For each mutual fund listed in the table above, complete the following schedule:

1	2	3	4
		Amount of Mutual	
		Fund's Book/Adjusted	
		Carrying Value	
	Name of Significant Holding of the	Attributable to the	Date of
Name of Mutual Fund (from above table)	Mutual Fund	Holding	Valuation

# **GENERAL INTERROGATORIES**

31. Provide the following information for all short-term and long-term bonds and all preferred stocks. Do not substitute amortized value or statement value for fair value.

	1	2	3
			Excess of Statement
			over Fair Value (-), or
	Statement (Admitted)		Fair Value over
	Value	Fair Value	Statement (+)
31.1 Bonds	252,228,035	255,087,193	2,859,158
31.2 Preferred stocks	0	0	0
31.3 Totals	252,228,035	255,087,193	2,859,158

31.4	Describe the sources or methods utilized in determining the fair values:  For those securities that had prices in the NAIC SVO ISIS database, those prices were used; for those securities that did not have prices in the NAIC SVO ISIS database, pricing was obtained from Hub which is an external data sources vendor. Hub utilizes various pricing sources.							
32.1	Was the rate used to calculate fair value determined by a broker or custodian for any of the securities in Schedule D?	Υ	es [	]	No [ ]	X ]		
32.2	32.2 If the answer to 32.1 is yes, does the reporting entity have a copy of the broker's or custodian's pricing policy (hard copy or electronic copy) for all brokers or custodians used as a pricing source?							
32.3	If the answer to 32.2 is no, describe the reporting entity's process for determining a reliable pricing source for purposes of disclosure of fair value for Schedule D:  N/A							
33.1 33.2	Have all the filing requirements of the Purposes and Procedures Manual of the NAIC Investment Analysis Office been followed?	Υ	es [ )	( ]	No [	]		
34.	By self-designating 5GI securities, the reporting entity is certifying the following elements of each self-designated 5GI security:  a. Documentation necessary to permit a full credit analysis of the security does not exist or an NAIC CRP credit rating for an FE or PL security is not available.  b. Issuer or obligor is current on all contracted interest and principal payments.  c. The insurer has an actual expectation of ultimate payment of all contracted interest and principal.							
	Has the reporting entity self-designated 5GI securities?	Υ	es [	]	No [ ]	X ]		
35.	By self-designating PLGI securities, the reporting entity is certifying the following elements of each self-designated PLGI security:  a. The security was purchased prior to January 1, 2018.  b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security.  c. The NAIC Designation was derived from the credit rating assigned by an NAIC CRP in its legal capacity as a NRSRO which is shown on a current private letter rating held by the insurer and available for examination by state insurance regulators.  d. The reporting entity is not permitted to share this credit rating of the PL security with the SVO.							
	Has the reporting entity self-designated PLGI securities?	Υ	es [	]	No [ ]	Χ]		
36.	By assigning FE to a Schedule BA non-registered private fund, the reporting entity is certifying the following elements of each self-designated FE fund:  a. The shares were purchased prior to January 1, 2019.  b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security.  c. The security had a public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO prior to January 1, 2019.  d. The fund only or predominantly holds bonds in its portfolio.  e. The current reported NAIC Designation was derived from the public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO.  f. The public credit rating(s) with annual surveillance assigned by an NAIC CRP has not lapsed.  Has the reporting entity assigned FE to Schedule BA non-registered private funds that complied with the above criteria?	Υ	es [	1	No [ 2	X ]		
37.	By rolling/renewing short-term or cash equivalent investments with continued reporting on Schedule DA, Part 1 or Schedule E Part 2 (identified through a code (%) in those investment schedules), the reporting entity is certifying to the following:  a. The investment is a liquid asset that can be terminated by the reporting entity on the current maturity date.  b. If the investment is with a nonrelated party or nonaffiliate, then it reflects an arms-length transaction with renewal completed at the discretion of all involved parties.  c. If the investment is with a related party or affiliate, then the reporting entity has completed robust re-underwriting of the transaction for which documentation is available for regulator review.  d. Short-term and cash equivalent investments that have been renewed/rolled from the prior period that do not meet the criteria in 37.a - 37.c are reported as long-term investments.  Has the reporting entity rolled/renewed short-term or cash equivalent investments in accordance with these criteria?	1	No [	1	N/A	ſΧ		
	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1							

# **GENERAL INTERROGATORIES**

# OTHER

	1 Name	2 Amount Paid		
	Gorman Actuarial Inc.	24,698		
39.1	Amount of payments for legal expenses, if any?		\$	0
39.2	List the name of the firm and the amount paid if any such payment represented 25% or more of the total payment	nte for legal evnences		
J3.Z	during the period covered by this statement.	nis for legal expenses		
9.2		2 Amount Paid		
10.1	during the period covered by this statement.	2 Amount Paid		0
40.1	during the period covered by this statement.  1 Name	2 Amount Paid  ants of government, if ant expenditures in	ny?\$	0

# **GENERAL INTERROGATORIES**

# PART 2 - HEALTH INTERROGATORIES

1.1	Does the reporting entity have any direct Medicare Supplement Insurance in for		
1.2	If yes, indicate premium earned on U.S. business only.		\$ <u> </u>
1.3	What portion of Item (1.2) is not reported on the Medicare Supplement Insurance	e Experience Exhibit?	.\$0
	1.31 Reason for excluding		
1.4	Indicate amount of earned premium attributable to Canadian and/or Other Alien	not included in Item (1.2) above	\$ 0
1.5	Indicate total incurred claims on all Medicare Supplement Insurance.	_	
1.6	Individual policies:	Most current three years:	
	'	1.61 Total premium earned	\$0
		1.62 Total incurred claims	.\$0
		1.63 Number of covered lives	
		All years prior to most current three years:	
		1.64 Total premium earned	.\$0
		1.65 Total incurred claims	.\$0
		1.66 Number of covered lives	0
1.7	Group policies:	Most current three years:	
		1.71 Total premium earned	.\$0
		1.72 Total incurred claims	.\$0
		1.73 Number of covered lives	
		All years prior to most current three years:	
		1.74 Total premium earned	
		1.75 Total incurred claims	
		1.76 Number of covered lives	0
_	1114-T4		
2.	Health Test:	1 2	
		1 2 Current Year Prior Year	
	2.1 Premium Numerator		
	2.2 Premium Denominator		
	2.3 Premium Ratio (2.1/2.2)		
	2.4 Reserve Numerator		
	2.5 Reserve Denominator	215 , 144 , 829205 , 868 , 150	
	2.6 Reserve Ratio (2.4/2.5)	1.0001.000	
3.1	Has the reporting entity received any endowment or gift from contracting hospital returned when, as and if the earnings of the reporting entity permits?	als, physicians, dentists, or others that is agreed will be	Yes [ ] No [ X ]
4.1	Have copies of all agreements stating the period and nature of hospitals', physic dependents been filed with the appropriate regulatory agency?	cians', and dentists' care offered to subscribers and	Yes [ X ] No [ ]
4.2	If not previously filed, furnish herewith a copy(ies) of such agreement(s). Do the	se agreements include additional benefits offered?	Yes [ ] No [ ]
5.1	Does the reporting entity have stop-loss reinsurance?		Yes [ X ] No [ ]
5.2	If no, explain:		
5.3	Maximum ratained rick (see instructions)	5.31 Comprehensive Medical	¢ ^
5.3	Maximum retained risk (see instructions)	5.31 Medical Only	
		5.33 Medicare Supplement	
		5.34 Dental & Vision	
		5.35 Other Limited Benefit Plan	\$0
		5.36 Other	.\$0
6.	Describe arrangement which the reporting entity may have to protect subscriber hold harmless provisions, conversion privileges with other carriers, agreements agreements:  Hold harmless clauses in provider agreements and continuation of coverage en	rs and their dependents against the risk of insolvency including with providers to continue rendering services, and any other	
7.1	Does the reporting entity set up its claim liability for provider services on a service	Yes [ X ] No [ ]	
7.2	If no, give details		
8.	Provide the following information regarding participating providers:	8.1 Number of providers at start of reporting year	
		8.2 Number of providers at end of reporting year	136,301
9.1	Does the reporting entity have business subject to premium rate guarantees?		Yes [ ] No [ X ]
9.2	If yes, direct premium earned:	9.21 Business with rate guarantees between 15-36 months. 9.22 Business with rate guarantees over 36 months	

10.1	Does the reporting entity have Incentive Poo	ol, Withhol	ld or Bonus Arr	angements in its p	provider contracts?			Yes [ X	] No	[ ]
10.2	If yes:			1	0.21 Maximum amo	ount payable bonus	es	\$	11,	079,618
	,					lly paid for year bon				
						ount payable withho				
				10	0.24 Amount actual	lly paid for year with	holds	\$	2,0	087,817
11.1	Is the reporting entity organized as:									
					11.12 A Medica	I Group/Staff Model	,	Yes [	] No	[ X ]
					11.13 An Individ	dual Practice Assoc	iation (IPA), or, .	Yes [	] No	[ X ]
					11.14 A Mixed N	Model (combination	of above)?	Yes [	] No	[ X ]
11.2	Is the reporting entity subject to Statutory Mi	linimum Ca	anital and Surn	lue Requirements	2			Yes [ X	1 No	r 1
11.3	If yes, show the name of the state requiring							_	-	Island
11.4	If yes, show the amount required.			•				\$		857,873
11.5	Is this amount included as part of a continge	•	ve in stockhold	ler's equity?				Yes [	] No	[ X ]
11.6	If the amount is calculated, show the calcula		المعادات الماء ما	la alth Cara of Nov	. Francisco de como de como	750/ of DDC ACI				
	The Rhode Island Department of Business I	Regulation	i noids Unitedr	realinGare of New	England, Inc. to 2	75% OF RBC ACL.				
12.	List service areas in which reporting entity is	s licensed	to operate:							
	Г			1						
	-		Abaras of Name	Name of Service		- :				
					licensed statewid business. Addition					
					is licensed to ope					
					lk, Plymouth, and					
					licensed statewid					
	ls	sland for	all lines of b	ousiness						
					licensed in Carro					
					Strafford and Sull ent line of busine					
	U	JnitedHeal	thcare of New	England, Inc. is	licensed in Alleg	heny, Beaver,				
					rawford, Erie, Fay er, Northampton, V					
					Counties in Penns					
				•	licensed in Addise Rutland, Washingt	·				
					are and Retirement					
	þı	usiness								
	L									
13.1	Do you act as a custodian for health savings	s accounts	s?					Yes [	] No	[ X ]
13.2	If yes, please provide the amount of custodi	ial funda h	old as of the re	norting data				¢.		0
10.2	in yes, please provide the amount of custour	iai iulius lii	eid as of the re	porting date				Ψ		
13.3	Do you act as an administrator for health sa	avings acco	ounts?					Yes [	] No	[ X ]
13.4	If yes, please provide the balance of funds a	administer	ed as of the rep	porting date				\$		0
14.1	Are any of the captive affiliates reported on	Schedule	S Part 3 auth	orized reinsurers?			l seV	1 No f	1 N	I/A [ X ]
14.2	If the answer to 14.1 is yes, please provide t			onzeu remsurers :			Tes [	] NO [	] IV.	1/A [ A ]
			2	0				0 1"		1
	1		2 NAIC	3	4	Assets S	Supporting Reserve	7		1
	Company Name		Company Code	Domiciliary Jurisdiction	Reserve Credit	Letters of	Trust	Othor	-	
	Company Name			Jurisdiction	Credit	Credit	Agreements	Other		
										_
15.	Provide the following for individual ordinary	life insura	nce* policies (l	J.S. business only	) for the current yea	ar (prior to reinsuran	ce assumed or			
	ceded):				15.1 D	irect Premium Writt	en	\$		0
						otal Incurred Claims				
					15.3 N	umber of Covered I	_ives			0
	*Ordinary Life Insurance Includes Term(whether full underwriting, limited underwriting, jet issue, "short form app")									
			l underwriting, ithout seconda		ng, jet issue, "short	form app")	_			
				ry gurarantee) ary gurarantee)						
				t secondary gurara	antee)					
16.	Is the reporting entity licensed or chartered,	registered	l qualified olic	ible or writing bus	iness in at least two	states?	\	'es [ X ]	No I	1
10.	to the reporting entity needs ed or chartered,	, ogisiciet	, quaimed, elly	nale or writing bus	mooo maa idaal iWC	,		20 [ A ] I	[	1
16.1	If no, does the reporting entity assume reins							/ [ ] '	Na r	1
	domicile of the reporting entity?						\	'es [ ]	NO [	1

# **FIVE-YEAR HISTORICAL DATA**

1. T 2. T 3. S 4. T In 5. T 6. T	Galance Sheet (Pages 2 and 3)  Fotal admitted assets (Page 2, Line 28)  Fotal liabilities (Page 3, Line 24)  Statutory minimum capital and surplus requirement  Fotal capital and surplus (Page 3, Line 33)  ncome Statement (Page 4)  Fotal revenues (Line 8)	285,848,677	269,174,406			
1. T 2. T 3. S 4. T In 5. T 6. T	Fotal admitted assets (Page 2, Line 28)	285,848,677	269,174,406			
2. T 3. S 4. T 1r 5. T 6. T	Total liabilities (Page 3, Line 24)	285,848,677	269,174,406			
3. S 4. T In 5. T 6. T	Statutory minimum capital and surplus requirement  Fotal capital and surplus (Page 3, Line 33)  ncome Statement (Page 4)	91,857,873		1 1	000, 070, 081	212,527,967
<ol> <li>T</li> <li>Ir</li> <li>T</li> <li>T</li> </ol>	Total capital and surplus (Page 3, Line 33)ncome Statement (Page 4)			500,000		
Ir 5. T 6. T	ncome Statement (Page 4)		204,411,638			
5. T 6. T	, ,		, ,	, ,	, ,	
6. T	( ', '	1,584,388,273	1,433,651,095	1,305,229,228	1,160,842,788	974,456,602
	Fotal medical and hospital expenses (Line 18)					
	Claims adjustment expenses (Line 20)	55,244,420	51,311,487	57, 155, 750	49,941,411	41,030,276
8. T	Fotal administrative expenses (Line 21)				111,860,474	
	Net underwriting gain (loss) (Line 24)					
	Net investment gain (loss) (Line 27)					
	Fotal other income (Lines 28 plus 29)					
	Net income or (loss) (Line 32)				18,396,761	
	Cash Flow (Page 6)					
	Net cash from operations (Line 11)	82,781,185	112,070,371	28,603,208	(29,717,952)	
	Risk-Based Capital Analysis					
14. T	Fotal adjusted capital	206, 184, 444	204,411,638	163, 161, 782	132,604,785	113,865,940
15. A	Authorized control level risk-based capital	33,402,863	39,155,808	43,037,032	35,620,693	27,751,581
	Enrollment (Exhibit 1)					
16. T	Fotal members at end of period (Column 5, Line 7)	180,005	172,670	155,497	153,749	144,096
17. T	Fotal members months (Column 6, Line 7)	2,141,709	1,984,860	1,895,030	1,845,237	1,708,301
(I	Operating Percentage (Page 4) Item divided by Page 4, sum of Lines 2, 3 and 5) x 100.0					
	Premiums earned plus risk revenue (Line 2 plus Lines 3 and 5)	100.0	100.0	100.0	100.0	100.0
19. T	Fotal hospital and medical plus other non-health (Lines 18 plus Line 19)	85.2	82.8	85.4	84.1	85.6
20. C	Cost containment expenses	2.7	2.7	3.0	2.5	2.6
21. C	Other claims adjustment expenses	8.0	0.9	1.4	1.8	1.7
22. T	Fotal underwriting deductions (Line 23)	95.0	95.5	97.1	98.1	96.6
23. T	Fotal underwriting gain (loss) (Line 24)	5.0	4.5	2.9	1.9	3.4
	Jnpaid Claims Analysis U&I Exhibit, Part 2B)					
24. T	Total claims incurred for prior years (Line 13, Col. 5)	140,651,686	113,554,421	80,304,218	83,210,698	61,223,802
25. E	Estimated liability of unpaid claims-[prior year (Line 13, Col. 6)]	149,258,834	111,880,618	87,241,400	77,638,998	81,783,492
	nvestments In Parent, Subsidiaries and Affiliates					
26. A	Affiliated bonds (Sch. D Summary, Line 12, Col. 1)	0	0	0	0	0
27 Δ	Affiliated preferred stocks (Sch. D Summary, Line 18, Col. 1)					
28. A	Affiliated common stocks (Sch. D Summary, Line 24, Col. 1)	0	0	0	0	0
	Affiliated short-term investments (subtotal included in Schedule DA Verification, Col. 5, Line 10)	0	0	0	0	0
	Affiliated mortgage loans on real estate					0
	All other affiliated					0
	Fotal of above Lines 26 to 31					
33. T	Fotal investment in parent included in Lines 26 to 31 above.	0	0	0	0	0

# SCHEDULE T PREMIUMS AND OTHER CONSIDERATIONS

Allocated by States and Territories


					Allocati	ed by States			1			
			1	2	3	4	Dir 5	rect Business O 6	nly 7	8	9	10
				2	3	4	5	Federal	,	0	9	10
								Employees	Life and			
								Health	Annuity			
			Active	Accident and				Benefits	Premiums &	Property/	Total	
	C4-44-		Status	Health	Medicare	Medicaid	CHIP Title	Program	Other	Casualty	Columns 2	Deposit-Type
	States, etc.		(a)	Premiums	Title XVIII	Title XIX	XXI	Premiums	Considerations	Premiums	Through 8	Contracts
1.		AL	N	0	0	0	0	0	0	0	0	0
2.	Alaska	AK .	N	0	0	0	0	0	0	0	0	0
3.	Arizona	AZ	N	0	0	0	0	0	0	0	0	0
4.	Arkansas	AR .	N	0	0	0	0	0	0	0	0	0
5.	California	CA .	N	0	0	0	0	0	0	0	0	0
6.		CO	N	0	0	0	0	0	0	0	0	0
7.		CT	N	0	0	0	0	0	0	0	0	0
8.	Delaware	DE .	N	0	0	0	0	0	0	0	0	
												0
9.	District of Columbia		N	0	0	0	0	0	0	0	0	0
10.	Florida	FL .	N	0	0	0	0	0	0	0	0	0
11.	Georgia	GA .	N	0	0	0	0	0	0	0	0	0
12.	Hawaii	HI .	N	0	0	0	0	0	0	0	0	0
13.	Idaho	ID .	N	0	0	0	0	0	0	0	0	0
14.	Illinois	IL	N	0	0	0	0	0	0	0	0	0
15.		IN	N	0	0	0	0	0	0	0	0	0
16.		IA .	N N	0	0	0	0	0	0	0	0	0
					0 0	0					0	1
17.		KS .	N	0			0	0	0	0		0
18.	•	KY .	N	0	0	0	0	0	0	0	0	ļ0
19.	Louisiana		N	0	0	0	0	0	0	0	0	ļ0
20.	Maine	ME .	N	0	0	0	0	0	0	0	0	0
21.	Maryland	MD	N	0	0	0	0	0	0	0	0	0
22.	•	MA .	L	0	166,056,925	0	0	0	0	0	166,056,925	
23.		MI	N	0	0	0	0	0	0	0	0	0
24.	•	MN .	N	0	0	0	0	0	0	0	0	
												1
25.		MS .	N	0	0	0	0	0	0	0	0	
26.		MO .	N	0	0	0	0	0	0	0	0	ļ0
27.		MT .	N	0	0	0	0	0	0	0	0	0
28.	Nebraska	NE	N	0	0	0	0	0	0	0	0	0
29.	Nevada	NV	N	0	0	0	0	0	0	0	0	0
30.	New Hampshire		L	0	150 , 156 , 717	0	0	0	0	0	150 . 156 . 717	
31.	New Jersey		N N	0	0	0	0	0	0	0	n	n
	-		N	0	0	0	0	0	0	0	0	
32.		NM .										
33.		NY .	N	0	0	0	0	0	0	0	0	ļ0
34.	North Carolina		N	0	0	0	0	0	0	0	0	ļ0
35.	North Dakota	ND .	N	0	0	0	0	0	0	0	0	0
36.	Ohio	ОН	N	0	0	0	0	0	0	0	0	0
37.	Oklahoma	OK .	N	0	0	0	0	0	0	0	0	0
38.		OR	N	0	0	0	0	0	0	0	n	0
39.	Pennsylvania		L	0	264,434,234	0	0	0	0	0	264,434,234	0
	Rhode Island		 I	5,225,015				0	0	0		0
			L		279,640,303	687,088,473	0				971,953,791	0
	South Carolina		N	0	0	0	0	0	0	0	0	ļ0
42.		SD .	N	0	0	0	0	0	0	0	0	0
43.	Tennessee	TN	N	0	0	0	0	0	0	0	0	ļ0
44.	Texas	TX .	N	0	0	0	0	0	0	0	0	C
45.	Utah		N	0	0	0	0	0	0	0	0	
46.	Vermont	_	L	0	87,616,430	0	0	0	0	0	87,616,430	0
	Virginia		N	0	07,010,400	0	0	0	0	0	07,010,400	
				0	0	0	0	0	0	0	0	
		WA .	N									
	West Virginia		N	0	0	0	0	0	0	0	0	ļC
50.	Wisconsin		N	0	0	0	0	0	0	0	0	ļC
51.	Wyoming		N	0	0	0	0	0	0	0	0	ļ0
52.	American Samoa	AS .	N	0	0	0	0	0	0	0	0	C
53.	Guam	GU	N	0	0	0	0	0	0	0	0	c
54.	Puerto Rico		N	0	0	0	0	0	0	0	0	
	U.S. Virgin Islands		N	0	0	0	0	0	0	0	0	·
	Northern Mariana	٠.										
50.		MP .	N	0	0	0	0	0	0	0	0	
57.	Canada		N	0	0	0	0	0	0	0	0	
		CAN .			0			0	U	0	l0	
58.	Aggregate Other	OT	XXX	0	0	0	0	0	0	0	0	0
EO	Aliens						0					ļ
59.	Subtotal		XXX	5,225,015	947,904,609	687,088,473	0	0	0	0	1,640,218,097	0
60.	Reporting Entity	nale::										
	Contributions for Em	ipioyee	VVV	_	_	_	0	0		^	_	
	Benefit Plans		XXX	0	0	0			0	0	0	0
61.	Totals (Direct Busines		XXX	5,225,015	947,904,609	687,088,473	0	0	0	0	1,640,218,097	0
	DETAILS OF WRITE	-INS										
58001.			XXX									
58002.			XXX					<b> </b>	ļ		<b></b>	ļ
58003.			XXX								<b>1</b>	
	Summary of remaining											
	write-ins for Line 58 fr											
I	overflow page		XXX	0	0	0	0	0	0	0	0	0
	T-4-1- (1: F0004 4	hrouah										
58999.	Totals (Lines 58001 t											
58999.	58003 plus 58998)(Li above)		XXX	0	0	0	0	0	0	0	0	0


(a) Activ	e Status	Counts:


<sup>....5</sup> ....0


<sup>(</sup>b) Explanation of basis of allocation by states, premiums by state, etc. Premiums are allocated by state based on geographic market.


R - Registered - Non-domiciled RRGs......0
Q - Qualified - Qualified or accredited reinsurer......0



























































### PART 1 – ORGANIZATIONAL CHART

Entity Name	Juris.	Federal Tax ID	Entity Name	Juris.	Federal Tax ID
4C Medical Group, PLC	AZ 45-2402948 Empire Physicians' Medical Group, Inc.		CA	33-0181426	
A.G. Dikengil, Inc.	NJ	22-3149900	Everett Physicians, Inc. P.S.	WA	81-1625636
AbleTo Behavioral Health Services of Michigan, P.C.	MI	85-4328419	First Hill Surgery Center, LLC	WA	47-2066485
AbleTo Behavioral Health Services of New Jersey, P.C.	NJ	85-4306375	Greater Phoenix Collaborative Care, P.C.	AZ	27-2337725
AbleTo Behavioral Health Services, P.C.	CT	47-5519672	HealthCare Partners Affiliates Medical Group	CA	95-4526112
AbleTo Licensed Clinical Social Worker Services, P.C.	CA	85-0739865	HealthCare Partners ASC-HB, LLC	CA	26-4247365
American Health Network of Indiana, LLC	BV.	35-2108729	HealthCare Partners Associates Medical Group, P.C.	CA	45-5273760
AHN Accountable Care Orgnization, LLC	IN	45-4171713	HealthCare Partners Medical Group, P.C.	CA	95-4340584
AppleCare Hospitalists Medical Group, Inc.	CA	14-1890491	Homecare Dimensions of Florida, Inc.	TX	81-0884465
AppleCare Medical ACO, LLC	CA	45-2852872	Homecare Dimensions, Inc.	TX	74-2758644
AppleCare Medical Group St. Francis, Inc.	CA	33-0845269	IN Style OPTICAL, LLC	MA	27-3296953
AppleCare Medical Group, Inc.	CA	33-0898174	Inland Faculty Medical Group, Inc.	CA	33-0618077
ArchWell Health Professional Services Holding Co.	DE	86-3278602	Inspiris Medical Services of New Jersey, P.C.	NJ	45-2563134
ArchWell Health Professional Services of Alabama, LLC	AL	86-3152173	INSPIRIS of Michigan Medical Services, P.C.	MI	27-1561674
Archwell Health Professional Services of Arizona, LLC	AZ	87-2986923	INSPIRIS of New York Medical Services, P.C.	NY	13-4168739
ArchWell Health Professional Services of Kansas, P.A.	KS	86-3241870	INSPIRIS of Pennsylvania Medical Services, P.C.	PA	26-2895670
Archwell Health Professional Services of Nebraska, LLC	NB *	87-3065955	Landmark Connect of California, PC	CA	36-4886532
ArchWell Health Professional Services of North Carolina, P.C.	NC	86-3222071	Landmark Connect of Oregon, P.C.	OR	82-4121823
ArchWell Health Professional Services of Oklahoma, LLC	OK	86-3190019	Landmark Connect of Pennsylvania, PC	PA	82-4513634
ARTA Western California, Inc.	CA	33-0658815	Landmark Connect of Washington, P.C.	WA	82-4273042
Aspectus, Inc.	MA	04-3403101	Landmark Medical of Arkansas, P.A.	AR	85-0997438
Beaver Medical Group, P.C.	CA	33-0645967	Landmark Medical of California, PC	CA	47-4553619
Better Health Value Network, LLC	WA	47-4349079	Landmark Medical of Connecticut, PC	CT	83-2295301
Bexar Imaging Center, LLC	TX	22-3858211	Landmark Medical of Florida, P.A.	FL	85-0838149
California Spring Holdings, PC	CA	81-0881243	Landmark Medical of Idaho, PC	ID	-
CareMount Health Solutions ACO, LLC	NY	757	Landmark Medical of Kansas, P.A.	KS	82-4633545
CareMount Medical, P.C.	NY	13-3544120	Landmark Medical of Kentucky, PSC	KY	82-4881602
Centers for Family Medicine, GP	CA	33-0483510	Landmark Medical of Louisiana, a Professional Corporation	LA	82-4881732
Connect Medical, P.C.	NY	32-0551188	Landmark Medical of Massachusetts, PLLC	MA	81-5364097
David Moen, M.D. P.C.	NY	81-5101448	Landmark Medical of Michigan, P.C.	MI	86-3599871
David R. Ferrell, M.D., P.C.	NV	45-2380022	Landmark Medical of Mississippi, P.C.	MS	82-5084178
Day-OP Center Of Long Island Inc.	NY	11-2811353	Landmark Medical of Missouri, P.C.	MO	82-4857713
Durable Medical Equipment, Inc.	MA	04-3106404	Landmark Medical of New Hampshire, P.C.	NH	85-1174070

### PART 1 – ORGANIZATIONAL CHART

Entity Name	Juris.	Federal Tax ID	leral Tax ID Entity Name		Federal Tax ID
Landmark Medical of North Carolina, P.C.	NC	82-4256752	MedExpress Primary Care West Virginia, Inc.	WV	82-4401181
Landmark Medical of Ohio, Professional Corporation	ОН	82-4864947	MedExpress Primary Care Wisconsin, S.C.	W	81-4563448
Landmark Medical of Oregon, PC	OR	47-2926188	MedExpress Urgent Care - New Jersey, P.C.	NJ	45-5388778
Landmark Medical of Pennsylvania, PC	PA	81-1605378	MedExpress Urgent Care - Northern New Jersey PC	NJ	83-2089623
Landmark Medical of Rhode Island, PC	RI	84-2830065	MedExpress Urgent Care Arizona, P.C.	AZ	81-4030280
Landmark Medical of Tennessee, PC	TN	30-1288593	MedExpress Urgent Care Arkansas, P.A.	AR	46-4348120
Landmark Medical of Texas, PA	TX	83-2296389	MedExpress Urgent Care California, P.C.	CA	82-0930142
Landmark Medical of Utah, PC	UT	84-2660339	MedExpress Urgent Care Connecticut, P.C.	СТ	81-1956812
Landmark Medical of Virginia, P.C.	VA	85-0839774	MedExpress Urgent Care Idaho, P.C.	D	82-1135336
Landmark Medical of Washington, PC	WA	47-3028655	MedExpress Urgent Care Illinois, P.C.	L	47-4308614
Landmark Medical, P.C.	NY	47-1588943	MedExpress Urgent Care Iowa, P.C.	IA	81-5353472
Level2 Medical Services, P.A.	DE	84-5003916	MedExpress Urgent Care Kansas, P.A.	KS	47-1919283
Level2 Medical Services, P.A. New Jersey	NJ	87-2684015	MedExpress Urgent Care Minnesota P.C.	MN	81-1125396
Level2 Medical Services, P.C. Alaska	AK	87-2600511	MedExpress Urgent Care Missouri P.C.	MO	47-3132625
Level2 Medical Services, P.C. California	CA	84-5003916	MedExpress Urgent Care North Carolina, P.C.	NC	81-5138747
Level2 Medical Services, P.C. Utah	UT	87-0989804	MedExpress Urgent Care Oregon, P.C.	OR	82-1919436
March Vision Care Group, Incorporated	CA	95-4874334	MedExpress Urgent Care Rhode Island, P.C.	RI	81-5362765
March Vision Care IPA, Inc.	NY	27-3115058	MedExpress Urgent Care South Carolina, P.C.	sc	81-5380706
March Vision Care of Texas; Inc.	TX	45-4227915	MedExpress Urgent Care Texas, P.A.	TX	47-5147441
MAT-RX DEVELOPMENT, L.L.C.	TX	43-1967820	MedExpress Urgent Care Washington, P.C.	WA	82-2443118
Mat-Rx Fort Worth GP, L.L.C.	TX	35-2262695	MedExpress Urgent Care Wisconsin, S.C.	WI	81-4281678
ME Urgent Care Nebraska, Inc.	NB *	81-0936574	MedExpress Urgent Care, Inc West Virginia	WV	26-4546400
MedExpress Employed Services, Inc.	DE	81-1265129	MedExpress Urgent Care, P.C Georgia	GA	47-1804667
MedExpress Primary Care Arizona, P.C.	AZ	81-4550969	MedExpress Urgent Care, P.C Indiana	IN	90-0929572
MedExpress Primary Care Arkansas, P.A.	AR	84-4234388	MedExpress Urgent Care, P.C Maryland	MO	45-3461101
MedExpress Primary Care Kansas, P.A.	KS	81-4605885	MedExpress Urgent Care, P.C Massachusetts	MA	47-1857908
MedExpress Primary Care Maryland, P.C.	MD	82-3384324	MedExpress Urgent Care, P.C Michigan	MI	46-4793937
MedExpress Primary Care Massachusetts, P.C.	MA	82-1096099	MedExpress Urgent Care, P.C Oklahoma	ok	47-1824365
MedExpress Primary Care Minnesota P.C.	MN	81-4396738	MedExpress Urgent Care, P.C Pennsylvania	PA	26-3750502
MedExpress Primary Care Oklahoma, P.C.	OK	83-1077265	MedExpress Urgent Care, P.C Tennessee	TN	45-4973138
MedExpress Primary Care South Carolina, P.C.	sc	83-0764858	MedExpress Urgent Care, P.C Virginia	VA	45-3123110
MedExpress Primary Care Texas, P.A.	TX	84-2500750	MedExpress Urgent Care, P.S.C Kentucky	KY	83-1565124
MedExpress Primary Care Virginia, P.C.	VA	82-3395792	MedExpress, Inc Delaware	DE	45-5436856

### PART 1 – ORGANIZATIONAL CHART

Entity Name	Juris.	Federal Tax ID	Entity Name	Juris.	Federal Tax ID
Memorial Healthcare IPA, GP	CA	95-4688463	ProHEALTH Care Associates of New Jersey LLP	NJ	47-5656253
MH Physician Three Holdco, a Medical Corporation	CA	27-4691544	ProHEALTH Care Associates, L.L.P.	NY	11-3355604
MHCH, Inc.	CA	80-0507474	ProHEALTH Medical NY, P.C.	NY	47-1388406
MHIPA Physician Two Holdco, a Medical Corporation	CA	27-4691508	ProHealth Physicians, P.C.	CT	06-1469068
Mobile Medical Services of New Jersey, PC	NJ	81-2977678	ProHEALTH Urgent Care Medicine of New Jersey LLP	NJ	47-5661535
Mobile Medical Services, P.C.	NY	30-0445773	ProHEALTH Urgent Care Medicine, PLLC	NY	46-1883579
Moen, M.D., P.C.	CA	85-3287029	Prospero Health Partners Florida, Inc.	FL	85-0775386
Monarch Health Plan, Inc.	CA	22-3935634	Prospero Health Partners New York, P.C.	NY	82-2400620
Monarch HealthCare, A Medical Group, Inc.	CA	33-0587660	Prospero Health Partners North Carolina, P.C.	NC	84-4569314
Monika Roots, M.D., P.C.	CA	84-4887072	Prospero Health Partners, P.C.	MN	84-3234753
Mosaic Management Services, Inc.	CA	20-5892451	Prospero Medical Services New Jersey, P.C.	NJ	84-3844362
NAMM Medical Group Holdings, Inc.	CA	56-2627070	Prospero Medical Services, P.A.	FL	87-2406404
NAMM MGH, Inc.	CA	61-1627269	Psychiatry Services of New York, P.C.	NY	85-0921665
naviHealth Coordinated Care SC, P.C.	MI	85-0975337	Redlands Family Practice Medical Group, Inc.	CA	56-2627067
naviHealth Michigan HBPC, P.C.	MI	84-3469040	Reliant Medical Group The Endoscopy Center, LLC	MA	20-5251393
New York Licensed Clinical Social Work, P.C.	NY	86-3891057	Reliant Medical Group, Inc.	MA	04-2472266
Nifty After Fifty/Monarch, LLC	CA	26-2995765	Riverside Community Healthplan Medical Group, Inc.	CA	33-0055097
Northwest Medical Group Alliance, LLC	WA	91-1699944	Riverside Electronic Healthcare Resources, Inc.	CA	20-3420379
NPN IPA Washington, PLLC	WA	61-1855159	Riverside Pediatric Group, P.C.	NJ	22-3624559
OHR Physician Group, P.C.	OR	93-0979031	Robert B. McBeath, M.D. II, P.C.	NV	86-0857176
Optum Clinic, P.A.	TX	75-2778455	Robert B. McBeath, M.D. III, P.C.	NV	46-2662506
Optum Medical Services of California, P.C.	CA	30-0826311	Robert B. McBeath, M.D., Professional Corporation	NV	88-0310956
Optum Medical Services of Colorado, P.C.	co	45-5424191	San Bernardino Medical Group, Inc.	CA	-
Optum Medical Services, P.C.	NC	45-3866363	Sanvello Behavioral Health Services of Michigan, P.C.	DE	85-1941832
Oregon Healthcare Resources, LLC	OR	27-3674492	Sanvello Behavioral Health Services of New Jersey, P.C.	NJ	85-0666386
Physician Partners Medical Group, Inc.	CA	30-0516435	Sanvello Behavioral Health Services of North Carolina, P.C.	NC	85-1959641
Physicians Care Network, L.L.C.	WA	91-1822767	Sanvello Behavioral Health Services of Texas, P.A.	TX	84-3152209
Polyclinic Holdings, P.C.	WA	83-3042027	Sanvello Behavioral Health Services, P.A.	DE	84-1754732
Polyclinic Management Services Company, LLC	WA	46-0508606	Southern California Medical Practice Concepts, LLC	CA	30-0743767
Primary Care Associated Medical Group, Inc.	CA	33-0527335	Surgical Eye Experts, LLC	MA	65-1321064
Prime Community Care, Inc.	CA	30-0516440	Talbert Medical Group, P.C.	CA	93-1172065
ProHEALTH Accountable Care Medical Group, PLLC	NY	45-4469117	TeamMD Physicians, P.C.	IA	42-1446216
ProHEALTH Ambulatory Surgery Center, Inc.	NY	11-3447394	The Everett Clinic, PLLC	WA	91-0214500

### PART 1 – ORGANIZATIONAL CHART

Entity Name	Juris.	Federal Tax ID
The Polyclinic, PLLC	WA	91-0369070
USMD Diagnostic Services, LLC	TX	27-2803133
USMD Hospital at Arlington, L.P.	TX	73-1662763
USMD Hospital at Fort Worth, L.P.	TX	20-3571243
USMD of Arlington GP, L.L.C.	TX	73-1662757
Vitucci, LCSW, P.C.	L	85-1453387
Waypoint Minnesota PC	MN	46-2854394
WellMed Florida Medicare ACO, LLC	TX	84-2233329
WellMed Greater Texas Medicare ACO, LLC	TX	84-2178104
WellMed Medical Group, P.A.	TX	74-2574229
WellMed Network of Florida, Inc.	TX	35-2314192
WellMed Networks - DFW, Inc.	TX	41-2250215
WellMed Networks, Inc.	TX	74-2889447
WellMed of Las Cruces, Inc.	TX	92-0183013
WellMed Tampa/Orlando Medicare ACO, LLC	TX	84-2193803
WellMed Texas Medicare ACO, LLC	TX	84-2219968
WND Medical, PLLC	TX	45-2158334
XLHome Michigan, P.C.	MI	46-3537245
XLHome Northeast, P.C.	NJ	45-5530241
XLHome Oklahoma, Inc.	OK	46-2931689
XLHome, P.C.	MD	27-3543997

#### PART 1 – ORGANIZATIONAL CHART

### **Organizational Chart Footnotes**

- (1) Entity is owned in full or in part by a UnitedHealth Group Incorporated friendly physician.
- (2) Control of the Foundation is based on sole membership, not the ownership of voting securities.
- (3) The remaining percentage is owned either by a non-affiliated entity, outside investor(s), former company officer(s), or third party shareholder(s).
- (4) The minority percentage is owned by one or more affiliated UnitedHealth Group Incorporated subsidiaries. Voting rights do vary.
- (5) No information of the other shareholder(s) has been provided
- (6) General partnership interests are held by United HealthCare Services, Inc. (89.77%) and by UnitedHealthcare, Inc. (10.23%). United HealthCare Services, Inc. also holds 100% of the limited partnership interests. When combining general and limited partner interests, United HealthCare Services, Inc. owns 94.18% and UnitedHealthcare, Inc. owns 5.83%.
- (7) Branch offices in Iraq and Uganda.
- (8) H&W Indemnity (SPC), Ltd. is an exempted segregated portfolio company organized under the laws of the Cayman Islands and holds a Cayman insurance license.
- (9) Registered as a foreign shareholder in Brazil.
- (10) Registered in Nova Scotia and Newfoundland& Labrador.
- (11) Polar II Fundo de Investimento em Participações is a Brazilian private equity investment fund incorporated in the form of a closed-end condominium.
- (12) N/A
- (13) Entity has a representative office in Beijing, China.
- (14) Registered in the Dubai Silicon Oasis free zone.
- (15) Registered branch in the UK.
- (16) Registered in the Dubai Healthcare City free zone.
- (17) Entity is not directly owned by the parent. However, the parent does have a viable economic interest as well as control over the entity through contractual agreements.
- (18) Entity has a branch office in the United Kingdom.

### ANNUAL STATEMENT FOR THE YEAR 2021 OF THE UnitedHealthcare of New England, Inc.

# **OVERFLOW PAGE FOR WRITE-INS**

Additional Write-ins for Underwriting and Investment Exhibit Part 3 Line 25

		Claim Adjustment Expenses		3	4	5
		1	2			
		Cost	Other Claim	General		
		Containment	Adjustment	Administrative	Investment	
		Expenses	Expenses	Expenses	Expenses	Total
2504.	Managed Care & Network Access	29,631	6,887	38,443	0	74,961
2505.	Miscellaneous Losses	8,518	2,513	132,817	0	143,848
2506.	Interest	5,310	1,566	28,313	0	35, 189
2507.	Reimbursement of Expenses from Reinsurers	0	0	(638,439)	0	(638,439)
2597.	Summary of remaining write-ins for Line 25 from overflow page	43,459	10,966	(438,866)	0	(384,441)